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Abstract 
The aim of this study was to investigate three different radiation therapy treatment techniques; 3-
Dimensional conformal radiation therapy (3DCRT), intensity modulated radiation therapy 
(IMRT) and volumetric modulated arc therapy (VMAT) for the delivery of stereotactic ablative 
radiation therapy (SABR) for peripheral early stage non-small cell lung cancer (NSCLC).   
 
Twenty patients that met the eligibility criteria for SABR had their computed tomography scans 
de-identified and transferred to Pinnacle3 ™ radiation therapy treatment planning system.  All 
patients had completed their course of radiation therapy before this study so results had no 
clinical impact.  Structures including the planning target volume, and critical structures such as 
the spinal cord and heart were contoured.  Treatment plans were created for each of the three 
different techniques for the twenty patients.  Radiation therapy dose metrics such as high and 
intermediate radiation dose constraints, dose to the tumour, dose to critical structures and 
treatment delivery time were assessed.  Plan metrics were critiqued against the radiation therapy 
oncology group (RTOG) protocol number 1021, with either no deviation, acceptable deviation or 
unacceptable deviations to protocol. 
 
Mean tumour coverage was found to be 95.6%, 95.7% and 95.6% for the 3DCRT, IMRT and 
VMAT techniques respectively.  No deviations to the intermediate dose constraints were found 
in 65%, 65% and 85% of the patients for the 3DCRT, IMRT and VMAT plans respectively.  All 
plans adhered to the high dose constraints.  Mean treatment times were 20.0 minutes (16.4 – 21.5 
minutes), 25.2 minutes (22.1 – 27.9 minutes) and 11.7 (8.0 – 15.2 minutes) minutes respectively 
for 3DCRT, IMRT and VMAT. 
 
The VMAT technique was found to better adhere to the intermediate dose constraints stipulated 
by the RTOG 1021 protocol.  Tumour coverage was comparable between all three techniques 
with no statistically significant difference found.  Additionally, VMAT was found to reduce the 
treatment times of SABR delivery for peripheral lung tumours.   However, both 3DCRT and 
IMRT are viable and safe treatment options for the delivery of SABR for peripheral early stage 
NSCLC. 
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Chapter 1:  Introduction 
1.1 BACKGROUND 
1.1.1 Lung Cancer in Australia 
Lung cancer is the fifth most common cancer in Australia but the most common cause of cancer 
related deaths [1] . Currently there are more than 11,000 new cases diagnosed each year, which is 
expected to increase by 16% in 2020 [2].  In 2010, the risk of developing lung cancer before the age 
of 85 was 1 in 16, and in 2011 the risk of death was 1 in 21 [3].  Presently, survival rates for patients 
diagnosed with lung cancer, although poor are improving due to advancements in treatment options.  
From 2006 -2010 the five year relative survival rate for Australians diagnosed with lung cancer was 
14.1%, an increase from 8.1% since 1982-1987 [2] .  Lung cancer is believed to be the leading cause 
of cancer related burden of disease for men, and second highest for women [2] .  
 
1.1.2 Anatomy 
The lungs are the organ that allow for the exchange of carbon dioxide and oxygen into the blood 
stream.  The lungs are contained on either side of the mediastinum in the thorax, surrounded by 
pleura protected by the rib cage.  The lungs are compartmental in structure and compromised of 
lobes, with the right lung consisting of an upper, middle and lower and the left lung consisting of an 
upper and lower lobe.  The lower lobes rest directly adjacent to the muscle known as the diaphragm, 
which is used to control breathing.  Therefore, the lower lobes are more prone to large amount of 
movement when compared to the middle or upper lobes.   
 
The trachea is the organ which transports air from the larynx and pharynx inferiorly to the lungs.  
The trachea bifurcates at the carina into the right and left primary bronchus.  The bronchus continues 
to divide once inside the respective lung into smaller bronchi, eventually splitting into bronchioles.  
These bronchioles end in clusters of microscopic air sacs known as alveolus (plural: alveoli).  These 
pulmonary alveoli protrude from either alveolar sacs or ducts, and are the sites of gas exchange with 
the blood [4] . 
 
The lungs are known as parallel functioning organs, meaning that they comprise of parenchymal 
tissues of which subdivisions are performing a similar, independent function (in parallel).  For 
example the left lung is performing the same function as the right lung, acting in some ways, as a 
reserve function.  This allows for destruction or removal of part of the organ without obvious clinical 
toxicity [5]. 
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1.1.3 Aetiology, Histology and Staging 
Lung cancer is a malignant tumour that usually forms in the airways contained within the lungs.  
Carcinomas predominantly arise from alveolar lining cells of the pulmonary parenchyma or from the 
mucosa of the tracheobronchial tree [6].  There are two main subtypes of lung cancer; small cell lung 
cancer (SCLC) and non-small cell lung cancer (NSCLC) [7, 8].  NSCLC is a generic term to 
describe a subset of lung cancers including but not limited to adenocarcinoma and large cell 
carcinoma [9].  NSCLC is the more common of the two, accounting for 85% of all lung cancers 
[10]. Of the 15% of patients diagnosed with SCLC, 30% of these present with limited disease (LD), 
which is disease that is limited to one lung and nearby lymph nodes [11, 12]. Furthermore, only 5-
15% of LD-SCLC patients present with disease contained within the lung, without regional or nodal 
involvement [13].  
 
SCLC, due to it’s predisposition to metastasize before diagnosis, is usually classified as either 
limited stage, or extensive stage [14].  NSCLC is typically staged using the TNM staging system.  
This system as described by American Joint Committee on Cancer (AJCC) [6] uses T to describe the 
size of the tumour, N to describe the nodal involvement and M to describe the metastatic state of the 
disease.  Table 1.1 lists the TNM scale for staging lung cancer as given by the AJCC [6]. 
Table 1.1 - TNM staging for lung cancer 
Primary Tumour (T) 
TX 
Primary tumour can not be assessed, or tumour proven by the presence 
of malignant cells in sputum or bronchial washings but not visualized by 
imaging or bronchoscopy 
T0 No evidence of primary tumour 
Tis Carcinoma in situ
T1 
Tumour 3cm or less in greatest dimension, surrounded by lung or 
visceral pleura, without bronchoscopic evidence of invasion more 
proximal than the lobar bronchus (i.e. not the main bronchus)1  
T1a Tumour 2cm or less in greatest dimension 
T1b Tumour more than 2cm but less than 3cm in greatest dimension 
T2 
Tumour more than 3cm but less than 7cm or less or tumour with the 
following features (T2 tumours with these features are classified as T2a 
if 5cm or less): involves main bronchus, 2cm more distal to the carina; 
invades visceral pleura (PL1 or PL2); associated with atelectasis or 
obstructive pneumonitis that extends to the hilar region but does not 
involve the entire lung 
T2a Tumour more than 3cm but less than 5cm in greatest dimension 
T2b Tumour more than 5cm but less than 7cm in greatest dimension 
T3 
Tumour more than 7cm or one that directly invades any of the 
following; parietal pleural (PL3), chest wall (including superior sulcus 
tumours), diaphragm, phrenic nerve, mediastinal pleura, parietal 
pericardium; or the tumour in the main bronchus is less than 2cm distal 
to the carina1 but without involvement of the carina; or associated 
atelectasis or obstructive pneumonitis of the entire lung or separate 
tumour nodule(s) in the same lobe 
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T4 
Tumour of any size that invades any of the following; mediastinum, 
heart, great vessels, trachea, recurrent laryngeal nerve, oesophagus, 
vertebral body, carina, separate tumour nodule(s) in a different 
ipsilateral lobe 
Regional Lymph Nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastases 
N1 
Metastases in ipsilateral peribronchial and/or ipsilateral hilar lymph 
nodes and intrapulmonary lymph nodes, including involvement by 
direct extension 
N2 Metastases in ipsilateral mediastinal and/or subcarinal lymph nodes 
N3 Metastases in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes 
Distant Metastases (M) 
M0 No distant metastases 
M1 Distant Metastases 
M1a Separate tumour nodule(s) in contralateral lobe, tumour with pleural nodes or malignant (or pericardial) effusion2 
M1b Distant Metastases (in extrathoracic organs) 
  1The uncommon superficial spreading tumour of any size with its invasive component limited to 
the bronchial wall, which may extend proximally to the main bronchus, is also classified as T1a. 
2Most pleural (and pericardial) effusions with lung cancer are due to tumour.  In a few patients, 
however, multiple cytopathological examinations of pleural (pericardial) fluid are negative for 
tumour, and the fluid is nonblood and is not an exudate.  Where these elements and clinical 
judgement dictate that the effusion is not related to the tumour, the effusion should be excluded as a 
staging element and the patient should be classified as M0. 
 
In conjunction with the TNM scale there is also an Anatomic stage/prognostic group  (table 2.2) [6] 
which summarizes the staging of the tumour using a combination of the TNM score for each 
individual diagnoses. 
Table 1.2 - Anatomic Stage/Prognostic factors 
Occult Carcinoma TX N0 M0 
Stage 0 Tis N0 M0 
Stage IA T1a N0 M0 
T1b N0 M0 
Stage IB T2a N0 M0 
Stage IIA T2b N0 M0 
 T1a N1 M0 
 T1b N1 M0 
 T2a N1 M0 
Stage IIB T2b N1 M0 
 T3 N0 M0 
Stage IIIA T1a N2 M0 
 T1b N2 M0 
 T2a N2 M0 
 T2b N2 M0 
 T3 N1 M0 
 T3 N2 M0 
 T4 N0 M0 
 T4 N1 M0 
Stage IIIB T1a N3 M0 
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 T1b N3 M0 
 T2a N3 M0 
 T2b N3 M0 
 T3 N3 M0 
 T4 N2 M0 
 T4 N3 M0 
Stage IV Any T Any N M1a 
 Any T Any N M1b 
 
Table 1.2 gives an overview of how a tumour can be small in size, but due to its nodal involvement 
has the same prognosis as a larger tumour that doesn’t have nodal involvement.  Likewise, any 
tumour regardless of size, that has metastasized, is classified as stage IV. 
 
 
1.2 TREATMENT OF LUNG CANCER 
1.2.1 Prelude 
The treatment of lung cancer depends on the location of the primary tumour, extent of the disease 
(staging) and other medical co-morbidities [6]. Only a small cohort of patients present with early or 
limited stage SCLC (LD-SCLC), making it rarely suitable for radiation alone.  Typical treatment for 
LD-SCLC includes concurrent chemo-radiation (CRT) followed by prophylactic cranial irradiation 
(PCI) [15]. NSCLC on the other hand, presents with either localized or locally advanced disease at 
the time of staging, making surgery the typical treatment option [14]. For patients diagnosed with 
early stage NSCLC, either IA or IB (T1a/b, T2a, N0, M0), lobectomy is common practice due to 
high local control rates and regarded as the most oncologically sound surgical resection [16-18].  
However, 25 % of NSCLC patients are unfit for surgery due to other medical co-morbidities and 
external beam radiation therapy (EBRT) is the primary treatment option for these cases [16, 19]. 
1.2.2 Surgery 
Surgical intervention is the most common approach to remove early stage lung cancer.  Surgery is 
characteristically reserved for early stage disease and not for more advanced disease that has already 
metastasized.  There are three main surgical operations that can be performed; 
 
 Pneumonectomy: an entire lung is removed 
 Lobectomy: an entire lobe is removed 
 Wedge Resection (or Segmentectomy): part of a lobe is removed. 
 
The technique used depends on location and size of the tumour, along with lung function.  Typically, 
if a patient has good lung function, more normal lung tissue is removed as this increases the chance 
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of a disease free survival.  With all techniques, an incision is made in between adjacent ribs to access 
the lung tissue.  This incision is known as a thoractomy.   
 
A recent advancement in early stage lung cancer surgery is the video-assisted thoracic surgery 
(VATS).  VATS is a technique used to treat small, peripheral lung tumours.  This technique only 
requires a few small incisions that create a passage for a camera and surgical equipment into the 
patient’s chest, rather than performing the surgery through the larger thoractomy incision.  Due to 
the less invasive nature of this technique, it is associated with less pain and a shorter hospital 
admission. 
 
As with any medical procedure, there are possible risks associated with surgery.  Serious long term 
effects from surgery include excess bleeding, infections and pneumonia.  Furthermore, there is also 
the rare, but possible chance of postoperative mortality which is age related and occurring in 3-5% 
of all lobectomy operations.[20]   
 
1.2.3 External Beam Radiation Therapy (EBRT) 
 
Conventionally, due to technology restrictions, curative dose regimes were limited to 60-66 Gray 
(Gy) in 30-33 fractions [21, 22]. However, this conventional fraction of 2 Gy per day results in 50% 
local failure rates and only 10-30% 5 year survival rates [23-27].  Compare this to surgery with only 
5-20% failure rates, and it’s clear why conventionally fractionated radiation therapy is not the 
primary treatment option for medically operable patients.  To improve local control rates to above 
50% with EBRT, doses would need to exceed 85 Gy [28].   
 
However, historical field arrangements consisted of not only coverage of the primary tumour, but 
also regional lymphatics in the ipsilateral hilum and mediastinum.  The implications of such large 
fields are that they are potentially poorly tolerated by this cohort of patients (usually presenting with 
co-morbidities) due to their limited pulmonary reserve [29].  Therefore a hypofractionated (increased 
daily dose of radiation) regime with a historical standard beam and field arrangement is 
unacceptable, due to the increased amount of non-cancerous tissue receiving highly ablative doses of 
radiation.  Retrospective studies examined primary tumour fields compared to primary tumour and 
prophylactic nodal irradiation fields and found similar survival rates, demonstrating there was no 
advantage in treating nodes prophylactically [30-33].  Due to this reduction of field size when 
treating just the primary tumour, less normal tissue will be exposed to radiation and therefore 
hypofractionation is a potential treatment option.  Similarly stage IIB to IV define large tumour sizes 
(>7cm) or nodal involvement and therefore include too much normal tissue for hypofractionation.  
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Consequently, only early stage (IA, IB or some IIA) NSCLC are suitable for hypofractionated, 
stereotactic ablative radiation therapy (SABR) [15].  
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2Chapter 2:  Literature Review 
2.1 HISTORY OF SABR 
Stereotactic ablative radiation therapy (SABR) derives from stereotactic radiosurgery (SRS), first 
described by Lars Leksell as a method for safely delivering high daily doses of radiation to 
intracranial neoplasms [34].   Over 4000 publications have demonstrated the clinical value of SRS in 
the treatment of not only benign and malignant diseases, but also functional disorders [35]. As 
described, radiobiologically, the justification for using SABR is similar to SRS in that delivering a 
large dose, over a few short fractions (hypofractionation) results in a more potent biological effect 
[35, 36].  The ability to deliver the desired dose over a single or few (usually 1-5) fractions of 
ionizing radiation with improved targeting accuracy and dosimetry that requires steep dose gradients 
provide the foundations of SABR [37].  Furthermore, SABR has compared favourably for both 
primary and metastatic disease when compared to surgery in regards to disease control rates [35].   
 
The first published data on SABR outcomes was in 1995 by Blomgren et al, where they reported on 
31 patients, with 42 tumours located in the liver, lung or retroperitoneal space.  They observed local 
control of 80% with no disease progression during their follow up period of 1.5-38 months post 
treatment.  Furthermore, 51% of tumours decreased in size or disappeared  [38]. Since then, there 
have been numerous reports on the outcomes of SABR for the treatment of lung, liver and spinal 
tumours.  Initial investigations began in Germany where lung and liver treatments and retrospective 
publications reporting on the safety and accuracy of SABR were emerging, which then eventually 
lead to prospective Phase I/II trials [39-49].  More recently, published data has emerged for the 
treatment of spinal lesions using SABR [50-55]. 
 
SABR has transformed the role of radiation therapy for numerous cancer sites, particularly for those 
patients diagnosed with NSCLC.  It offers the patient a treatment that has fewer appointments and 
offers the medical community the ability to achieve low normal tissue toxicities and high local 
control rates comparable to surgery [56]. 
 
2.2 HYPOFRACTIONATION 
Hypofractionation is the process of increasing the dose given to the tumour per fraction and reducing 
the number of fractions.  Hypofractionation is not a new theory, nor is it applicable to every type of 
cancer or situation. 
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Hypofractionation was the initial fractionation schedule used for the delivery of radiation therapy.  
Treatments were basic, dose was delivered mostly to the skin rather than deep seated tumours and 
treatment was given in single sessions.  However, this delivery of radiation was abandoned quite 
quickly due to the emergence of late effects.  Late effects, as implied by the name, are side effects 
from the radiation that appear months or even years after the treatment is finished.  Unlike early 
effects which are usually associated with damage to mucosa or epithelial lining, late effects usually 
involve the damage of vascular tissue [36].  These experiences led to the introduction of fractionated 
radiation therapy treatments. In 1928 and 1930 Coutard reported results from his experience of 
treating head and neck cancer where the choice of fractionation should depend on the size of the 
tumour and that the final dose to the tumour should depend on an ongoing response to treatment, for 
example mucositis [34, 36].  Excitement was generated over the better than expected results and was 
credited to the protracted-fractionation method.  The majority of radiation oncologists therefore 
stepped away from using hypofractionation until the 1950’s, when neurosurgeon Lars Leksell 
investigated the use of hypofractionated radiation to treat the radio-resistant central nervous system 
[34, 36]. Historically, large single doses were intolerable by the patient due to the aforementioned 
late effects, however, Leksell challenged conventional approaches by the use of technology, that 
allowed for rigid immobilisation, which altered the manner (daily dose) in which the radiation was 
delivered [36]. 
 
Conventionally, treatment fields were larger than the tumour and included a significant volume of 
the surrounding normal tissue [29, 36]. Conversely, Leksell endeavoured to make sure that large 
amounts of normal tissue surrounding the tumour, received as little dose as possible.  The only 
normal tissue that was then damaged was tissue directly adjacent to the tumour or tissue that was 
treated due to poor dosimetry.  Leksell observed that if this area of normal tissue receiving dose was 
small enough, then the patient did not suffer symptomatic clinical toxicity, even as a late effect [36]. 
This resulted in SRS, an effective and convenient treatment for patients with intracranial disease, and 
as discussed earlier, lead to the application of SABR for extracranial sites. There are two main issues 
associated with radiation delivery, acute and late affects. 
 
2.3 RADIOBIOLOGY  
The linear quadratic model describes how the tumour and normal tissue repairs itself after being 
damaged by radiation.  Post-irradiation cell survival (SF) is given by the relationship: 
 
SF = e-n = e-αD –βD^2 
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where n = (αD + βD2) = number of radio-induced lethal injuries; D = radiation dose administered; α, 
β = dose-effect co-efficients of lethal injury and α/β = dose at which the effect of α is equal to the 
effect of β.  Furthermore, α represents the lethal single impact injury and β represents lethal injury 
due to repetitive sub-lethal damage.  The linear component of the survival curve (αD) was ignored 
completely from the model, until 1973, when its importance in 2 Gy per day schemes was reported.  
However, it is now considered impossible to achieve tumour control by means of radiation without 
taking into account the single hit factor of irreparable cell injury[57].  Therefore, because damage 
caused by the β dose co-efficient is partially reparable, when a tumour and normal late responding 
tissue are irradiated together at 2 Gy per day, the radio-induced effect is greater in the tumour, than 
in the normal tissue.  This is how conventional fractionation works and the main method of 
delivering lethal doses of radiation to the tumour, but still allowing the normal tissue time to repair 
itself [57]. Furthermore, malignant tumour biological behaviour is less homogenous than normal 
tissue.  A downfall of the genetic make up of a tumour is their accelerated growth in response to the 
cytocidal (killing or tending to kill individual cells) action of radiation, which then means that longer 
treatment times have a negative effect on tumour control, a further reason for why hypofractionation 
is used for SABR  [57]. 
 
Taking then the; a) α dose co-efficient and b) β co-efficient we get the α/β ratio.  This is the dose 
where the late effects equal the early effects.  Each different tissue has a different ratio depending on 
the genetic make up.  There are two types for normal tissue; 
 
 Rapidly proliferating tissues – Bone marrow, intestinal epithelium, skin, oropharyngeal 
mucosa, seminiferous tubule epithelium etc 
 Non-proliferating tissues – Central and peripheral nervous system, liver, lung, kidneys, 
connective tissue, cartilage, bone vessels 
 
For proliferating tissues functional impairment arises from the damage to stem cells, where as non-
proliferating tissues are damaged by the loss of function in a number of mature, well-differentiated 
cells that make up the tissues’ structure.  Due to the nature of proliferation, early or acute radiation 
effects are noticed in proliferating tissues, and late effects are noticed in non-proliferating tissues.  
Malignant tumours act more like early-responding tissues [57]. 
 
As previously mentioned, hypofractionation was and still is, largely avoided due to complications 
arising from late effects.  To describe and mathematically explain this phenomenon, the isoeffect 
equation of the linear quadratic model was derived; 
 
D2 = D1 (d1 + α/β) / (d2 + α/β) 
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where D2 = total equivalent dose, D1 = total reference dose, d1 = the original dose per fraction 
(typically 2 Gy), d2 = the new dose per fraction and  α/β equals the ratio for the corresponding tissue.  
Take for example a standard fractionation schedule for lung cancer treatment; 66 Gy over 33 
fractions.  Therefore, using an α/β of 3 for normal lung tissue; 
 
D2 = 66 (2 + 3) / (3 + 3) 
D2 = 66 x  (.83) 
 
which gives a total equivalent dose of  55 Gy for normal tissues.  Then using an α/β of 10 for 
tumour, we get a total equivalent dose for the tumour of 60.9 Gy.    
 
D2 = 66 (2 + 10) / (3 + 10) 
D2 = 66 x  (.92) 
 
Therefore, if we choose to use this fractionation to reduce the late affects, then the tumour is only 
receiving 90% (.83/.92 = .9) of the reference dose.  Likewise, if we aimed to produce the same 
percentage of tumour control, then doses to late responding tissues would increase by 11 % 
(.92/0.83).  However, as reported by Lars Leksell, if this normal tissue receiving high dose is kept to 
a minimum, then this area of tissue did not receive symptomatic clinical toxicity, even as a late effect 
[36].  This is why when using SABR for lung cancer, patient’s inclusion criteria stipulate that the 
tumour must be staged either IA or IB, meaning that it is 5cm or less in dimension.  We know 
however, from reports, that 66 Gy does not produce the biologically effective dose to have 
comparable tumour control rates to surgery [58]. 
 
The biologically effective dose (BED) is the biological dose that is delivered to the patient and is 
calculated using the combination of dose per fraction, total dose and the specific α/β of the tissue.  
The equation for BED is; 
 
BED = nd (1 + d/(α/β)) 
 
where, n is the number of fractions, d is the dose delivered per fraction and α/β is the ratio of the 
specific tissue [59]. Therefore, when using a total dose of 66 Gy over 33 fractions, the total BED is 
only 67.2 Gy.  However, a Japanese study reported inferior local control if the BED <100 Gy [58]. 
The Radiation Therapy and Oncology Group (RTOG) RTOG 0236 trial, a phase II trial of SABR, 
treating using 54 Gy in 3 fractions treated 55 patients.  Primary tumour failure was only 2% at three 
years and three year estimated overall survival was 56%.  There are however, reports that suggest the 
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linear quadratic model is unreliable when high daily doses are given. [60]  Treating NSCLC with 54 
Gy in 3 fractions, results in a BED of 151.2 Gy. Furthermore, the equivalent dose in 2 Gy per 
fraction (EQD2) can be calculated.  This formula is; 
 
EQD2 = BED / (1 + 2/α/β) 
 
where BED is the BED calculated in the previous formula, and α/β is the ratio of the specific tissue 
[61].  The EQD2 equation is a rephrasing of the D2 equation previously investigated. Taking for 
example a BED of 54 Gy in 3 fractions, if it was then to be treated in 2 Gy per fraction, it would be 
equivalent to 126 Gy.  This means that to have the same biological cell kill, the patient would require 
63 x 2 Gy fractions.  This is unreasonable for both the patient and department. 
 
As demonstrated, hypofractionation can increase the biologically effective dose to the tumour.  This 
allows for patients that were deemed medically inoperable, to be given a treatment that is 
comparable to surgery in regard to local control.  However, it was also demonstrated that doses to 
normal tissues also increase and therefore the radiation treatment fields must be kept as small as 
possible.  Similarly, if the treatment times are excessive the patient is more likely to move, creating 
intra-fraction motion.  This intra-fraction motion is enough for the tumour to move out of the 
treatment field and a larger amount of normal tissue to get a higher dose.  This would then violate 
one of the key principles of SRS and SABR.  To aid in the reduction of intra-fraction motion and 
random error, the use of sophisticated tumour delineation and immobilization equipment is also a 
necessary part of a SABR treatment.   
 
2.4 SABR FOR NSCLC 
Due to poor local control rates, external beam radiation therapy has typically been reserved for those 
patients unfit for surgery [22].  For the inoperable patient, RTOG 0236 produced results that show 
SABR has emerged as a viable treatment option for inoperable NSCLC.  Reported control rates of 
98% at three years and a three-year overall survival of 56% with toxicity in the order of 16%, justify 
SABR as a standard of care for inoperable patients [62].  Of importance is the differentiation 
between peripheral lung tumours and central lung tumours as this definition plays an important role 
in deciding if SABR is a clinically appropriate treatment option.  Until recently, lung SABR has 
been restricted to peripheral tumours as dose to the central normal tissues has caused significant 
toxicity.  RTOG defines peripheral lung tumours as a tumour (GTV) that is >2 cm away from the 
proximal bronchial tree.  To aid in visualization, RTOG 0236 has a defined “no fly zone”.   
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Figure 2.1 -  No Fly Zone for peripheral lung SABR 
2.5 MOTION, TUMOUR DELINEATION AND IMMOBILIZATION  
  
Treatment fields and tumour volumes need to be relatively small for the patient to be a suitable 
candidate for SABR.  Historically, a computed tomography (CT) scan was acquired to delineate the 
tumour.  This CT scan is quite fast and can capture the tumour at any given point during the 
breathing cycle, be it inspiration, expiration or somewhere in between.  As defined by ICRU 50, 
there are three levels of voluming/contouring for any cancer patient [63]; 
 
 Gross tumour volume (GTV) – tumour that is physically visible, palatable or visible on 
imaging 
 Clinical tumour volume (CTV) – is an expansion around the GTV that accounts for any 
micro/macroscopic disease that isn’t visible 
 Planned target volume (PTV) – an expansion around the CTV that accounts for daily setup 
error and patient/organ movement.  
 
With any radiation therapy plan the aim is to always deliver the prescribed dose to the PTV.  
However, generally the expansion from CTV to PTV for lung cancers is over determined to account 
for tumour motion, in order not to under dose it.  Until recently, a CT scan of the patient for planning 
could result in an image which represents any part of the breathing cycle.  Due to the uncertainty 
surrounding the actual extents of the tumour motion, generous PTV margins were added to the CTV.  
This resulted in large PTVs and excess amounts of normal tissue receiving damaging doses.   
 
Tumour delineation is the process of defining the tumour for treatment.  Conventional fractionation 
requires contouring of a GTV, followed by an expansion to create the CTV, accounting for 
micro/macroscopic disease and then finally an expansion for the PTV.  However, with SABR, the 
GTV is directly expanded to the PTV. 4-dimensional computed tomography (4DCT) allows for 
accurate representation the GTV over the entire breathing cycle.  When each of the individual GTVs 
Chapter 2:  Literature Review Page 24 
© 2016 FITZGERALD Page 24 
are contoured, they are combined to create an internal target volume (ITV).  The ITV therefore, 
represents the entire range of motion during the patients breathing cycle [64].  A PTV is then created 
from the ITV to account for systematic and random errors.  The reason the GTV can be expanded 
straight to the PTV with SABR is the thought that they dose directly outside the PTV would still 
likely be high enough to destroy any microscopic disease. [65, 66].  Typically the ITV is expanded 5 
mm isotropically to create a PTV [67].  An expansion of up to 10 mm cranio-caudally can be 
justified if tumour motion is excessive [42].  Recent advancements in technology have led to the 
implementation of 4DCT that makes contouring the ITV possible [65]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 -  Example of 4DCT “binning” process 
 
4DCT uses amplitude or phase based methods of monitoring breathing motion.  During a 4DCT 
scan, a marker or belt is placed on the patient’s surface that measures the extent of the patient’s 
diaphragmatic movement.  During the scan each acquired projection can be correlated with a point 
in the patient respiratory cycle.  The reconstruction software is then able to associate a particular 
slice, with a particular point in the breathing cycle and reconstruct multiple CT datasets for different 
parts of the respiratory cycle, i.e. 0%, 10% - 90% [68].  Figure 2.2 [69] displays how the software, in 
this instance has “binned” this 4DCT into 4 different respiratory phases.       
 
The method of accounting for tumour motion is described as either motion assessment or motion 
management.  Motion assessment is the act of taking into account tumour movement due to 
respiration, but does not reduce the effects of the motion.  Motion control is the act of intervening 
and modifying the breathing pattern of the patient to reduce tumour motion.  Motion control is 
recommended if the tumour motion exceeds 5mm [70].  Different devices allow for motion control 
including an abdominal compression plate, or Active Breathing Control © (ABC©) Reducing the 
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motion allows for a more stationary GTV, therefore a smaller ITV and PTV, which will result in less 
normal tissue receiving ablative doses.  Additionally there is the problem of interplay, where a 
modulated beam is calculated to deliver dose to a stationary GTV in lung tissue on a stationary CT 
dataset, yet will be delivered to a moving GTV on the treatment machine [71].  This can be 
described as intra-fraction organ motion.  This motion, during treatment, needs to be as low as 
possible to replicate the desired dose distribution calculated at planning.  
 
To aid in the safe and accurate delivery of SABR, intra- and inter- fraction motion needs to be 
minimized.  This can be achieved with the use of specific patient immobilization devices.  Devices 
such as evacuated cushions and chest boards are two methods of patient immobilization [72].  Grills 
et al [73] investigated the use of a stereotactic body frame (SBF) or an alpha cradle for 
immobilization in lung SABR and found that both were suitable for immobilization.  However, these 
two devices alone were not optimal for lung SABR treatment and required the use of daily treatment 
verification images, known as image guided radiation therapy (IGRT).   
 
2.6 TREATMENT PLANNING 
While treatment modality plays an important role in SABR planning, there are particular plan 
characteristics and constraints that are required, independent of treatment technique.  The crux of 
SABR is to deliver ablative doses to the tumour, while having a steep isotropic dose fall off, 
reducing doses to normal tissues.  There are certain plan aspects which vary from conventional 
planning methods that allow for suitable plan delivery.  This section explores plan criteria required 
for safe delivery and then explores the techniques in which it can be achieved. 
 
All treatment planning was carried out using Pinnacle v9.4 with a collapsed cone convolution 
algorithm.  The CCC algorithm is classified as a type B algorithm and is more rigorous in 
accounting for changes in lateral electron transport and is a nessicity in modern day lung SABR 
treatment planning.  Only 6MV was used for all planning techniques as the use 10MV for lung 
radiation therapy should be avoided as the pitfalls of the dose calculation algorithms are further 
enhanced with higher energies. 
 
IMRT and VMAT plan specific quality assurance (QA) performed in which planned fluences 
were measured against actual delivered fluences for each field and arc of the IMRT and VMAT 
plans only, using a gamma analysis acceptance criteria of 3%/3mm [74] 
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2.6.1 Prescription dose 
The prescription dose is the dose that is prescribed to the tumour volume, and planning involves 
making sure this dose totally encapsulates the tumour.  The earliest reported Phase 1 trial for 
prescription doses was the Indiana University Experience which demonstrated the safety of a 3 
fraction treatment regime [75].  Subsequently, an RTOG study (0236) was designed to determine if 
radiation therapy involving high biological doses with limited treatment volume (using SABR 
techniques) achieves acceptable local control (> 80%) in frail patients with medically inoperable 
early stage non-small cell lung cancer.  RTOG 0236 reported that for 54 Gy in 3 fractions, primary 
tumour control failure at three years was only 2%.  Furthermore, three-year estimated overall 
survival was 56% with grade 3 and 4 toxicity occurring in only 16% of patients [62].  Studies using 
lower doses report not only increased primary tumour control failure, but also increased local and 
regional failure.  A regularly cited Japanese study demonstrated that >100 Gy BED resulted in 
superior local control.  Overall local recurrence occurred in 20% of patients who had <100 Gy, but 
reduced to 6.5% when >100 Gy was administered [76].  Survival curve review expresses 1 and 2 
year survivals of 90% and 75% for patients treated with >100 Gy, and 85% and 65% for patients 
treated with <100 Gy.  The 54 Gy in 3 fractions approached has been widely adopted by North 
American centres.  Japanese centres are more commonly prescribing 48 Gy in 4 fractions [77, 78].  
Using the BED equation (BED = nd (1 + d/(α/β))) , 54 Gy in 3 fractions will deliver a 151.2 Gy 
biologically effective dose, and 48 Gy in 4 fractions will be 105.6 Gy. 
 
2.6.2 Prescription Isodose 
 
The prescription isodose or covering isodose refers to the isodose value, which is intended to cover 
the PTV.  The prescription isodose is independent of the prescription dose, which is the absolute 
dose prescribed to the PTV.  Conventional planning involves prescribing a dose to the 100% isodose 
line, and then covering the PTV with the 95% isodose line [63].  For example, conventional lung 
planning would prescribe 66 Gy to the 100% isodose.  This would then require 100% of the PTV to 
receive 62.7 Gy (95% of 66Gy).  This would ensure that plan maximum doses stayed below 107% 
(ideally) of the 66 Gy to reduce normal tissue toxicity.  However, with SABR, due to the small target 
volumes, PTV coverage is prescribed differently. 
 
Firstly, the maximum dose in the plan is defined as the 100% isodose, so there can be no dose higher 
than this in the plan. Secondly, the PTV is planned to receive 100% of the prescription dose, i.e. for 
a prescription of 54 Gy, >95% of the PTV should receive 54 Gy, this negates the need for a CTV.  
Furthermore when prescribing conventionally to the 100% isodose line, the 95% isodose line would 
be the prescription isodose for the PTV.  This would in turn relate to 88% of the maximum dose if it 
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was kept to 107%.  However, with SABR, the 54 Gy dose will require a prescription isodose to be 
somewhere in the range of 59% to 90% [79], relative to the maximum dose in the plan.  This means 
that the 54 Gy isodose will be in the beam penumbra.  Penumbra is the region between the 20-80% 
isodose [80] at the edge of the beam where rapid dose fall off occurs.  Figure 2.3 shows the isodose 
distribution for a 10x10 cm2, 6 megavoltage (MV) beam prescribed at maximum dose depth in water 
(1.5 cm).  It demonstrates the distance between the 100% line and 95% line, and why it is 
challenging to achieve steep dose fall off if prescribing to these higher isodoses.  The broad-field 
penumbra collimated to the central axis for a single field represents the limit of dose gradient that 
can be achieved.  In contrast, it displays how tight the distance is between the lower isodoses and 
how prescribing to these allow for a steep dose fall off adjacent to the PTV.  Normal tissue just 
outside the PTV is going to receive ablative doses, but if this can be kept to a minimum, no acute 
side effects are noted.  Furthermore, this process of prescribing SABR treatments causes a very high 
maximum dose in the tumour, which for conventional fractionation of 2 Gy a day is unacceptable, 
but for stereotactic ablative radiation therapy, is ideal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 -  Isodose distribution for a 10x10 cm2, cm 6 MV photon field 
 
Prescribing so that the 95% isodose line covers the PTV means that there is a distance before the 
beam penumbra, and therefore, a distance until steep dose fall off occurs.  Thus, allowing for a 
higher maximum dose in the PTV results in the prescription isodose falling somewhere in the 80-
20% isodose regions, where dose fall off is the steepest.  For example, if the maximum dose in the 
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plan is 85 Gy, then the 54 Gy covering isodose will be 63% of the maximum dose. While the 20-
80% region of penumbra is defined as the steepest, for dosimetry purposes, a prescription isodose 
lower than 50% creates a large amount of heterogeneity within the PTV and isn’t recommended 
[79].  This is why a value of between 59% and 90% is recommended.  Additionally, a report by 
Ding et al [79] reports that if the prescription isodose gets too low (<50%) , then the high dose 
region in the plan (conformity index) and intermediate doses (R50%, and D2cm) begin to worsen, and 
don’t meet RTOG guidelines, negating the effect. 
 
 As the penumbra of the beam is at the edge of the field, then this requires planning which 
deviates from conventional methods.  Typically, because of penumbra, a margin has to be added to 
the shielding of the beam to allow coverage of the PTV with the 95% isodose.  However, because 
SABR requires the prescription isodose to be within the penumbra, then there is no margin, or 
sometimes a negative margin for shielding.  The reason for having a lower prescription isodose is to 
lower the amount of normal tissue receiving intermediate doses.  If the dose fall off is steep around 
the PTV then less normal tissue is going to receive high doses.  A number of techniques can be used 
to achieve this sharp dose fall off.  A typical margin is minus 2mm anterior, posterior, left and right 
and then plus 2mm superior and inferior.  The 2mm negative margin forces the covering isodose to 
be in the penumbra.  The expansion superiorly and inferiorly is due to a loss of lateral equilibrium 
superiorly and inferiorly because there is no direct superior or inferior beam.  These values are 
generally recommended but will change based on tumour location and prescription isodose 
requirements.  Figure 2.4 shows the difference in MLC margins for conventional versus SABR 
planning. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 – Comparison of a negative block margin typically used for SABR (left) and 
conventional block margin (right) typically used for conventionally fractionated treatments 
Chapter 2:  Literature Review Page 29 
© 2016 FITZGERALD Page 29 
2.6.3 High and Intermediate Dose Constraints 
As previously described, SABR is largely based on the work reported by Leksell, treating SRS using 
a GammaKnife [34].  In order to replicate the physical principles (i.e. conformal and steep dose fall 
off) achievable with GammaKnife, there are certain objectives [81] that need to be achieved with a 
linear accelerator; 
1) The shape of the iso-surface defined by the prescription dose conforms to the outline of the target 
and highest doses delivered outside the tumour are confined to regions that spread uniformly on the 
outer boundary of the target volume 
2) Rapid fall off of dose from the tumour volume to healthy tissue isotropically in all directions 
3) Non-uniform dose distribution throughout the volume of the tumour, with the highest dose 
delivered to the central portion of the tumour where the hypoxic cells potentially reside. 
 
In section 2.6.2 it was explained that a prescription isodose in the penumbra of the beam is used to 
lower the prescription isodose, which in turn reduces the normal tissue receiving certain doses and 
contributes to objective 2 and 3 being achieved.  These objectives have later been given specific 
values which need to be adhered to in numerous RTOG protocols [82-84].   These are as follows; 
High dose spillage 
 Conformality or conformity index (CI) of the PTV coverage will be judged such that the 
ratio of the volume of the prescription isodose to the volume of the PTV is >0.75.  The 
conformity index[85] (CI) will be calculated using the formula;  
 
 
 
where TVPTV is the total volume of PTV covered by the covering isodose (54Gy), TV is the 
total volume of the PTV and PIV is the total volume of the covering isodose in the patient. 
 
Intermediate dose spillage 
 The maximum total dose over all fractions in Gray (Gy) to any point 2cm or greater away 
from the PTV in any direction must be no greater than D2cm where D2cm is given in Table 2.1 
 
 The ratio of the volume of 50% of the prescription dose isodose to the volume of the PTV 
must be no greater than R50% where R50% is given in Table 2.1 
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Figure 2.5a - Graph displaying how the change in prescription isodose (x) effects the R50% (y) value [79]  
 
 
  
 
 
 
 
 
Figure 2.6b - Graph displaying how the change in prescription isodose (x) effects the CI (y) value [79] 
 
 
 
 
 
 
 
 
Figure 2.7c - Graph displaying how the change in prescription isodose (x) effects the D2cm (y) value [79] 
 
PTV Volume 
(cm3) 
Ratio of 27 Gy 
Isodose volume to 
the PTV, R50% 
Maximum dose at 2 cm away from 
the PTV in any direction as % of the 
prescription dose. D2cm = % x 54 Gy 
Ratio of Prescription 
Isodose Volume to 
the PTV (CI) 
 None Minor None Minor None Minor 
1.8 <5.9 <7.5 <50.0 <57.0 >.75 >.65 
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These planning objectives/constraints inherently make the planner conform both the high and 
intermediate dose as tightly and isotropically around the PTV as possible.  Without these objectives, 
more normal tissue than necessary will be receiving high doses of radiation.  One method of 
achieving these values is with the use of a large number of, and in many situations non-coplanar, 
beams.  The use of such a large number of beams results in an increased treatment time for patients. 
 
2.6.4 Normal Tissue Constraints 
 
Normal tissue refers to the tissue that is not the tumour.  For the purpose of lung SABR, the tumour 
is defined as the ITV which accounts for all tumour motion during treatment.  Since the tumour 
position, without respiratory gating, cannot be accurately accounted for at any given point in time, 
the ITV represents the worst case scenario and is therefore getting the full prescription dose and is 
not included in normal tissue constraints.  The PTV however, does include normal tissue in its 
margins.  Therefore some of the constraints will still require portions of the PTV to be included as 
normal tissue.  Normal tissues are sensitive to radiation and the chances of acute or late side effects 
occurring are dependent on the dose that is given to the tissue.  Different tissues respond to different 
ways to radiation damage, depending on their genetic makeup, capacity for oxygenation and their 
cell cycle.  The normal tissues tolerances from RTOG 1021, [86] are listed in table 2.2. 
 
3.8  <5.5 <6.5 <50.0 <57.0 >.75 >.65 
5.6 <5.3 <6.25 <50.0 <57.0 >.75 >.65 
7.4 <5.1 <6.0 <50.0 <58.0 >.75 >.65 
10.3 <4.9 <5.9 <50.0 <58.0 >.75 >.65 
17.6 <4.6 <5.6 <53.0 <60.5 >.75 >.65 
22 <4.5 <5.5 <54.0 <63.0 >.75 >.65 
28 <4.4 <5.4 <56.0 <65.5 >.75 >.65 
34 <4.3 <5.3 <58.0 <68.0 >.75 >.65 
50 <4.0 <5.0 <62.0 <77.0 >.75 >.65 
70 <3.5 <4.8 <66.0 <86.0 >.75 >.65 
95 <3.3 <4.4 <70.0 <89.0 >.75 >.65 
126 <3.1 <4.0 <73.0 <91.0 >.75 >.65 
Table 2.1 – Acceptable High and Intermediate Dose Spillage Guidelines [86] 
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OAR Volume (cm2) Volume Max 
(Gy) 
Max Point Dose* 
(Gy) 
Endpoint (≥Grade 3) 
Spinal Cord <0.35  18.0  21.9  myelitis 
<1.2  12.3  
Oesophagus <5  17.7  25.2 Stenosis/fistula 
Brachial Plexus <3  22  26 neuropathy 
Heart/Pericardium <15  24  30  pericarditis 
Great Vessels <10 39  45  aneurysm 
Trachea  <5  15  30  Stenosis/fistula 
Rib  <5  40  50  Pain or fracture 
Lung (Rt and Lt) 1500 10.5  Basic Lung Function 
Lung (Rt and Lt) 1000 11.4   Pneumonitis 
CW 30 30  Chest Wall Pain 
Skin <10 30  33  Ulceration 
Table 2.2 – Normal tissue tolerances for 3 fraction SABR [86] 
*Max point dose is defined as a volume of 0.035 cm3.   
 
2.6.5 Planning Priorities 
 
Generally, attempts should be made to adhere to all constraints, including tumour coverage and 
normal tissues constraints. Due to the nature and delivery of lung SABR, the high daily doses 
required for tumour control may lead to normal tissue tolerances (table 2.1) being exceeded.  For this 
reason, there are a set of guidelines [86] that list in order of priority which can constraints should be 
met;   
 
1. Meet the spinal cord and brachial plexus dose constraints 
2. Meet the “dose compactness” constraints including the high dose conformity constraint, 
D2cm and R50% 
3. Meet organ at risk constraints other than the spinal cord 
 
These rules differ dramatically from those used in conventional planning.  The organ at risk 
constraints are last in priority, other than the spinal cord and brachial plexus, because these values 
are the least validated from phase 1 trials.  It is suggested that if both the OAR and dose compactness 
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constraints (D2cm and R50%) can’t be met, then the dose compactness constraints (without deviation) 
take priority, even at the expense of normal tissues (except spinal cord and brachial plexus) having 
acceptable deviations.  One acceptable deviation is when normal tissue abutting the PTV is allowed 
a maximum dose of 105% of the prescription dose.  However, the volume constraint must still be 
adhered to.  For example, for a PTV overlapping or adjacent to a rib, then the rib is able to receive a 
maximum dose of 56.7 Gy, but no more than 40 Gy to 5 cm3.  Another example is where a minor 
violation of the intermediate dose constraints is allowed, if an abutting normal tissue constraint is 
over tolerance [86].   
2.7 IMAGE GUIDED RADIATION THERAPY 
Due to the delivery of highly ablative fractionation, the importance of the use of isocentre 
verification cannot be overstated.  The use of in-room imaging, known as cone-beam computed 
tomography (CBCT) is an essential part of SABR.  CBCT allows for better soft tissue contrast than 
other forms of in-room imaging such as MV electronic portal imaging.  It has been reported that 
soft-tissue matching for CBCT is integral to safe delivery of SABR as the use of bony landmarks for 
treatment localization can result in erroneous results [87].  Such is the importance of CBCT, trials 
such as CHISEL [88] stipulate the use of 3 CBCTs per treatment in order to monitor intrafraction 
motion.  These images are taken before treatment, mid-way through treatment and after treatment.  
Due to the large number of beams required for safe delivery of SABR, the treatment time can be 
quite extensive, which results in long treatment times.  It is reported that >34 minutes on the 
treatment couch can result in intra-fractional shifts of >5mm [87].  This is why the use of 3 CBCTs 
during treatment has been employed.   
 
2.8 TREATMENT DELIVERY TECHNIQUES  
2.8.1 3DCRT 
3-Dimensional conformal radiation therapy is the most commonly used treatment method used for 
RTOG trials [82-84, 86] to deliver lung SABR.  For hypofractionated techniques the number of 
beams required dramatically increases due to the higher daily dose and the importance placed on 
daily dose to normal tissues [89].  It has been reported that coplanar and non-coplanar beam 
arrangements consisting of between 7-11 beams can be used to satisfy all dose constraints for 
hypofractionated lung treatments. However, the European Organisation for Research and Treatment 
of Cancer (EORTC) recommends the use of only coplanar beams, and only if dose constraints 
cannot be met then the use of non-coplanar beams is suitable.  This is due to tumour motion during 
SABR, and increased treatment time results in the likelihood of greater intra-fraction motion [87, 
90].   
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However, when investigating low doses, coplanar beams may increase “dose bathing” (increased 
volume of low and intermediate doses) and a non-coplanar beam approach can have fewer 
deviations from recommended protocols [91].  Lim et al [91] report that all beam arrangements with 
5, 7, 9,11, 13 or 15 beams either coplanar or non-coplanar, satisfied high dose and organ at risk 
constraints, but non-coplanar beams were required to reach the low (intermediate) dose constraints.  
Similarly Fakiris et al [92] report on using 10 -12 non-coplanar, non-opposing beams to achieve 
SABR constraints.  However, both these articles do not account for tissue heterogeneity in the 
planning dose calculation which Xiao et al [93] reported on the importance of.  
 
Although it may increase the dose bathing, Richmond et al, propose using a 7 field technique with an 
equal beam spacing of 50°, in an effort to reduce the number of beams that overlap on the skin 
surface, and decrease the risk of erythema [94].  They report that a 7 field technique was suitable for 
17 out of 19 patients with two or fewer high and intermediate dose constraint minor deviations per 
plan.  However, the dose constraints used in this study were from the ROSEL protocol [95], which 
have a more generous approach to D2cm (Gy) and R50% (ratio) constraints.  When these plans are 
critiqued against the RTOG protocol, then there would be more deviations from protocol.  
Richmond et al [94] detail that a direct comparison between their work and other work is misleading 
as earlier work [91] does not account for tissue heterogeneity, whereas the current study does.  
Furthermore, they state the difference between RTOG 0236 and their study changes the “goal posts”.  
RTOG states a R50% deviation of less than 3.4-4.4, whereas with ROSEL, the deviation constraint is 
6-12 for the corresponding PTV size.  However, Xiao et al [93] evaluate the changes observed when 
the heterogeneity correction was applied to RTOG 0236.  Where a previous value of 3.4 would have 
been a deviation, it is changed to approximately 4.0, with heterogeneity correction due to the 
differences in secondary electron transport.  This change in value is much different to the ROSEL 
study of 6.   
 
Increasing the beam number to 9 or more static non-coplanar beams is reported to comply with 
organ at risk tolerances when delivering 60Gy in 8-10 fractions [96-99].  The Department of 
Radiation Oncology, Washington University School of Medicine describes a minimum of 7 non-
coplanar, non-opposing beams as their protocol [100, 101] with another group reporting the use of 
up to 20 non-coplanar beams for treatment of NSCLC [102].  Brock et al [103] describes significant 
differences in recommended beam arrangements depending on to the tumour location.   
 
Finally, the reasoning behind the use of a larger number of beams is due to the effect of congregating 
multiple beams at the isocentre.  This creates a highly conformal dose distribution around the PTV 
with a steep dose gradient at the margin of the volume, thus reducing dose to normal tissue, in 
particular the lung and chest wall [99, 104].  Ding et al [79] report using 10 beams with 6 or more 
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non-coplanar.  This beam arrangement is reported to satisfy dose conformity and constraints.  
Verbakel et al [80] describe that their 10 field non-coplanar technique is better at conforming the 
high doses to the PTV.  Furthermore they reported reduced incidence of reduction in rib fractures 
compared to reported studies that only use 4 to 6 non-coplanar beams.   
 
2.8.2 IMRT 
Intensity modulated radiation therapy (IMRT) is the delivery of dose using a non-uniform radiation 
fluence [105].   The literature on IMRT for lung SABR is relatively scarce and not well defined.  
However, it is reported that IMRT, like 3DCRT, can utilize coplanar and non-coplanar beams for 
hypofractionated treatment of lung cancer.  The Netherlands Cancer Institute, reports a predefined 
class solution of either 9 coplanar IMRT beams or 12 to 16 non-coplanar beams, attempting to 
minimize segment overlap on the skin.  [106].  They reported on average, a better R50% value for the 
non-coplanar IMRT when compared to coplanar IMRT. The Cleveland Clinical Foundation have 
also reported a SABR planning approach that uses an average of 7 non-coplanar, non-opposing 
inversely planned beams [107].  However, no clear reasoning or beam arrangement comparison was 
given.   
 
Le et al [108] report using 6-8 non-coplanar IMRT beams for their lung SABR technique.  No 
gantry angles were specified, the number of segments per beam was limited to 5, to reduce the 
interplay effect.  Furthermore, Kim et al [109] report using on average 6.4 IMRT fields for lung 
SABR.      
 
A reason for the lack of literature on IMRT for lung SBRT could be due to the concern of leaf 
interplay.  The interplay effect, as described by Yu et al [71] is the combination of a dynamic 
intensity modulated beam, coupled with the internal organ motion of the patient.  As the intensity 
modulated beam is planned using a single free breathing respiratory phase, the intensity modulation 
is planned on the GTV, and therefore a more dense tissue at a specific point in the lung tissue.   The 
GTV is in the same spot for the entire calculation, whereas for treatment, the GTV will be moving 
due to respiration.  This group reports that the mechanistic interplay of the GTV and the beam can 
cause large errors in the delivered dose, for clinical realistic organ motion.  Wu et al [110] describe a 
difference of 20 % in calculated dose to delivered dose for liver SABR.  Although they experienced 
these differences with liver SABR, the same principles could be applied for lung, especially those 
close to, or on the diaphragm.  There are however, recent investigations that utilize volumetric 
modulated arc therapy (VMAT) [111-113] that refute any interplay effect for lung SABR.  
Furthermore, the lack of IMRT papers may also be due to the fact that 3DCRT is able to deliver the 
desired plan, in a timely manner compared with IMRT, and therefore would only be used to achieve 
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OAR tolerances in certain plans [80].  There are some suggestions from the Advanced Radiation 
Therapy Committee of the International Association for the Study of Lung Cancer, that IMRT is 
more beneficial in centrally located tumours, firstly due to the improved ability to spare adjacent 
normal tissues and secondly because central tumours tend to not move as much as peripheral 
tumours the concern over MLC interplay is negated. 
 
2.8.3 VMAT 
Volumetric Modulated Arc Therapy (VMAT) is similar to IMRT in that it is inversely planned, but 
instead of delivering the radiation using static fields, VMAT involves the continuous delivery of 
dose while the linear accelerator rotates around the patient.  Furthermore there is the ability to vary 
dose rate and gantry speed during treatment [114].   
 
An advantage that VMAT has over IMRT is that it is not a fixed angle technique, so the challenge of 
selecting optimal fixed gantry angles is somewhat eliminated [115].  However, caution needs to be 
applied, making sure normal tissues are not receiving unwanted, avoidable dose.  To avoid 
overdosing normal tissue, one available option is partial arcs.  For example, it is reported that 2 
partial arcs are created with a 204° degree rotation [116].  The first rotation is counter-clockwise 
from gantry angle 179°-335°, then a second clockwise arc from 335°-179° was used to limit dose to 
the contralateral lung parenchyma.  This beam arrangement is for a left sided lung tumour, but the 
arc angles are mirrored for a right sided tumour [116].  Although Chan et al [116] did not treat using 
SABR, the philosophies of reducing dose to the contra-lateral lung are the same.  Similarly Le et al 
[108] use a 200° degree arc, using a gantry spacing of 4° between arc control points (segments).  A 
control point or segment is the term of reference given to the positions of the MLCs during an IMRT 
or VMAT delivery.  It defines how many times the MLCs have to move to produce a different shape 
for each IMRT beam or VMAT arc [115]. 
 
Other studies [103, 117] have described using full (>358°) arcs for treatment.  Verbakel et al [80] 
also noted that due to the higher fractional dose, multiple deliveries of the same arc may be required, 
as their machine limitations required each arc to have less than 999 monitor units (MU) and in some 
cases they report using up to 5 full arcs.  The William Beaumont Hospital, initially used an arc of 
360°, however, after careful consideration and attempts to lower doses to the contra-lateral lung, 
changed to a partial arc protocol of 180°.  The start and stop angles are manually chosen to 
maximize tumour coverage while reducing dose to the contra-lateral lung [118].   
 
Holt et al [106] describe a dual partial arc technique for delivery of an 18 Gy per fraction lung 
SABR plan.  Arc lengths of between 180°-264° are used to reduce dose to the contra-lateral lung.  
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Similarly to Le et al, this group also describe using a final gantry spacing of 4° as there was no 
appreciable improvement in the plan if the final resolution is less than 4°.  The SmartArc algorithm 
in Pinnacle3 (Stockholm, Sweden) separates an arc into separate control points, similar to those 
control points on a sliding window fixed gantry IMRT technique.  This gantry spacing feature tells 
the planning system at what angular separation the control points are to be placed.  Over a 360° arc, 
a gantry spacing of 4 degrees will give 91 control points (starting gantry angle also has a control 
point).  The smaller the gantry spacing, the more control points per arc, and higher the degree of 
beam modulation.  As SABR is delivered using high doses to generally, cylindrical structures, highly 
modulated beams are not a necessity.     
 
Flattening filter free (FFF) techniques are becoming a much published area of interest with lung 
SABR.  Conventionally, there is a tungsten flattening filter in the head of the machine to flatten and 
harden the beam, essentially flattening the dose profile.  However, with new techniques such as 
IMRT and VMAT, the beam is being modulated and unflattened.  Rather than flattening a beam, and 
then un-flattening, the FFF technique removes the filter from the beam, which consequently allows 
dose rates of up to 2400 Mu/min, decreasing treatment times for patients [119].  At the time of this 
study the Princess Alexandra Hospital was not currently equipped to deliver these treatment 
techniques, therefore they have not been included in this study.  
 
2.9 TREATMENT TIMES 
The extended treatment time for lung SABR is one of the main motivations for this thesis.  The 
ability to reduce treatment times will mean less chance of intra-fraction motion.  Purdie et al [87] 
reports that for treatment times >34 minutes the difference in mean tumour position increases from 
2.2 mm to 5.3 mm.  As the expansion on the PTV is only 5 mm, the tumour deviation caused by 
extended treatment times needs to be reduced.  In regards to 3DCRT, Ong et al [97] report on 
average a treatment time of 11.6 minutes for a 10 field non-coplanar technique.  They also report 
that for coplanar IMRT and full arc VMAT treatment times were 12 minutes and 10.5 respectively.  
However, their VMAT plans required, in some cases, multiple copies of the same beam due to 
limitations of 999 monitor units per arc.  As 18 Gy is delivered per fraction, even with no shielding 
or compensation, the minimum number of monitor units would be 1800.  McGrath et al [118] report 
that for 7 – 10 non-coplanar 3DCRT beams that a mean treatment time of 11 minutes, 56 seconds 
can be achieved for the delivery of 12 Gy per fraction.  Conversely the treatment time for 180 degree 
partial VMAT arc was 6 minutes, 9 seconds.  For the delivery of 7.5 Gy fraction, reported treatment 
times are 2 minutes and 8 seconds, 12 minutes and 40 seconds and 7 minutes and 45 seconds for 
VMAT, five field non-coplanar and seven field coplanar techniques respectively.  Finally, Holt et al 
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[106] report that full arc VMAT can reduce treatment times for an 18 Gy fraction by up to 70% 
when compared to coplanar and non-coplanar IMRT. 
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3Chapter 3:  Research Question 
3.1 AIM, OBJECTIVES AND RESEARCH QUESTIONS 
This study aimed to determine if IMRT and VMAT give comparable tumour coverage and normal 
tissue sparing when compared to 3DCRT for patients who are diagnosed with early stage NSCLC.  
The hypothesis was that VMAT will give comparable tumour coverage to both IMRT and 3DCRT 
while reducing treatment times for patients.  To achieve this aim, the following objectives were 
investigated; 
 Identified the best treatment planning approach for lung SABR using 3DCRT, by 
examining different numbers of beams and arrangements 
 Identified the best treatment planning approach for lung SABR using IMRT, by examining 
different numbers of beams and arrangements 
 Identified the best treatment planning approach for lung SABR using VMAT, by examining 
different numbers of arcs and arrangements 
 Identify the best treatment planning approach for lung SABR from the tested techniques 
 Developed a standardized protocol for VMAT treatment planning of lung SABR 
 
The study therefore answered the following questions related to the delivery of SABR for lung 
cancer patients; 
 What is the best beam arrangement for lung SABR using 3DCRT, IMRT and VMAT? 
 Can IMRT and VMAT achieve comparable or improved treatment plans when compared to 
3DCRT for lung SABR? 
 Can treatment times for patients be reduced with the use of either IMRT or VMAT for lung 
SABR? 
 Can IMRT and/or VMAT replace 3DCRT as the standard treatment option for lung SABR? 
 
3.2 RESEARCH METHOD 
This study design is a prospective dosimetric comparison of 3DCRT, IMRT and VMAT for the 
treatment of early stage NSCLC patients deemed eligible for SABR. 
 
Because best practice has not yet been established for either 3DCRT, IMRT or VMAT, this study 
was broken into two phases.  Phase 1 compared different beam arrangements within each of the 
three techniques for the first 10 out of 20 patients.  The results from Phase 1 will identified which 
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3DCRT, IMRT and VMAT beam arrangement best adhered to RTOG procotocls.  Each of the 
3DCRT and IMRT plans had six different beam arrangements to compare, and the VMAT had 3 
different arc arrangements to compare (table 3.1). Determining the “gold standards” for each 
delivery technique gives assurance that the overall results from the study were obtained using the 
best possible plans.  Phase 2 of the study then took the best beam arrangements of the nominated 
techniques and compares them against each other for the entire 20 patient dataset.  
 
3.3 STATISTICAL METHODOLOGY 
R statistical software (http://www.r-project.org) will be used to perform statistical analysis.  The 
treatment plans will be compared using a repeated measures ANOVA (parametric test) for 
normally distributed data and the Friedman test (non-parametric test) for non-normally 
distributed data. The Shapiro-Wilk test will used to test the normality of the data.   Post hoc 
tests (paired t-tests for normally distributed data or Wilcoxon signed-rank tests for non-normally 
distributed data) will be performed to confirm where the differences occurred between treatment 
plans when an overall significant difference between treatment plans was demonstrated.  A 
Bonferroni correction will be used to adjust p-values for multiple comparisons.  Statistical 
significance was defined as p≤0.05.  
 
 
3.4 RESEARCH IMPORTANCE AND SIGNIFICANCE 
This study aimed to provide a treatment technique for NSCLC patients that is suitable for lung 
SABR and that is an improvement on current conventional practice. Some departments due to 
technological limitations may not be able to deliver a desired technique; this study will also identify 
all possible treatment technique options, which may benefit a wide number of departments. 
Theoretical – This study outlines the importance that is placed on SABR and how delivery is a 
complex process.  It outlines the possible beam arrangements that can be achieved with either 
3DCRT, IMRT and VMAT and allows radiation oncology departments to make informed decisions 
about best practice. 
Practical – This study aims to provide the Princess Alexandra hospital with an evidence based 
protocol for delivering lung SABR.  It will aim to provide the best possible treatment technique, 
either 3DCRT, IMRT or VMAT that can be delivered safely and effectively in the shortest amount 
of time.  In summary this study will determine a method for treating lung SABR patients in an 
attempt to standardise current practice. 
3.5 STRUCTURE OF THESIS 
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 A review of the literature was performed to determine what current treatment techniques are being 
used to deliver lung SABR.  Paper 1 (chapter 4) investigates the first phase of this project and 
compares 6 different 3DCRT beam arrangements for lung SABR for ten patients.  The objective of 
this article is to determine the optimal 3DCRT beam arrangement for lung SABR to compare against 
the optimal IMRT and VMAT techniques. Chapter 5 is the comparison of the 6 different IMRT 
techniques for phase 1 of the project.  It aims to determine which IMRT technique is the most 
optimal for lung SABR delivery.  Paper 2 (chapter 6) investigates the first phase of this project and 
compares 3 different VMAT beam arrangements for lung SABR for ten patients.  The objective of 
this article is to determine the optimal VMAT beam arrangement for lung SABR to compare against 
the optimal 3DCRT and IMRT techniques. Paper 3 (chapter 7) investigates the main aim of this 
thesis.  It compares the best 3DCRT, IMRT and VMAT techniques against each other to determine 
the optimal delivery technique for lung SABR that can be delivered in the quickest treatment time. 
The discussion (chapter 8) brings together the entire project and pitches itself against current 
literature on lung SABR.  The conclusion summarizes the main findings of the project and provides 
recommendations for implementing lung SABR in a clinical setting. 
 
Table 3.1 – Layout of Study 
PHASE 1 (10 Patients) 
3DCRT IMRT VMAT 
6 different beam 
arrangements 
6 different beam 
arrangements 
3 different arc arrangements 
PHASE 2 (10 Patients) 
3DCRT IMRT VMAT 
Best Beam Arrangement 
from Phase 1 
Best Beam Arrangement 
from Phase 1 
Best Arc Arrangement from 
Phase 1 
Chapter 4:  Paper 1 - The effect of beam arrangements and the impact of non-coplanar beams on the treatment 
planning of stereotactic ablative radiation therapy (SABR) for early stage lung cancer Page 42 
© 2016 FITZGERALD Page 42 
4Chapter 4:  Paper 1 - The effect of beam 
arrangements and the impact of non-coplanar 
beams on the treatment planning of 
stereotactic ablative radiation therapy 
(SABR) for early stage lung cancer 
All authors were responsible for manuscript revisions and provided changes and guidance on 
multiple occasions.  For the project, author’s contributions are as follows: Rhys Fitzgerald, the 
primary author was responsible for the project design, planning the SABR plans, analyzing the 
data and preparing the manuscript for author review.  Dr Rebecca Owen was instrumental in the 
design of the project and data analyses and was a constant source of mentorship during the 
process.   Tamara Barry and Cathy Hargrave provided planning consultation and reviewed all 
the plans for the project to ensure that they satisfied protocols as per the manuscript.   Drs Pryor, 
Mai and Lehman provided a clinical perspective for the project design and data analyses.  Anne 
Barnard provided statistical support for the project and aided in presenting the data provided.  
Dr Andrew Fielding played an important role in project design, data analysis and mentorship 
during the project. 
Published: Journal of Medical Radiation Sciences - Article first published online: 14 JUL 
2015, DOI: 10.1002/jmrs.118 
Author names and affiliations. 
Rhys Fitzgeraldab*, Rebecca Owenc, Tamara Barrya, Cathy Hargravec,  David Pryord, Anne 
Bernarde, Margot Lehmand, Tao Maid and Andrew Fieldingb  
 
aDivision of Radiation Therapy, Princess Alexandra Hospital, Woolloongabba, Queensland, 
Australia 
bScience and Engineering Faculty, Queensland University of Technology, Brisbane, 
Queensland, Australia 
cRadiation Oncology Mater Centre, South Brisbane, Queensland, Australia 
dDepartment of Radiation Oncology, Princess Alexandra Hospital, Woolloongabba, 
Queensland, Australia 
eQFAB Bioinformatics, The University of Queensland, Queensland Bioscience Precinct, 
Queensland, Australia 
 
Corresponding author. 
*Rhys Fitzgerald Tel.: +61 7 3176 6509 
E-mail address: rhys.fitzgerald@health.qld.gov.au 
Address:  Level G, Building 1, Princess Alexandra Hospital, Woolloongabba, QLD 4102 
Chapter 4:  Paper 1 - The effect of beam arrangements and the impact of non-coplanar beams on the treatment 
planning of stereotactic ablative radiation therapy (SABR) for early stage lung cancer Page 43 
© 2016 FITZGERALD Page 43 
 
Abstract 
Introduction: The aim of this study was to compare various coplanar and non-coplanar 3-
dimensional conformal radiation therapy (3DCRT) beam arrangements for the delivery of 
stereotactic ablative radiation therapy (SABR) to patients with early stage lung cancer, based on 
the dosimetric criteria from the Radiation Therapy Oncology Group (RTOG) 1021 protocol. 
Methods: Ten medically inoperable lung cancer patients eligible for SABR were re-planned 
using 3 different coplanar and 3 different non-coplanar beam arrangements.  The plans were 
compared by assessing planning target volume (PTV) coverage, doses to normal tissues, the 
high dose conformity (conformity index) and intermediate dose spillage as defined by the D2cm, 
(the dose at any point 2cm away from the PTV), and the R50% (the ratio of the volume of half the 
prescription dose to the volume of the PTV).   
Results:  60 plans in total were assessed.  Mean PTV coverage with the prescription isodose was 
similar between coplanar (95.14%) and non-coplanar (95.26%) techniques (p=0.47). There was 
significant difference between all coplanar and all non-coplanar fields for the R50% (p=<0.0001) 
but none for the D2cm (p=0.19). The 7 and 9 field beam arrangements with 2 non-coplanar fields 
had less unacceptable protocol deviations (10 and 7) than the 7 and 9 field plans with only 
coplanar fields (13 and 8). The 13 field coplanar fields did not improve protocol compliance 
with 8 unacceptable deviations.  The 10 field non-coplanar beam arrangement achieved best 
compliance with the RTOG 1021 dose criteria with only 1 unacceptable deviation (maximum 
rib dose).   
Conclusion:  A 3DCRT planning technique using 10 fields with ≥6 non-coplanar beams best 
satisfied high and intermediate dose constraints stipulated in the RTOG 1021 trial. Further 
investigations are required to determine if minor protocol deviations should be balanced against 
efficiency with the extended treatment times required to deliver non-coplanar fields and if 
treatment times can be improved using novel intensity modulated techniques.  
Keywords: 
Stereotactic Ablative Radiation Therapy (SABR) 
Lung Cancer  
3-Dimensional Conformal radiation therapy (3DCRT) 
Dosimetry 
Treatment Planning 
 
Introduction: 
Lung cancer is the fifth most common cancer in Australia but the most common cause of cancer 
related deaths.[1]  The majority of patients diagnosed with early stage (I/IIa) non-small cell lung 
cancer (NSCLC) are able to undergo surgical resection.  However, 33% of patients present with 
co-morbidities that make them unfit for surgery. [120] For these patients local failure following 
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conventionally fractionated external beam radiation therapy is in the order of 40% and treatment 
involves 20 to 30 attendances over 4 to 6 weeks.[22]  Stereotactic ablative radiation therapy 
(SABR) has emerged as an alternative treatment option capable of delivering a higher 
biologically effective dose (BED) resulting in higher local control rates in excess of 85%. [99, 
120-122] SABR involves the delivery of hypo-fractionated schedules of >7.5 Gy per day in 1-5 
fractions, typically to a BED10 of >100 Gy.[48]  SABR utilises advanced immobilisation, 
motion management and image guidance systems and utilises complex planning techniques to 
achieve highly conformal, ablative doses with rapid dose fall off outside the planning target 
volume (PTV).[35, 90, 123]   
 
Dosimetric parameters such as high and intermediate dose constraints have been established in 
an attempt to quantitatively describe the quality of SABR plans in regards to dose fall off and 
conformity.  The high dose constraint refers to the conformity of the prescription isodose to the 
PTV, measured using the conformity index (CI).  The intermediate dose constraints refer to both 
the maximum dose to any point 2 cm from the edge of the PTV (D2cm) and the ratio of the 
volume encompassed by the 50% isodose line (relative to the prescription dose) to the volume 
of the PTV (R50%).  These planning quality metrics have been integrated into Radiation Therapy 
Oncology Group (RTOG) trial protocols evaluating lung SABR.[82-84]  The high and 
intermediate dose constraints are important dose metrics as a rapid dose fall-off minimizes 
toxicity. [36] 
 
Several groups have reported on their experiences with SABR beam arrangements that were 
required to meet the high and intermediate dose constraints.[91, 92, 94]   Both Lim et al and 
Fakiris et al report on using multiple non-coplanar beams to achieve SABR constraints. [91, 92]  
However, Richmond et al  report that in 17 out of 19 cases, 7 equidistant coplanar fields 
produced no more than 2 minor deviations. [94]  This group however used high and 
intermediate dose constraints from the ROSEL study [95], which are more relaxed than those of 
RTOG.  Furthermore, both Lim et al  and Fakiris et al  did not apply tissue heterogeneity 
corrections, which when reported by Xiao et al, is shown to change the value of an acceptable 
and unacceptable protocol deviation. [91], [92], [93] The present study was therefore designed to 
compare different beam arrangements (coplanar and non-coplanar) for lung SABR taking into 
account heterogeneity correction to determine which best satisfies RTOG 1021 dosimetric 
criteria. 
 
Methods and Materials: 
Patient selection 
Institutional ethical approval was granted for ten patients that had previously received treatment 
for lung cancer at the Princess Alexandra Hospital and who met the SABR eligibility criteria to 
be randomly identified from our local radiation oncology information system database.  Patient 
eligibility was defined as early stage (IA/B or IIA), with the planning target volume (PTV) 
<5cm in the largest dimension and the gross tumour volume (GTV) >2cm away from the 
proximal bronchial tree.   
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Simulation  
All patients had been positioned in the supine position with their forearms above head in a 
Civco® (Iowa, USA) Vac-lok cushion.  All patients had a 4-dimensional computed tomography 
(4DCT) scan with 10 respiratory phase bins created.   A free breathing scan with a 2mm slice 
thickness was obtained with the length including the entire lung volume and exported and 
registered to the 4DCT in Pinnacle v9.4 (Philips Medical Systems, Stockholm, Sweden).  The 
free breathing scan was nominated as the primary data set for planning purposes.  The GTV was 
contoured on each of the respiratory phases and then combined to create an internal target 
volume (ITV).  The PTV was created by expanding the ITV 5mm isotropically.  In addition, the 
organs at risk (OAR) were contoured and their constraints are listed in table 1. The chest wall 
was defined as a 2 cm expansion anteriorly, posteriorly and laterally on the ipsilateral lung, 
excluding the mediastinum, vertebral body and sternum.  A 2cm expansion of the PTV was used 
to create the D2cm.  All reported doses are to a minimum clinically relevant measurable volume 
of 0.03 cm3. 
 
Dose prescribing 
Patients were planned to receive a prescription dose (PD) of 54 Gy in 3 fractions at the 
periphery of the PTV.  Dose was prescribed so the covering (prescription) isodose fell between 
59-90% of the absolute maximum dose in the plan as recommended by RTOG.[79, 82-84]. PTV 
coverage was required to be >95% for the prescription dose (PTV54Gy), and >99% for 90% of 
the prescription dose (PTV48.6Gy). All D2cm and R50% constraints (RTOG 1021) are relative to 
PTV size (table 2) and were interpolated as required for each patient.  In this study, the CI was 
calculated using equation 1, 
 
 
 
 
where TVPTV is defined as the total volume of PTV covered by the covering isodose (54Gy), TV 
is defined as the total volume of the PTV and PIV is defined as the total volume of the covering 
isodose in the patient [124].  A CI value of ≥0.75 was desirable, with ≥0.65 constituting an 
acceptable deviation and anything <0.65 was considered unacceptable.   
Treatment planning 
All plans were constructed by a single planner and calculated with Pinnacle v9.4 using the 
collapsed cone convolution (CCC) algorithm with a grid spacing of 0.25 cm3.  The CCC 
algorithm is a type B algorithm and accounts for changes in lateral electron transport and should 
therefore be used for lung tumour treatments.  As large differences are noted in calculations, the 
dose prescription and spillage guidelines (table 2) that were calculated using a type A or water 
based algorithm (0236) should not be used when using a type B algorithm. 8, 19  As a consensus 
does not exist in the literature, beam arrangements were derived from multiple sources to 
PIVTV
TVPTV
*
)( 2
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account for a wide range of recommendations. RTOG recommends the use of 7 beams as a 
minimum, where as a retrospective review of local departmental preference showed 9 beams, 
including 2 non-coplanar beams was typical.  Furthermore, the use of 10 beams, with six being 
non-coplanar is recommended by Ding et al, while the European Organisation for the Research 
and Treatment of Cancer (EORTC) recommend against non-coplanar beams due to the 
associated increase in treatment times. [79, 90] Lastly a 13 field evenly spaced all coplanar 
arrangement was also investigated to assess if number of coplanar beams, or non-coplanar 
beams improves plan quality.  Treatment plans investigated in this study therefore included: 7 
coplanar beams (7C), 9 coplanar beams (9C), 13 coplanar beams (13C), 7 beams including 2 
non-coplanar beams (7NC), 9 beams including 2 non-coplanar beams (9NC) and 10 beams with 
6 or more non-coplanar beams (10NC).  Starting beam angles for a right-sided tumour where G 
represents gantry and angle and F represents floor angle were; 7C technique, G180, G210, 
G240, G270, G300, G330 and G10, all with a floor of 0 (F0), the 9C technique, G180, G210, 
G240, G270, G300, G330 and G10, G40, G100 all with a floor of 0 (F0), the 7NC technique, 
G210F0, G330F90, G240F0, G270F0, G300, G330 and G30F90, the 9NC technique G210F0, 
G330F90, G240F0, G270F0, G300, G330 and G30F90, G40F0 and G100F0.  The 10NC used 
beam angles as referenced by Ding et al [79] and the 13C technique used 13 evenly spaced 
beams around 360° with a floor of 0. Beam angles were adjusted as necessary to achieve 
protocol compliance.  Angles were mirrored for a left sided tumour. All beam angles were 
checked for clearance on the treatment machine. 
 
Every attempt was made to ensure the 7C field techniques used beam angles entering only 
through the ipsilateral lung to avoid unnecessary exposure of the contra-lateral lung to radiation.  
However, the 9C field technique required beams entering through the contra-lateral to avoid 
overlapping beams and consequently increasing the low and intermediate dose wash.  Two 
coplanar beams in the 7C and 9C techniques were made non-coplanar for the 7NC and 9NC 
techniques.  These were typically superior anterior and superior posterior oblique fields.  The 
10NC technique used 6 non-coplanar beams and only introduced more non-coplanar beams if 
the D2cm or R50% values were unachievable.  Beam weights were manipulated by the planner to 
achieve isotropic dose fall off in accordance with criteria listed in table 2, apart from the 13C 
technique, where each beam was given equal weighting and only adjusted if OAR were over 
tolerance.  PTV coverage below 95% was only allowed if the spinal cord or brachial plexus 
constraints could not be met. 
 
A structure for creating a block margin was created by shrinking the PTV 2mm laterally, 
anteriorly and posteriorly and expanding 2mm superiorly and inferiorly.  The multi-leaf 
collimator (MLC) shielding of each beam was then shaped to the structure.  This structure was 
adjusted as necessary to achieve PTV coverage and a prescription isodose between 59-90%.  
The block margin structure results in the MLC shielding the periphery of the PTV such that the 
prescription isodose falls into the beam penumbra, allowing for a steep dose gradient beyond the 
PTV.  An expansion superior and inferior to the block margin structure was needed to account 
for limitations of non-coplanar beams.  Even though non-coplanar beams are used, most of the 
dose is still delivered across the transverse plane.  Dose in all plans was normalized to the 
maximum dose in the plan which was generally located in the centre of the PTV. 
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Planning Priorities and Protocol Deviations 
Planning priorities were first and foremost, to adhere to the spinal cord and brachial plexus 
constraint, secondly to meet the high and intermediate dose constraints and lastly to meet the 
remaining OAR constraints. [86]  The RTOG 1021 protocol defines plan deviations as either 
being none or acceptable, with an unacceptable deviation for plans that exceeds the acceptable 
deviation.  With all plans, every attempt was made to achieve the no deviation values (table 2).  
However, some situations resulted in unavoidable digression from the priorities.  For instance, if 
an OAR is immediately adjacent to the PTV, then adhering to the maximum dose constraint 
could be challenging.  In this instance the maximum dose to the adjacent OAR can be105% of 
the prescription dose and registering as an acceptable deviation.  However, all volumetric dose 
constraints to the structure must still be respected.  Furthermore, to avoid clinical toxicity due to 
overdosing OAR, the dose fall off may be weighted so it is not isotropic, but still falls within the 
acceptable deviation.  Plans were considered clinically suitable if there were no unacceptable 
deviations from protocol. 
To represent protocol deviations with respect to the D2cm and R50% constraints, a scoring system 
was devised.  As intermediate dose constraints are dependant on PTV size, mean D2cm and R50% 
for each planning technique would not best represent the cohort.  Therefore, the absolute 
difference (if any), from the no deviation constraint was calculated.  For example, if the no 
deviation constraint for D2cm was 30 Gy, and the technique achieved 32 Gy, then this would 
result in a value of 2.  Conversely, if another technique achieved 29.5 Gy at D2cm, this would 
give a value of -0.5.  Therefore, a D2cm or R50% value of 0 represents compliance with a no 
deviation.   
Statistical methodology 
Statistical analyses was performed using R statistical software (http://www.r-project.org).  To 
compare coplanar and non coplanar arrangements statistical tests for paired data were performed 
with the normality of the data tested using the Shapiro-Wilk test. The paired Student parametric 
test has been used for normally distributed data and Wilcoxon signed-rank non parametric test 
for non-normally distributed data. Statistical significance was defined as p≤0.05.  
 
 
Results: 
 
Median patient age was 76, with 70% being male.  Median PTV size was 27.5cm3 (22.8 - 
79.1cm3).  In 50% of cases, the PTV was overlapping the chest wall (CW).  There were between 
6 and 8 non-coplanar beams for the 10NC technique.  The 10NC beam arrangement was the 
only technique where the number of non-coplanar beams was varied and the resultant plans met 
the dosimetric criteria.  Across all techniques, only 19 of the 60 plans had no more than 2 minor 
protocol deviations. Total mean monitor units (MU) for the 7C, 9C, 7NC, 9NC, 10NC and 13C 
were 2867.65, 3019.54, 2919.23, 2996.87, 3225.36 and 3088.51 respectively.  The largest 
Chapter 4:  Paper 1 - The effect of beam arrangements and the impact of non-coplanar beams on the treatment 
planning of stereotactic ablative radiation therapy (SABR) for early stage lung cancer Page 48 
© 2016 FITZGERALD Page 48 
difference in monitor units was between the 7C and 10NC with a total of 357.71 MU. Plans 
were delivered at 600 MU/min. 
Protocol Deviations 
A summary of the plan deviations, relative to RTOG 1021 (table 2) is presented in table 3.  
Overall, as the number of beams increased, there were fewer protocol deviations.  Only on one 
occasion was the 10NC beam arrangement unable to produce an acceptable plan.   In this case 
the PTV was overlapping the chest wall by 6.7 cm3 and the maximum dose could not be 
lowered to 56.7 Gy (105%), while maintaining PTV coverage. 
PTV Coverage 
Table 5 reports the PTV coverage for all beam arrangements.  No statistically significant 
difference was found between PTV coverage for coplanar versus non-coplanar techniques 
(p=0.47 and p=0.87 for PTV54Gy and PTV48.6Gy respectively). The median prescription isodose, 
independent of technique was 68% (60.9%-87%).  Median prescription isodoses values and 
ranges were 68.4% (63.8-85.7%), 67.9% (62.2-86.9%), 66.8% (63.2-85.8%), 68.2% (63.3-
86.4%), 62.6% (60.9-87%) and 68.8% (63.3-87%) for the 7C, 9C, 7NC, 9NC, 10NC and 13C 
plans respectively.  Across all techniques, median prescription isodoses were 65.8% for PTVs 
not overlapping the CW, and 74.6% for PTVs overlapping the CW.   
High and Intermediate Constraints 
The recorded D2cm and R50% deviations are reported in table 4.  The D2cm values for combined 
techniques were 1.14 and 0.66 for all coplanar and all non-coplanar arrangements respectively 
with a non-significant p value of 0.19.   Combined techniques recorded a R50% value of 1.06 for 
coplanar, and 0.62 for non-coplanar with a significant p value of <0.0001.  CI values, different 
to D2cm and R50% constraints are independent of PTV size and can be reported as the actual 
value.  The mean CI values are reported in table 5 with no statistically significant difference 
(p=.71).  
Organs at Risk 
Forty-three percent (n=26) of plans had OAR tolerance dose violations, independent of 
technique.  The maximum rib dose was responsible for the majority of protocol deviations.  Five 
patients had PTVs overlapping the chest wall, limiting the rib to a maximum dose of 56.7 Gy.  
For the 7C, 9C, 7NC, 9NC and 13C, the mean maximum rib dose was on average for these 
plans, 60.5 Gy, 60.4 Gy, 60.5 Gy, 59.7 Gy and 60.4 Gy respectively, all of which are over the 
allowed tolerance. When removing patient 8 from the mean, the values for the aforementioned 
techniques are 61.0 Gy, 60.7 Gy, 60.8 Gy, 60.0 Gy and 60.8 Gy respectively. The 10NC 
technique had a mean maximum rib dose of 56.7 Gy (excluding patient 8), the allowable 
tolerance of 105% of the prescription dose. There was however an increase in the lung volume 
receiving 10.5 Gy and 11.4 Gy for the 10NC compared to other techniques.  The results in table 
5 show there was no statistically significant difference in mean lung dose between the coplanar 
and non-coplanar techniques (p=0.68).  
 
Discussion: 
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This study investigated dosimetric factors of various coplanar and non-coplanar beam 
arrangements for the treatment of patients eligible for lung SABR with heterogeneity 
corrections applied. 
There were no significant differences in PTV coverage (PTV54Gy or PTV48.6Gy) between beam 
arrangements, given that they are compulsory protocol requirements and coverage beyond 95% 
was only improved if the D2cm and R50% constraints maintained a no deviation.  The 10NC 
technique had the greatest PTV54Gy coverage of 95.37%, which is on average 0.5% higher than 
any other technique.   
The prescription isodoses for the plans were kept to between 59% and 90% as recommended by 
RTOG and Ding et al.[79, 82-84]  The median prescription isodose value in this study was 68% 
(62.6%-68.7%), which is consistent with previous reports on optimal prescription isodoses for 
peripheral lung SABR. [79] There was a difference in prescription isodoses for plans where the 
PTV was overlapping the CW.  For those plans where PTV was overlapping the CW the 
prescription isodose could be increased from a median value of 65.8% to 74.6%.  This is due to 
the more dense soft tissue adjacent to one side of the PTV and the reduced secondary electron 
range in the tissue.  
Furthermore, without comprehensive rib maximum and dose volume constraints, it is 
considered best practice to minimize the dose where possible. [125-129]  Because plans are 
prescribed in a way so the maximum dose typically falls within the centre of the PTV, those 
patients whose PTV overlaps a rib could have a maximum dose that is well beyond the 105% of 
the PD.  Only the 10NC technique was able to consistently achieve the maximum rib dose 
constraint while still achieving 95% coverage of the PTV (with the exception of patient 8).  This 
is likely due to a greater ability to improve shielding of the rib by increasing the number of non-
coplanar beams coupled with a higher prescription isodose attainable on the chest wall.  
The dosimetric study by Lim et al performed without a tissue heterogeneity correction found 
that increasing the number of non-coplanar beams increased the possibility of achieving 
intermediate dose constraints. [91]  Our study accounted for tissue heterogeneity and confirmed 
that an increase in non-coplanar beams resulted in less protocol deviations.  The greatest 
protocol deviations were found for the 7 and 9 field all coplanar beam arrangements.  There 
were 13 and 8 instances respectively, where these techniques had major protocol deviations 
(table 3).  The 10NC was found to produce the best plan with only one protocol deviation for 
the maximum rib dose on patient 8 (59.1 Gy).   
The dosimetric advantages of using non-coplanar beams has previously been reported, however, 
the results of the current study illustrate that non-coplanar beams are necessary to meet the 
intermediate and OAR dosimetric constraints for any single plan. [81]  We demonstrated that 
there is a statistically significant difference in the volume of the 27 Gy isodose (R50%), for 
coplanar versus non-coplanar techniques. Furthermore, there was no case where any technique 
apart from the 10NC was able to produce a plan with no protocol deviations.  Increasing the 
number of fields (13C) resulted in a slight improvement when compared to either of the 
coplanar and non-coplanar 7 and 9 field techniques with fewer protocol deviations in regards to 
the intermediate dose.  However, it was not able to replicate the intermediate dose sparing 
achievable with the 10NC technique.  Figure 1 demonstrates a dose wash of all 6 techniques 
through the isocentre highlighting the reduction in intermediate dose achievable with the 10NC 
technique. In theory, increasing the number of beams reduces the dose delivered through each 
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beam, spreading out the low dose and overlapping beams, resulting in a lower intermediate 
dose.  This is the philosophy of SABR and allows for a steep isotropic fall off and is shown 
clearly in our study. 
Our findings differ from those reported by Richmond et al where in 89.5% of cases a 7 field, all 
coplanar technique had 2 or less minor deviations. [94]  They too accounted for heterogeneity 
correction, but used the less stringent intermediate dose constraints from the ROSEL trial.[95]  
The difference in intermediate dose constraints between RTOG 1021 and ROSEL significantly 
alters which beam arrangements are deemed acceptable.  All the techniques tested in this study 
had intermediate doses that were acceptable following the ROSEL guidelines.  However, 
following RTOG 1021 criteria we report that a 7 field technique, with beams entering through 
only the ipsilateral lung produced no plans with equal to, or less than 2 minor deviations.  The 
difference in acceptable D2cm and R50% constraints is believed to be the main reason for 
disparity. 
The EORTC recommend avoiding the use of non-coplanar beams as this increases the treatment 
time, and chance of intra-fraction motion [90].  Furthermore, Purdie et al suggest that for 
treatment times >34 minutes intra-fraction motion can increase by up to 5 mm. [87]  The trade 
off between small gains in intermediate dose sparing versus increased treatment time and the 
potential for intra-fractional error with increasing non-coplanar beams should be critiqued on an 
individual patient basis.   
 
Conclusion: 
Increased use of non-coplanar beams for 3DCRT lung SABR allows for improved control of 
intermediate dose objectives and produces fewer protocol deviations when correcting for tissue 
heterogeneity and following RTOG 1021 guidelines.. A technique using 10 beams, six or more 
of which were non-coplanar provided the greatest compliance to high and intermediate dose 
constrains, while lowering doses to some critical structures.  However, increased non-coplanar 
beams results in an increased treatment time that needs to evaluated for each individual patient.  
The ability to deliver adequate PTV coverage and acceptable intermediate doses using coplanar 
techniques may be possible with novel techniques such as intensity modulated radiation therapy 
or volumetric modulated arc therapy and will be the subject of future work. 
 
 Table 4.1 - Organ at risk dose constraint 
Organ Constraint(s) 
Spinal Cord 18 Gy < 0.35 cm3 
12.3 Gy < 1.2 cm3 
MPD < 21.9 Gy 
Brachial Plexus 20.4 Gy < 3 cm3 
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Abbreviations IVC = inferior vena cava, SVC = superior vena cava, ITV = internal target volume, CW = chestwall, MPD = 
maximum point dose (defined as ≥0.03 cm3) 
 
 
 
 
 
MPD < 24 Gy 
IVC 39 Gy < 10 cm3 
MPD < 49 Gy 
SVC 39 Gy < 10 cm3 
MPD < 49 Gy 
Aorta 39 Gy < 10 cm3 
MPD < 49 Gy 
Pericardium 24 Gy < 15 cm3 
MPD < 30 Gy 
Trachea 15 Gy < 4 cm3 
MPD < 30Gy 
Combined Lungs – ITV 11.4 Gy < 1000 cm3 
10.5 Gy < 1500 cm3 
Oesophagus 17.7 Gy < 5 cm3 
MPD < 25.2 Gy 
Rib 40 Gy < 5 cm3 
MPD < 50 Gy 
CW 30 Gy < 30 cm3 (<70 cm3 for tumours on 
the CW) 
Skin 30 Gy < 10 cm3 
MPD < 33 Gy 
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Table 4.2 - Acceptable dose spillage guidelines from RTOG 1021 
Deviation values can be interpolated as required. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ratio of Prescription 
Isodose Volume to the 
PTV 
Ratio of 27 Gy Isodose 
Volume to the PTV R50% 
Maximum Dose at 2 cm 
from PTV in any direction 
as % of Prescribed dose 
(PD). D2cm (gy) = % x PD 
Percent of lung 
receiving 20 Gy total 
of more V20 (%)  
PTV 
Volume 
(cc) 
Deviation  Deviation Deviation Deviation  
None Acceptable None Acceptable None Acceptable None Acceptable  
<1.2 <1.5 <5.9 <7.5 <50.0 <57.0 <10 <15 1.8 
<1.2 <1.5 <5.5 <6.5 <50.0 <57.0 <10 <15 3.8 
<1.2 <1.5 <5.1 <6.0 <50.0 <58.0 <10 <15 7.4 
<1.2 <1.5 <4.7 <5.8 <50.0 <58.0 <10 <15 13.2 
<1.2 <1.5 <4.5 <5.5 <54.0 <63.0 <10 <15 22.0 
<1.2 <1.5 <4.3 <5.3 <58.0 <68.0 <10 <15 34.0 
<1.2 <1.5 <4.0 <5.0 <62.0 <77.0 <10 <15 50.0 
<1.2 <1.5 <3.5 <4.8 <66.0 <86.0 <10 <15 70.0 
<1.2 <1.5 <3.3 <4.4 <70.0 <89.0 <10 <15 95.0 
<1.2 <1.5 <3.1 <4.0 <73.0 <91.0 <10 <15 126.0 
<1.2 <1.5 <2.9 <3.7 <77.0 <94.0 <10 <15 163.0 
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Table 4.3 - Beam arrangements and protocol deviations following RTOG 1021 criteria. 
 
Abbreviations D2cm = dose at any point 2cm from the PTV, R50% = ratio of the volume of half the prescription dose to the volume of 
the PTV, CI = conformity index, OAR = organ(s) at risk  
 
 
 
 
 7C 9C 13C 7NC 9NC 10NC 
D2cm 
None 
Acceptable 
Unacceptable 
 
1 
6 
3 
 
2 
8 
0 
 
6 
4 
0 
 
2 
6 
2 
 
4 
6 
0 
 
10 
0 
0 
R50% 
None 
Acceptable 
Unacceptable 
 
0 
5 
5 
 
1 
6 
3 
 
1 
6 
3 
 
1 
6 
3 
 
1 
7 
2 
 
5 
5 
0 
CI 
None 
Acceptable 
Unacceptable 
 
9 
1 
0 
 
10 
0 
0 
 
10 
0 
0 
 
10 
0 
0 
 
9 
1 
0 
 
9 
1 
0 
OAR 
None 
Acceptable 
Unacceptable 
 
4 
1 
5 
 
4 
1 
5 
 
3 
1 
5 
 
4 
1 
5 
 
4 
1 
5 
 
5 
4 
1 
Total Deviations 
None 
Acceptable 
Unacceptable 
 
14 
13 
13 
 
17 
15 
8 
 
20 
12 
8 
 
17 
13 
10 
 
18 
15 
7 
 
29 
10 
1 
Clinically Suitable Plans 1 2 2 3 3 9 
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Table 4.4 - Mean dose statistics for each technique, categorized into coplanar and non-coplanar 
and mean values for all coplanar and non-coplanar techniques combined with associated P 
values. 
 
Abbreviations PTV54Gy = Percentage of the PTV receiving 54 Gy, PTV48.6Gy = Percentage of the PTV receiving 48.6 Gy, D2cm = dose 
at any point 2cm from the PTV, R50% = ratio of the volume of half the prescription dose to the volume of the PTV, CI = conformity 
index 
 
 
 
 
 
 PTV54Gy 
(%) 
PTV48.6Gy 
(%) 
Mean Lung 
Dose (Gy) 
R50% 
(Deviation) 
D2cm 
(Deviation) 
CI 
Coplanar 
7 Fields 
9 Fields 
13 Fields 
 
95.2 
95.12 
95.09 
 
99.48 
99.59 
99.63 
 
3.91 
4.12 
4.26 
 
1.22 
1.05 
0.91 
 
3.12 
1.16 
-0.86 
 
0.79 
0.80 
0.82 
Non-Coplanar 
7 Fields 
9 Fields 
10 Fields 
 
95.07 
95.12 
95.6 
 
99.58 
99.57 
99.58 
 
4.10 
4.13 
4.38 
 
0.79 
0.71 
0.35 
 
2.06 
0.70 
-0.76 
 
0.80 
0.81 
0.81 
Mean Values 
All Coplanar 
All Non-Coplanar 
P value 
 
95.14 
95.26 
0.47 
 
99.57 
99.58 
0.87 
 
4.01 
4.12 
0.09 
 
1.10 
.62 
<0.0001 
 
1.14 
0.66 
0.19 
 
0.80 
0.80 
0.71 
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Table 4.5 - Mean values for recorded OAR doses for selected OAR categorized by technique 
and all coplanar and all non-coplanar techniques combined. 
 
 
Abbreviations SC = Spinal canal, ITV = Internal target volume, CW = Chest wall, MPD = Maximum point dose 
 
 
 
 
 SC Pericardium 
Combined Lung - 
ITV 
Ribs CW Oesophagus 
Technique/ 
Constraint (Aim) 
18Gy 
(<0.35 
cm3) 
12.3Gy 
(<1.2 cm3) 
MPD 
(<21.9
Gy) 
24Gy 
(<5 
cm3) 
30 Gy 
(<30 
cm3) 
10.5Gy 
(<1500 
cm3) 
11.4Gy 
(<1000 
cm3) 
40Gy 
(<5 cm3) 
MPD 
(<50Gy) 
 
30 Gy 
(<30 
cm3) 
17.7 
Gy 
(<5 
cm3) 
MPD 
(<25.
2 Gy) 
Coplanar 
7 Fields 
9 Fields 
13 Fields 
 
0 
0 
0 
 
0.1 
0.2 
0.3 
 
10.2  
10.6  
12.3 
 
0.4 
0.7 
2.0 
 
18.3 
17.5 
18.3 
 
450.1 
472.9 
465.5 
 
422.0 
438.9 
419.1 
 
1.4 
1.4 
1.5 
 
46.0 
45.6  
45.5 
 
19.9 
19.1 
18.8 
 
0.3 
0.1 
0.0 
 
9.4 
12.3 
14.0 
Non-Coplanar 
7 Fields 
9 Fields 
10 Fields 
 
0 
0 
0 
 
0.1 
0.1 
0.2 
 
8.3 
8.8 
9.9  
 
0.2 
0.4 
0.5 
 
15.9 
15.8 
13.6 
 
453.9 
451.3 
508.9 
 
420.4 
416.5 
461.7 
 
1.5 
1.5 
1.2 
 
45.2 
45.6 
42.6 
 
18.0 
17.4 
15.4 
 
0.2 
0.0 
0.0 
 
9.8 
12.9 
12.4 
Mean Values 
All Coplanar 
All Non-Coplanar 
 
0 
0 
 
0.2 
0.1 
 
11.0  
9.0  
 
1.0 
0.4 
 
18 
15.1 
 
462.8 
471.4 
 
426.7 
432.9 
 
1.4 
1.4 
 
45.7 
44.5  
 
19.3 
16.9 
 
0.0 
0.0 
 
11.9 
11.7 
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Figure 4.1 - Dose wash through a transverse slice for each of the six techniques. A, 7C. B, 7NC. 
C, 9C. D, 9NC. E, 10NC. F, 13C. 
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Abstract 
 
Purpose: The aim of this study was to investigate six different beam arrangements for the 
delivery of intensity modulated radiation therapy (IMRT) to peripheral lung tumours using 
stereotactic ablative radiation therapy (SABR). 
Methods and Materials: Six new IMRT treatment plans were created for 10 patients who were 
deemed eligible for SABR.  Plans consisted of between 7 and 10 beams, with 3 coplanar and 3 
non-coplanar beam arrangements.  These plans were critiqued against dosimetric parameters 
incorporated in the RTOG 1021 protocol including: planning target volume (PTV) coverage, 
dose to organs at risk (OAR), conformity index (CI) and intermediate dose constraints (D2cm and 
R50%).  For statistical calculations, the 3 coplanar and 3 non-coplanar techniques were group 
together. 
Results: 60 plans (30 coplanar and 30 non-coplanar) were generated for comparison. Clinically 
acceptable plans (no unacceptable protocol deviations) were achieved in 10 out of 30 coplanar 
plans and 20 out of 30 non-coplanar plans.  PTV coverage (V54Gy and V48.6Gy) was similar 
between the coplanar (95.2%, 99.97%), and non-coplanar techniques (95.35%, 99.99%) with no 
statistically significant difference found (p=0.64, 0.29).  There was no difference in the CI 
between all coplanar and all non-coplanar techniques (p=0.9).    Non-coplanar techniques 
provided better intermediate dose sparing with a statistically significant difference for the D2cm 
(<0.01) and R50% (<0.01) when compared to coplanar techniques. 
Conclusion:  Non-coplanar IMRT provided better compliance with RTOG 1021 protocol for 
intermediate dose sparing and OAR avoidance. Nine or more treatment fields (either coplanar or 
non-coplanar) are recommended for tumours adjacent to the chest wall. 
 
Introduction: 
 
Lung cancer has a high burden on the Australian population with 1 in 13 men, and 1 in 23 
women expected be diagnosed in their lifetime[130].  Surgical resection is the current standard 
treatment option for the majority of patients.  However, for those patients that are medically 
inoperable or refuse surgery, external beam radiation therapy (EBRT) is a practical alternative.  
EBRT for early stage peripheral lung cancer is more commonly being delivered in the form of 
stereotactic ablative radiation therapy (SABR).  SABR is the delivery of ≥10 Gy per fraction in 
≤5 fractions.  This highly ablative dose regime requires advanced radiation therapy treatment 
planning techniques, which generally involve a high number of non-coplanar beams[131].  
Numerous groups have previously reported on the use of 3-dimensional conformal radiation 
therapy (3DCRT) for the delivery of lung SABR.[91, 94, 131-133] 
 
Intensity modulated radiation therapy (IMRT) is now a well established practice for many 
tumour sites due to its ability to better conform the dose to the tumour, resulting in reduced 
doses to critical structures adjacent to the tumour [134].  However, its use in lung SABR has 
been rarely reported on.  In 2010, Videtic et al [107] report that there were no published reports 
on outcomes of lung SABR treated with IMRT.  Both Ong et al [97] and Holt et al [106] have 
reported on dosimetric indices IMRT for peripheral lung SABR against other delivery 
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techniques.  Ong et al [97]  compared dynamic conformal arc therapy with coplanar 3DCRT and 
only used IMRT for those patients whose tumours where adjacent to the chest wall (CW).  Holt 
et al [106] compared coplanar and non-coplanar IMRT against VMAT. To the best of the 
authors’ knowledge, there is no previous study comparing different beam arrangements for lung 
SABR using IMRT. This study therefore explores six different beam arrangements for the 
delivery of peripheral lung SABR using IMRT.   
 
Material and methods: 
 
Ten patients whose tumours were early stage disease (Ia/b or IIa) measuring <5cm in the largest 
dimension and were >2cm away from the proximal bronchial tree were identified from our 
radiation oncology information system database. The inclusion criteria was as per RTOG 
1021[86].   
 
Patients underwent planning simulation as previously reported.[131] Both a 4 dimensional 
computed tomography (4DCT) and a free breathing CT scan were exported to Pinnacle v9.6 
(Philips Medical Systems, Stockholm, Sweden) for treatment planning.  An internal target 
volume (ITV) was created by contouring the gross tumour volume on each respiratory phase of 
the 4DCT.   A 5mm isotropic expansion was used to generate the planning target volume (PTV) 
from the ITV. All OAR (table 1) contouring and treatment planning was done using the free 
breathing CT scan.   
 
For each plan, 54 Gy in 3 fractions was prescribed to the periphery of the PTV.  Planning aims 
were to achieve >95 % coverage of the PTV with the prescription dose (PTV54Gy) and 99% 
coverage of the PTV with 90% of the prescription dose (PTV48.6Gy).  Maximum doses in the plan 
were allowed not allowed to exceed 90.5 Gy, but were expected to be relatively high (75-85 Gy) 
to achieve a steep dose gradient.  OAR tolerances used were those reported in RTOG 1021 
(table 1).  The D2cm, (the dose at any point 2cm from the PTV), and R50% (the ratio of the 
volume of half the prescription dose to the volume of the PTV) were used to measure 
intermediate dose spillage and protocol deviations (RTOG 1021) and are shown in table 2.  To 
quantify the conformity of the prescription dose to the PTV, the conformity index (CI) was 
used[131], 
 
 
 
 
 
where TVPTV was defined as the total volume of PTV covered by the prescription dose, TV was 
defined as the total volume of the PTV and PIV was defined as the total volume of the 
prescription dose in the patient .  A CI value of ≥0.75 was no deviation, ≥0.65 was an acceptable 
deviation and <0.65 was considered an unacceptable deviation, based on translating the RTOG 
1021 CI constraints (table 2) to this formula.   
 
Each plan was created using the initial set of objectives (table 3) as reported by the authors 
[131]  and other non-target tissue objectives (heart, spinal cord etc.) were contoured and given 
an objective as clinically necessary on a patient by patient basis.  The rationale for beam 
arrangements was derived from previously published reports by Ding et al [79]  and Fitzgerald 
et al [131].  Treatment plans investigated in this study included: 7 coplanar beams (7C), 9 
PIVTV
TVPTV
*
)( 2
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coplanar beams (9C), 13 coplanar beams (13C), 7 beams including 2 non-coplanar beams 
(7NC), 9 beams including 2 non-coplanar beams (9NC) and 10 beams with 6 or more non-
coplanar beams (10NC).  Starting beam angles used were as per Fitzgerald et al [131].  Beam 
angles were adjusted by the treatment planner to achieve target coverage and OAR sparing as 
per protocol.  All beam angles were checked for clearance on the treatment machine.  Standard 
IMRT based physics QA was performed in which planned dose distributions (fluence) were 
measured against actual delivered distributions (fluence) for each field using a gamma analysis 
acceptance criteria of 3%/3mm[74]. 
 
Intermediate doses were limited by two different control structures.  Primarily, a structure which 
consisted of the patient’s body contour minus a PTV expansion of 2cm was used to control the 
dose at D2cm and given a maximum dose objective as per table 2 (27 Gy Ring).  If this structure 
wasn’t able to achieve the R50% constraint (table 2) as well, then another dose limiting structure 
was created.  This structure was typically a 1 cm isotropic expansion of the PTV removed from 
the patient’s body contour, but was altered on an individual patient basis as needed.  A 54 Gy 
ring, a 0.1cm expansion on the PTV, minus the PTV was used to control the prescription dose 
and improve conformity.  Maximum doses in OAR directly adjacent to the PTV were allowed 
to receive up to 105% of the prescription dose.  Planning priorities, in order, were to firstly 
respect the spinal cord constraint, secondly, cover the PTV with 95% of the prescription dose, 
thirdly, adhere to intermediate (D2cm and R50%) dose constraints while generating a steep 
isotropic dose fall off, and lastly to meet non-spinal cord OAR constraints. The number of 
segments was limited to 70 for all 10 beams using the direct machine parameter optimization 
(DMPO) algorithm.  The collapsed cone convolution (CCC) algorithm was used for 
calculations, with a minimum field size of 4cm2, and a grid size of 0.3 cm2. 
 
The R statistical software (http://www.r-project.org) was used to perform statistical analysis.  
The six IMRT treatment plans were compared using a repeated measures ANOVA (parametric 
test) for normally distributed data and the Friedman test (non-parametric test) for non-normally 
distributed data. The Shapiro-Wilk test was used to test the normality of the data.   Post hoc 
tests (paired t-tests for normally distributed data or Wilcoxon signed-rank tests for non-normally 
distributed data) were performed to confirm where the differences occurred between treatment 
plans when an overall significant difference between treatment plans was demonstrated.  A 
Bonferroni correction was used to adjust p-values for multiple comparisons.  Statistical 
significance was defined as p≤0.05.  
 
Results: 
 
 
Deviations to protocol (RTOG 1021 (table 2)) in regards to D2cm, R50%, CI and OAR are 
reported in table 4.  Acceptable plans which were defined as having no major protocol 
deviations were achievable in 2, 3, 5, 3, 7 and 10 of the 10 plans for the 7C, 9C, 13C, 7NC, 9NC 
and 10NC techniques respectively. Specific dosimetry metrics are reported in table 5.  There 
was no statistically significant difference between the individual plans for PTV54Gy or PTV48.6Gy 
coverage (table 5).   There was no statistical difference between all coplanar techniques, when 
compared to all non-coplanar techniques for PTV coverage.  The CI was similar among 
techniques, and for coplanar versus non-coplanar. 
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A previously used scoring system for measuring the absolute difference of the D2cm and R50% 
was used to evaluate the deviations from an acceptable value (no deviation) [131].  This method 
was used as the intermediate dose constraints are dependent on PTV size and therefore, mean 
R50% and D2cm for the entire cohort could be misleading.  A value of zero would indicate 
compliance, >0 would be a deviation and <0 would mean no deviation.  The mean absolute 
difference from the R50% no deviation value (table 2) was 1.42, 0.98 and 0.99 for the 7C, 9C and 
13C techniques respectively.  Mean differences for the non-coplanar techniques were 1.1, 0.90 
and 0.30 respectively for 7NC, 9NC and 10NC.  Additionally, combined coplanar and non-
coplanar techniques had a mean R50% difference from no deviation of 1.13 and 0.60 respectively. 
D2cm absolute mean differences from no deviation were, -0.67, -2.46, -3.82, -1.67, -2.62 and -
3.92 for the 7C, 9C, 13C, 7NC, 9NC and 10NC techniques respectively.  Furthermore, 
combined coplanar and combined non-coplanar had mean D2cm differences from no deviation of 
-1.84 and -2.74 respectively. 
 
OAR sparing was similar among techniques (table 6).  Spinal cord maximum doses were lower 
with the non-coplanar techniques (table 6).  Maximum rib doses were achievable in 7, 8, 9, 7, 
10 and 10 of the 10 plans respectively for the 7C, 9C, 13C, 7NC, 9NC and 10NC techniques.  
Additionally, there was one patient where the 7C and 7NC techniques couldn’t achieve 40 Gy < 
5 cm3 of the rib. Other acceptable OAR deviations were recorded for the skin maximum dose 
(two patients), heart maximum dose (two patients) and greater than 30 cm3 of CW receiving 
above 30 Gy (3 patients). Median prescription isodose values were 65.4 % (60.8 – 79.4 %), 63.6 
% (59.9 – 79.4 %), 63.5 (59.8 – 77.5 %), 65.2 % (59.8 – 78.6 %), 62.9 % (59 – 78.5 %) and 
61.6 % (59.8 – 77.4 %) for the 7C, 9C, 13C, 7NC, 9NC and 10NC techniques respectively.  
Mean monitor units for each of techniques were 3112.8, 3328.9, 3475.0, 3113.8, 3372.4 and 
3622.2 for the 7C, 9C, 13C, 7NC, 9NC and 10NC respectively.    
 
 
Discussion: 
 
This study investigates the use of six different beam arrangements for the use of IMRT in the 
delivery of SABR to peripheral lung tumours.  Non-coplanar IMRT, similar to findings using 
3DCRT[131] provides better compliance with the RTOG 1021 protocol than purely coplanar 
techniques.  
 
 
The 10NC technique produced the highest quality plan, with less deviation to the RTOG 1021 
protocol than the other techniques.  The R50% dose constraint was the main protocol deviation 
for the 7C, 9C, 13C, 7NC and 9NC techniques, with an increase in beam number reducing the 
protocol deviations.  This finding suggests that regardless of technique, either 3DCRT or IMRT, 
a larger amount of beam numbers provides greater distribution of the intermediate dose 
allowing for R50% constrains to be met.  Including non-coplanar beams further reduces the 
intermediate dose wash.  This finding is aligned with that of Holt et al [106] where they also 
report improved intermediate dose wash with non-coplanar IMRT.    
 
As beam number increased, the amount of unacceptable OAR deviations decreased.  Similarly 
to Holt et al [106], spinal cord sparing was improved using non-coplanar techniques.  The mean 
reduction in spinal cord maximum dose was 2.5 Gy.  Only the 13C technique registered a 
(mean) volume of the spinal cord getting above 12.3 Gy.  Although the 13C technique angles 
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were altered (from evenly spaced) to avoid the spinal cord in some patients, it still marginally 
increased this dose metric.  This is similar to findings comparing full arc volumetric modulated 
arc therapy (VMAT) to partial arc (VMAT) for lung SABR[135].  The V30Gy received by the 
chest wall was not improved with increasing number of beams (coplanar or non-coplanar) 
except for one patient where the volume was reduced 17.8 cm3 with the 10NC, compared to the 
mean value of all other techniques.  OAR sparing was similar for all other OAR (table 6).   
 
The interplay effect was taken into consideration when designing this study. The effect that the 
breathing motion has on the resultant dosimetry when treatment is delivered has been previously 
investigated, mainly for VMAT treatments [111-113, 136].  Studies have shown that for 
conventionally fractionated treatments the interplay effect is less than 1-2%.  Additionally, due 
to the increased treatment times and increased monitor units associated with SABR, the 
interplay effect for hypofractionated treatments (>1 fraction) is negligible [134].  
 
The authors acknowledge that a potential limitation of the study is the mixture of tumours 
adjacent to the chest wall, and those entirely surrounded by lung parenchyma.  As the planning 
objectives of achieving PTV coverage and meeting intermediate dose constraints (with isotropic 
dose fall off) were prioritized higher than non-spinal cord OAR constraints, then there is some 
bias that the non-coplanar beam arrangements will always be superior to coplanar arrangement.  
This is due to the fact that isotropic fall off will be more achievable with non-coplanar 
beams[81], therefore allowing non-coplanar beam arrangements to place higher weightings on 
rib tolerances with the IMRT optimisation parameters.  However, this study has demonstrated 
that rib tolerances can be achieved in 63.3 % of cases regardless of technique tested.  Of the 
plans where rib maximum doses were unachievable, only four plans (two 7C and two 7NC) had 
an R50% that failed to reach an acceptable deviation.  This highlights that maximum rib dose 
constrains only impact intermediate dose objectives if 7 (coplanar on non-coplanar) or less 
fields are used.  Therefore, from the beam arrangements tested, >9 fields (either coplanar or 
non-coplanar) are required for tumours adjacent to the chest wall in order to meet both 
intermediate and OAR dose constraints.       
 
 
 Conclusion: 
 
An IMRT beam arrangement consisting of 10 beams, with ≥6 non-coplanar beams provided best 
compliance with the dose constraints in the RTOG 1021 protocol.  The 10NC provided 
improved intermediate dose sparing and a reduction in doses to OAR when compared to the 
other techniques.  The 9NC achieved clinically acceptable plans in 70 % of cases and may be a 
viable alternative in select patient’s if treatment times are required to be shorter. Nine or more 
treatment fields are recommended for tumours adjacent to the chest wall. 
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Table 5.1 - Organ at risk dose constraints 
 
 
Abbreviations IVC = inferior vena cava, SVC = superior vena cava, ITV = internal target 
volume, CW = chestwall, MPD = maximum point dose (defined as ≥0.03 cm3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organ Constraint(s) 
Spinal Cord 18 Gy < 0.35 cm3 
12.3 Gy < 1.2 cm3 
MPD < 21.9 Gy 
Brachial Plexus 20.4 Gy < 3 cm3 
MPD < 24 Gy 
Aorta, SVC and  IVC 39 Gy < 10 cm3 
MPD < 49 Gy 
Pericardium 24 Gy < 15 cm3 
MPD < 30 Gy 
Trachea 15 Gy < 4 cm3 
MPD < 30Gy 
Combined Lungs – ITV 11.4 Gy < 1000 cm3 
10.5 Gy < 1500 cm3 
Oesophagus 17.7 Gy < 5 cm3 
MPD < 25.2 Gy 
Rib 40 Gy < 5 cm3 
MPD < 50 Gy 
CW 30 Gy < 30 cm3 (<70 cm3 for tumours on the 
CW) 
Skin 30 Gy < 10 cm3 
MPD < 33 Gy 
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Table 5.2 - Acceptable dose spillage guidelines from RTOG 1021 
 
Ratio of Prescription 
Isodose Volume to the 
PTV 
Ratio of 27 Gy Isodose 
Volume to the PTV R50% 
Maximum Dose at 2 cm from 
PTV in any direction as % of 
Prescribed dose (PD). D2cm (gy) 
= % x PD 
PTV 
Volume 
(cc) 
Deviation  Deviation Deviation 
None Acceptable None Acceptable None Acceptable 
<1.2 <1.5 <5.9 <7.5 <50.0 <57.0 1.8 
<1.2 <1.5 <5.5 <6.5 <50.0 <57.0 3.8 
<1.2 <1.5 <5.1 <6.0 <50.0 <58.0 7.4 
<1.2 <1.5 <4.7 <5.8 <50.0 <58.0 13.2 
<1.2 <1.5 <4.5 <5.5 <54.0 <63.0 22.0 
<1.2 <1.5 <4.3 <5.3 <58.0 <68.0 34.0 
<1.2 <1.5 <4.0 <5.0 <62.0 <77.0 50.0 
<1.2 <1.5 <3.5 <4.8 <66.0 <86.0 70.0 
<1.2 <1.5 <3.3 <4.4 <70.0 <89.0 95.0 
<1.2 <1.5 <3.1 <4.0 <73.0 <91.0 126.0 
<1.2 <1.5 <2.9 <3.7 <77.0 <94.0 163.0 
PTV = planning target volume 
 
 
 
 
 
Table 5.3- List of starting objectives for all techniques 
 
ROI Objective Type Target Dose (Gy) Volume (%)* Weight 
PTV Minimum DVH 54 100 5 
ITV Minimum Dose 60  1 
ITV Maximum Dose 91.5  5 
D2cm Maximum Dose Table 3  5 
27 Gy Ring Maximum Dose 27  5 
54 Gy Ring Maximum Dose 54  1 
Abbreviations: ROI = Region of interest, DVH = Dose volume histogram, PTV = planning 
target volume, ITV = internal target volume 
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* Only applicable for Maximum or Minimum DVH objective types  
 
 
 
 
 
 
Table 5.4 - Beam arrangements and protocol deviations following RTOG 1021 criteria. 
 
 
 
CI = conformity index 
 
 
 
 
 
 
 
 
 
 
 
 
 7C 9C 13C 7NC 9NC 10NC 
D2cm 
None 
Acceptable 
Unacceptable 
 
5 
5 
0 
 
8 
2 
0 
 
10 
0 
0 
 
8 
2 
0 
 
8 
2 
0 
 
10 
0 
0 
R50% 
None 
Acceptable 
Unacceptable 
 
1 
3 
6 
 
0 
5 
5 
 
0 
6 
4 
 
2 
3 
5 
 
1 
6 
3 
 
3 
7 
0 
CI 
None 
Acceptable 
Unacceptable 
 
10 
0 
0 
 
10 
0 
0 
 
10 
0 
0 
 
10 
0 
0 
 
10 
0 
0 
 
10 
0 
0 
OAR 
None 
Acceptable 
Unacceptable 
 
3 
3 
4 
 
3 
5 
2 
 
3 
6 
1 
 
4 
2 
4 
 
4 
6 
0 
 
5 
5 
0 
Total Deviations 
None 
Acceptable 
Unacceptable 
 
19 
11 
10 
 
21 
12 
7 
 
23 
12 
5 
 
24 
7 
9 
 
23 
14 
3 
 
28 
12 
0 
Clinically Suitable 
Plans 
2 3 5 3 7 10 
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Table 5.5 - Mean dose statistics for each technique, categorized into coplanar and non-coplanar 
and mean values for all coplanar and non-coplanar techniques combined with associated P 
values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PTV = Planned targe volume, CI = conformity index, OAR = organs at risk 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 PTV54Gy 
(%) 
PTV48.6Gy 
(%) 
R50% 
(Deviation) 
D2cm 
(Deviation) 
CI 
Coplanar 
7 Fields 
9 Fields 
13 Fields 
 
95.18 
95.14 
95.19 
 
99.98 
99.97 
99.97 
 
1.42 
0.98 
0.99 
 
-0.67 
-2.46 
-2.4 
 
0.86 
0.88 
0.87 
Non-Coplanar 
7 Fields 
9 Fields 
10 Fields 
 
95.10 
95.13 
95.83 
 
99.98 
99.98 
100.00 
 
1.09 
0.90 
0.30 
 
-1.67 
-2.62 
-3.92 
 
0.86 
0.87 
0.88 
Mean Values 
All Coplanar 
All Non-Coplanar 
P value 
 
95.17 
95.35 
0.64 
 
99.97 
99.99 
0.29 
 
1.13 
.60 
<0.01 
 
-1.84 
-2.74 
<0.01 
 
0.87 
0.87 
0.9 
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Table 5.6 - Mean values for recorded OAR doses for selected OAR categorized by technique 
and all coplanar and all non-coplanar techniques combined. 
 
 
*Adjusted p value of post hoc tests. MPD = Maximum point dose, CW = chest wall, SC = 
spinal cord, ITV = Internal target volume 
 
 SC Pericardium Combined 
Lung - ITV 
Ribs CW 
Technique/ 
Constraint 
(Aim) 
18Gy 
(<0.35 
cm3) 
12.3Gy 
(<1.2 
cm3) 
MPD 
(<21.9
Gy) 
24Gy 
(<5 
cm3) 
MPD 
(30 
Gy) 
 
10.5G
y 
(<150
0 cm3) 
11.4G
y 
(<100
0 cm3) 
40Gy 
(<5 
cm3) 
MPD 
(<50G
y) 
 
30 Gy 
(<30 
cm3) 
Coplanar 
7 Fields 
9 Fields 
13 Fields 
 
0 
0 
0 
 
0.0 
0.0 
0.3 
 
10.4  
10.3   
12.6 
 
0.6 
1.1 
1.2 
 
19.8 
21.9 
20.5 
 
460.4 
458.3 
458.1 
 
429.5 
424.6 
420.0 
 
1.8 
1.8 
1.7 
 
43.2 
43.6  
41.7 
 
22.4 
21.3 
20.4 
Non-Coplanar 
7 Fields 
9 Fields 
10 Fields 
 
0 
0 
0 
 
0.0 
0.0 
0.0 
 
8.1 
8.5 
9.2  
 
0.5 
0.6 
0.3 
 
19.3 
22.5 
19.2 
 
451.5 
461.0 
457.5 
 
412.1 
422.9 
408.9 
 
1.9 
1.8 
1.7 
 
42.9 
42.5 
42.5 
 
22.4 
20.9 
18.9 
Mean Values 
All Coplanar 
All Non-
Coplanar 
 
0 
0 
 
0.0 
0.0 
 
11.1  
8.6 
 
0.9 
0.5 
 
20.7 
20.3 
 
458.9 
456.7 
 
424.7 
414.6 
 
1.7 
1.8 
 
42.8 
42.6  
 
21.4 
20.8 
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Abstract: 
 
Introduction: The purpose of this study was to investigate coplanar and non-coplanar volumetric 
modulated arc therapy (VMAT) delivery techniques for stereotactic ablative radiation therapy 
(SABR) to the lung. 
Methods:  For ten patients who had already completed a course of radiation therapy for early 
stage lung cancer, 3 new SABR treatment plans were created using 1.) a coplanar full arc 
technique (FA), 2.) a coplanar partial arc technique (PA) and 3.) a non-coplanar technique 
utilising three partial arcs (NCA).  These plans were evaluated using planning target volume 
(PTV) coverage, dose to organs at risk and high and intermediate dose constraints as 
incorporated by RTOG 1021. 
Results:  When the FA and PA techniques were compared to the NCA technique, on average the 
PTV coverage (V54Gy) was similar (p=0.15); FA (95.1%), PA (95.11%) and NCA (95.71%).  
The NCA resulted in a better conformity index (CI) of the prescription dose (0.89) when 
compared to the FA technique (0.88, p = 0.23) and the PA technique (0.83, p=0.06).  The NCA 
technique improved the intermediate dose constraints with a statistically significant difference 
for the D2cm and R50% when compared to the FA (p <0.03 and <0.0001) and PA (p<0.04 and 
<0.0001) techniques. The NCA technique reduced the maximum spinal cord dose by 2.72 Gy 
and 4.2 Gy when compared to the PA and FA techniques respectively.  Mean lung doses were 
4.09 Gy, 4.31 Gy and 3.98 Gy for the FA, PA and NCA techniques respectively.  
Conclusion:  The NCA VMAT technique provided the highest compliance to RTOG 1021 when 
compared to coplanar techniques for lung SABR.  However, single full arc coplanar VMAT was 
suitable for 70 percent of patients when minor deviations to both the intermediate dose and 
OAR constraints were accepted. 
 
Keywords: 
Stereotactic Ablative Radiation Therapy (SABR) 
Lung Cancer  
Volumetric Modulated Arc Therapy (VMAT) 
Dosimetry 
Treatment Planning 
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Stereotactic ablative radiation therapy (SABR) is the delivery of a highly ablative radiation dose 
in a few fractions.  It was originally introduced for early stage lung cancer patients who were 
deemed medically unfit for surgery. [5] SABR is commonly delivered using a high number of 
coplanar and non-coplanar 3 dimensional conformal radiation therapy (3DCRT) beams.  In a 
previous single centre dosimetry comparison the authors demonstrated that a predominantly 
non-coplanar, 10 beam technique had the most favourable compliance with the RTOG 1021 
protocol.[86, 131]  A highly non-coplanar beam arrangement allowed for improved intermediate 
dose conformity and organ at risk (OAR) sparing.  However, the engagement of a high number 
of couch rotations can extend the treatment times to potentially unfavourable lengths.[97]  It has 
previously been reported that for treatment times extending over 34 minutes that a base line 
shift in tumour position of up to 5 mm can occur.[87]  Delivery times for lung can SABR can 
vary depending on the equipment used, fractional dose, patient compliance and the delivery 
technique itself.  
 
Volumetric modulated arc therapy (VMAT) is a novel technique that delivers the dose while the 
linear accelerator rotates continuously around the patient.[80, 115]  The dose rate, gantry 
rotation speed and multileaf collimator (MLC) positions are all variables that can be altered 
while the machine is delivering the dose.  Single coplanar arcs have already been shown to 
reduce treatment times for SABR to the lung when compared to 3DCRT, whilst achieving 
highly conformal dose distributions.[97]  However, non-coplanar beam arrangements improve 
the intermediate dose conformity, which is one of the key dosimetry metrics for SABR.  
Therefore, this study was designed to quantify any benefits arising from non-coplanar VMAT 
when compared to coplanar VMAT for SABR to the lung.  
 
Methods: 
 
Institutional ethics approval was granted for this retrospective study.  Ten patients who were 
eligible for SABR and had completed their course of radiation therapy were identified from our 
local radiation oncology information system.  Inclusion criteria was limited to early stage 
disease (Ia/b or IIa) measuring <5cm in the largest dimension.  Furthermore, the gross tumour 
volume (GTV) was required to be >2cm away from the proximal bronchial tree.   
 
Patients were simulated as previously reported.[131]  A 4 dimensional computed tomography 
(4DCT) scan was acquired at the time of simulation along with a free breathing CT scan.  Both 
scans were exported to Pinnacle v9.4 (Philips Medical Systems, WI, USA) with the 4DCT used 
to generate an internal target volume (ITV). The PTV was created by expanding the ITV 5mm 
isotropically.  The free breathing simulation CT scan was used for all OAR (table 1) contouring 
and treatment planning.  All maximum doses reported were to a clinically significant and 
measurable volume of 0.03cm3.  The chest wall contour was defined as a 2 cm expansion on the 
ipsilateral lung, excluding the vertebral body, sternum and mediastinal structures.  A structure 
was also created for reporting the maximum dose at any point 2cm from the PTV (D2cm).   
 
Treatment planning was carried out with Pinnacle v9.4 and the SmartArc™ algorithm.  The 
final gantry spacing option in Pinnacle allows for the treatment planner to select the angular 
separation (in degrees) of the arc segments.  It has previously been reported that a gantry 
spacing of 4° (new segment every 4°) is optimal, with no benefit in reducing the spacing any 
further.[106]  In the present study, a full 360° arc will always have 91 segments with 0°, or the 
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starting angle, being included as a segment.  The plans were computed using an Elekta Axesse 
beam model with the beam modulator collimator system with 4 mm MLC leaves.  A dose grid 
resolution of 0.25 cm3 was used for all plans.  All plans were calculated using the collapsed 
cone convolution algorithm (CCC).  The CCC algorithm is a type B algorithm and accounts for 
changes in lateral electron transport and should therefore be used for lung tumour treatments. 
Treatment planning was performed by a single planner and the machine quality assurance was 
performed by a medical physicist to ensure the plans were clinically deliverable with a gamma 
analysis passing rate of 3 mm/3%.  
 
Unlike 3DCRT where the isocentre is placed in the centre of the PTV, the isocentre for the arc 
plans was placed on the patient’s midline.  This was to avoid any further complications that 
could cause a collision, such as when the bed is shifted laterally and is coupled with a rotating 
gantry and non-coplanar floor angles.  The isocentre could have been placed in the PTV for the 
coplanar arcs but was left on the patient’s midline to avoid any bias. All fields used 6 MV 
photons delivered with a collimator angle of zero. 
 
The single full arc (FA) technique started at 181°, and travelled in a clockwise (CW) direction 
for 359° to stop at 180°.  The partial arc (PA) technique started at either 181° or 180° and 
travelled an arc length of 180-200° around the ipsilateral side of the patient either in a CW or 
counter-clockwise (CCW) direction.  The non-coplanar partial arc technique (NCA) used three 
partial arcs, one with a couch angle of 0° and two using non-coplanar couch angles.  For left 
sided tumours the couch angles were 0°, 15° and 340° and for right sided tumours they were 0°, 
20° and 345°.  These angles were chosen as they were the greatest possible couch rotations 
away from zero (allowing for less overlapping of beams, and reducing the intermediate dose 
wash) without the gantry head and couch colliding.  The arc angles for the NCA technique were 
the same as used for the PA technique.  MLC speed was constrained to 0.46 cm/degree as per 
department protocol. 
 
A total dose of 54 Gy in 3 fractions was prescribed to the periphery of the PTV ensuring that 
>95 % of the PTV received the prescription dose (PTV54Gy) and that 99% of the PTV received 
90% of the prescription dose (PTV48.6Gy).  The 54 Gy isodose (prescription isodose) was planned 
to fall between 59-90% of the maximum dose in the plan, resulting in a maximum dose of no 
more than 91.5 Gy.  OAR tolerances used were those reported in RTOG 1021 (table 1).  The 
constraints to limit the intermediate doses, D2cm, the dose at any point 2cm from the PTV, and 
the ratio of the volume of half the prescription dose to the volume of the PTV (R50%) are also 
shown in table 2.  To quantify the conformity of the prescription isodose the conformity index 
(CI) was used[131], 
 
 
 
 
 
where TVPTV is defined as the total volume of PTV covered by the covering isodose (54Gy), TV 
is defined as the total volume of the PTV and PIV is defined as the total volume of the covering 
isodose in the patient .  A CI value of ≥0.75 was no deviation, with ≥0.65 constituting an 
acceptable deviation and anything <0.65 was considered unacceptable.  This CI formula was 
used instead of the RTOG formula as it is more robust and less prone to errors. 
 
PIVTV
TVPTV
*
)( 2
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Each technique was created using the initial set of objectives outlined in table 3.  Other 
objectives such as the maximum dose to the spinal cord, pericardium, chest wall, trachea and 
oesophagus were used on an individual patient basis as necessary.  As the dose being delivered 
to the PTV is of an ablative nature, limiting the dose to surrounding tissues directly adjacent to 
the PTV is extremely important.  Therefore, unlike conventional intensity modulation, no 
expansion was made to the PTV for dose optimization. The objective used on the PTV was a 
dose volume histogram (DVH) objective to cover a minimum of 100% of the PTV with 54 Gy.  
To promote a steep dose gradient, a minimum and maximum dose objective was used to control 
dose to the ITV.  This would ensure that the maximum dose would be between 60 Gy and 91.5 
Gy, and that the 54Gy isodose would fall within 59-90% of the maximum dose.  To control the 
prescription dose, a ring with a 1mm gap to the PTV was created with a maximum dose 
objective equal to the prescription dose.  This gave the optimisation algorithm a 1 mm gap to 
place the 54 Gy isodose, ensuring a tight and compact high dose region.  To limit the 
intermediate dose, two different objective functions were used.  Firstly, a structure constructed 
from the patients external contour minus the PTV plus a 2 cm expansion was used to control the 
dose at D2cm.  This ROI was given a maximum dose objective as per the relevant values in the 
no deviation column for D2cm in table 2.  Furthermore, to help meet the R50% (the value of half 
the prescription dose divided by the volume of the PTV) constraint (table 2) a structure 
constructed from the patients external contour minus an expansion on the PTV was used to 
control the 27 Gy isodose.  This expansion was typically a 1 cm isotropic expansion of the PTV 
based on the assumption that dose reduction of 5%/mm is achievable.  The expansion on the 
PTV was reduced/increased but was altered on an individual patient basis as needed to better 
control the 27Gy isodose volume.   The weights in the objective list were chosen to firstly cover 
the entire PTV with 54 Gy isodose, and then use the ring structures to control the intermediate 
dose to meet the dose conformity constraints.  For PTVs adjacent to or overlapping the chest 
wall, the allowable maximum dose to the rib was increased to 105% of the prescription dose and 
recorded as an acceptable deviation.    
 
Statistical analyses were performed using R statistical software (http://www.r-project.org).  The 
three new SABR treatment plans were compared using a repeated measures ANOVA 
(parametric test) for normally distributed data and the Friedman test (non-parametric test) for 
non-normally distributed data. Normality of the data has been tested using the Shapiro-Wilk 
test.   When an overall significant difference between treatment plans was demonstrated, post 
hoc tests (paired t-tests for normally distributed data or Wilcoxon signed-rank tests for non-
normally distributed data) were performed to confirm where the differences occurred between 
treatment plans. The p-values have been adjusted for multiple comparisons using False 
Discovery Rate (FDR) correction to control the expected proportion of incorrectly rejected null 
hypotheses.  The p-values obtained have been adjusted for 
multiple comparisons with a Bonferroni correction.  Statistical significance was defined as 
p≤0.05.  
 
Results: 
 
Mean planning target volume (PTV) size was 32.3 cm3 with five of the ten patients having 
tumours adjacent to the chest wall.  Patient characteristics are detailed in table 4.  Acceptable 
plans, defined as having no major protocol deviations as outlined in RTOG 1021 (table 2) were 
obtained for 70 percent, 40 percent and 100 percent of the FA, PA and NCA techniques 
respectively.  A summary of the dosimetry parameters for each technique are reported in table 5.   
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PTV54Gy coverage was similar for the FA, PA and NCA techniques achieving 95.09%, 95.11% 
and 95.71% respectively.  Coverage for the PTV48.6Gy objective was 99.97%, 99.92% and 
99.99% for the FA, PA and NCA respectively with a statistically significant difference (p=0.04) 
between the PA and NCA.  The NCA technique provided the best high dose conformity with a 
value of 0.89, when compared to the FA (0.88) and PA (0.82) techniques.    
 
The NCA technique resulted in the highest compliance with the no deviation criteria in table 2.  
A previously used scoring system for measuring the absolute difference of the D2cm and R50% 
was used to evaluate the deviations from an acceptable value.[131]  The mean absolute 
difference from the R50% no deviation value (table 2) was 1.04, 0.52 and 0.12 for the PA, FA 
and NCA techniques respectively.  The mean absolute difference from the D2cm no deviation 
was of, -5.33, -3.71 and -0.46 for the NCA, FA and PA respectively.  This resulted in a 
statistically significant difference of 0.03 when comparing the FA and PA, and p=0.04 when 
comparing the NCA and PA for the R50% constraint and <0.0001 for the D2cm between all 
techniques.    Figure 1 plots the achieved R50% values against the PTV size for each of the ten 
patients.  OAR sparing was similar among techniques (table 5).  For doses to the combined lung 
minus the ITV volume, the NCA reduced the 10.5 Gy wash by a mean volume of 44 cm3 and 24 
cm3 for the PA and FA technique respectively, and the 11.4 Gy dose wash by a mean volume of 
44 cm3 and 25 cm3 respectively. Spinal cord maximum doses were lower with the NCA 
technique (table 5).  The FA had 1 plan and the PA technique had 3 plans where the maximum 
dose to the ribs could not be achieved. Conversely the NCA technique was able to achieve 
maximum rib doses for all 10 patients.  The chest wall volume receiving 30 Gy (V30Gy) ranged 
from 0-62.07 cm3, 0-52.36 cm3 and 0-53.30 cm3 for the PA, FA and NCA techniques 
respectively for all ten patients.  Where the PTV was overlapping the chest wall, the mean V30Gy 
was 35.79 cm3, 33.18 cm3 and 32.46 cm3 for the PA, FA and NCA techniques respectively. 
 
Discussion: 
 
This study presents an expansion on previous work where the effects of non-coplanar beam 
arrangements for lung SABR using 3DCRT were reported.  Similar to those findings with 
3DCRT, the non-coplanar VMAT technique tested in this current study also provides greater 
compliance with the RTOG 1021 protocol when compared to single arc coplanar techniques.  
 
The NCA technique provided the most optimal plan with greater adherence to the RTOG 1021 
guidelines than the other two techniques. All 10 of the NCA treatment plans adhered to RTOG 
1021 protocol guidelines.  The technique that had the least compliance with the planning 
objectives was the PA technique.  Only 40 % of the plans were acceptable with a majority of the 
deviations being associated with the intermediate dose constraints.  Having an arc only enter 
through a 180-200° sector did not allow for enough low dose spread throughout the normal 
tissue, resulting in higher than favourable intermediate doses.  The FA technique had 7 out of 10 
plans which were clinically acceptable.  Of the three not acceptable, the R50% was above an 
acceptable deviation in 2 plans and the rib maximum dose was over tolerance in the other.   
 
Similarly to Holt et al we also report that the CI for the prescription isodose were  within 
acceptable limits for all techniques.[106]  Holt et al report a few exceptions to achieving an 
optimal CI for the prescription dose.  In the present study we report no deviations to the CI 
regardless of delivery technique.  This could be due to a number of different factors including 
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the different CI equations used, different treatment machine and contrasting intensity 
modulation objectives.  Furthermore, there was also an improvement in the CI with the FA and 
NCA techniques, which is largely due to the greater number of segments, and therefore 
“individual beams” used with the FA and NCA techniques. 
 
OAR sparing was similar between each technique.  There was improved spinal cord sparing 
with the NCA and PA technique which is due to the fact that neither of these techniques had 
beams entering through the spinal cord, an unavoidable consequence of the FA technique.  
Furthermore, the NCA was able to improve both the maximum dose and specific volumetric 
dose constraint for all midline structures such as the aorta, trachea and oesophagus.  The NCA 
technique was able to either achieve the constraint or limit the maximum rib dose to acceptable 
deviation for all 10 patients.  Furthermore, the maximum V30Gy (62.07 cm3) to the chest wall for 
the PA technique was able to be reduced by almost 10 cm3 (52.36 cm3 and 53.33 cm3 for the FA 
and NCA respectively) by the other two techniques.  Although still within the 70 cm3 constraint, 
this reduction in chest wall dose is likely to be clinically significant, as reported by both Ong et 
al and Dunlap et al, where a V30Gy < 30 cm3 could reduce the risk of toxicity, especially if SABR 
offers an improvement in long term survival. [97, 126] The improvement to OAR sparing could 
be due to the larger number of control points for the NCA and FA techniques, and therefore 
larger number of opportunities to shield out OAR. 
 
A universal issue arising from arc based techniques is the increased dose wash to the lungs, 
especially the contra-lateral lung.  Pre-established 3DCRT non-coplanar techniques enter 
through the contralateral lung, however they are generally only from one or two static angles.  
The FA technique used in this study enters through the entire contralateral lung, exposing more 
volume to a lower dose.  The effect of this can be seen with the increase in the mean lung dose 
(MLD).  Holt et al report a MLD of 4.2 Gy for single coplanar VMAT which is on par with our 
result of an average MLD of 4.3 Gy.[106]  The reduction in MLD for the PA technique is 
because a smaller volume of lung is receiving low dose.  Furthermore, dose is being deposited 
through non-coplanar angles with the NCA technique, further reducing the MLD.  In a matched 
analysis study, Palma et al investigated radiobiological and clinical pneumonitis after both 
VMAT (RapidArc) and 3DCRT and concluded that there was no difference in the severity of 
clinical or radiobiological sequelae after treatment.[117] Figure 2 displays the reduced dose 
wash to the contra-lateral lung with both the PA and NCA techniques when compared to the full 
arc technique. 
 
A general concern with intensity modulated treatments for lung cancer is the interplay effect, 
which is the potential difference in the planned dose to the delivered dose.  This is caused by 
differences in the MLC movements to tumour motion when comparing the static respiratory 
phase the planning CT captured with the breathing cycle during treatment.[112]  Several groups 
have investigated this phenomenon (VMAT or RapidArc) and report that for a single fraction 
split over two arcs, or >1 treatment fractions, the interplay effect is negligible and the actual 
delivered dose is within reasonable tolerance to the planned dose. [111, 112, 136]  
 
Although the NCA provides improved plan quality, these small gains in intermediate dose 
reduction may be of little importance in the current clinical setting.  With R50% and D2cm values 
achieved by the FA technique within acceptable protocol deviations, the advantage of a single 
coplanar arc may outweigh the improved performance of non-coplanar techniques.  In a clinical 
setting where patients are generally from an older population and may not tolerate long 
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treatment times and a high emphasis is placed on departmental efficiency, the FA technique 
provides acceptable treatment plans in a majority of cases and can be delivered in a shorter 
treatment time.  However, if the delivery of highly ablative doses is beneficial to a younger 
cohort of patients diagnosed with early stage lung cancer, increased reduction in intermediate 
doses available with the NCA may be of benefit. Furthermore, a coplanar arc technique may 
better lead to advanced treatment techniques such as dynamic MLC tracking or breath hold 
techniques where quicker treatment times are a necessity.  
 
 
 Conclusion: 
 
The non-coplanar (NCA) VMAT technique utilizing three non-coplanar partial arcs produced 
optimal plans that demonstrated better compliance with the dose constraints in the RTOG 1021 
protocol when compared to the single arc coplanar techniques.  For those tumours entirely 
encapsulated in lung parenchyma, full single arc coplanar VMAT provided acceptable plans 
when accepting small deviations to the intermediate dose constraints. Single full arc coplanar 
VMAT is a suitable treatment option for lung SABR when intermediate and OAR doses are 
within acceptable limits. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.1 - Organ at risk dose constraints 
 
Organ Constraint(s) 
Spinal Cord 18 Gy < 0.35 cm3 
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Abbreviations IVC = inferior vena cava, SVC = superior vena cava, ITV = internal target 
volume, MPD = maximum point dose (defined as ≥0.03 cm3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12.3 Gy < 1.2 cm3 
MPD < 21.9 Gy 
Brachial Plexus 20.4 Gy < 3 cm3 
MPD < 24 Gy 
Aorta, SVC and  IVC 39 Gy < 10 cm3 
MPD < 49 Gy 
Pericardium 24 Gy < 15 cm3 
MPD < 30 Gy 
Trachea 15 Gy < 4 cm3 
MPD < 30Gy 
Combined Lungs – ITV 11.4 Gy < 1000 cm3 
10.5 Gy < 1500 cm3 
Oesophagus 17.7 Gy < 5 cm3 
MPD < 25.2 Gy 
Rib 40 Gy < 5 cm3 
MPD < 50 Gy 
Chestwall 30 Gy < 30 cm3 (<70 cm3 for tumours on the 
CW) 
Skin 30 Gy < 10 cm3 
MPD < 33 Gy 
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Table 6.2 - Acceptable dose spillage guidelines from RTOG 1021 
 
Ratio of Prescription 
Isodose Volume to the 
PTV 
Ratio of 27 Gy Isodose 
Volume to the PTV (R50%) 
Maximum Dose at 2 cm from 
PTV in any direction as % of 
Prescribed dose (PD). D2cm 
(Gy) = % x PD 
PTV 
Volume 
(cc) 
Deviation  Deviation Deviation 
None Acceptable None Acceptable None Acceptable 
<1.2 <1.5 <5.9 <7.5 <50.0 <57.0 1.8 
<1.2 <1.5 <5.5 <6.5 <50.0 <57.0 3.8 
<1.2 <1.5 <5.1 <6.0 <50.0 <58.0 7.4 
<1.2 <1.5 <4.7 <5.8 <50.0 <58.0 13.2 
<1.2 <1.5 <4.5 <5.5 <54.0 <63.0 22.0 
<1.2 <1.5 <4.3 <5.3 <58.0 <68.0 34.0 
<1.2 <1.5 <4.0 <5.0 <62.0 <77.0 50.0 
<1.2 <1.5 <3.5 <4.8 <66.0 <86.0 70.0 
<1.2 <1.5 <3.3 <4.4 <70.0 <89.0 95.0 
<1.2 <1.5 <3.1 <4.0 <73.0 <91.0 126.0 
<1.2 <1.5 <2.9 <3.7 <77.0 <94.0 163.0 
 
 
 
 
 
Table 6.3 - List of starting objectives for all techniques 
 
ROI Objective Type Target Dose (Gy) Volume (%)* Weight 
PTV Minimum DVH 54 100 5 
ITV Minimum Dose 60  1 
ITV Maximum Dose 91.5  5 
D2cm Maximum Dose Table 3  5 
27 Gy Ring Maximum Dose 27  5 
54 Gy Ring Maximum Dose 54  1 
Abbreviations: ROI = Region of interest, DVH = Dose volume histogram 
* Only applicable for Maximum or Minimum DVH objective types  
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Table 6.4 - Patient characteristics 
Gender (n) 
Male 
Female 
Age (y) 
Range 
Median 
Mean 
Staging 
T1aN0M0 
T1bN0M0 
T1NOSN0M0 
Location 
RUL 
RML 
RLL 
LUL 
LLL 
Overlapping with CW (n) 
Yes 
No 
ITV Size (cm3) 
Range 
Median 
Mean 
PTV Size (cm3) 
Range 
Median 
Mean 
 
7 
3 
 
61 - 83 
76 
74.8 
 
5 
2 
3 
 
5 
1 
2 
1 
1 
 
5 
5 
 
4.43 – 29.9 
8.3 
10.4 
 
22.8 – 79.12 
27.49 
32.26 
Abbreviations NOS = not specified, CW = chest wall, ITV = internal target volume, PTV = 
planned target volume 
RUL = right upper lobe, RML = right middle lobe, RLL = right lower lobe; LUL = left upper 
lobe,  LLL = left lower lobe 
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Table 6.5 - Mean dose statistics for each technique with associated P values. 
 
Metric Parameter PA FA NCA P value* 
(PA-NCA) 
P Value* 
(FA-NCA) 
PTV54Gy (%) 95.11 95.09 95.71 0.15 0.15 
PTV48.6Gy (%) 99.92 99.97 99.99 0.04  
D2cm Absolute 
Difference 
-0.46 -3.71 -5.33 <0.0001 <0.0001 
R50% Absolute 
Difference 
1.04 0.52 0.12 0.04 0.03 
CI  0.83 0.88 0.89 0.06 0.23 
MLD (Gy) 4.09 4.31 3.98 0.05 <0.0001 
Spinal Cord Dmax (Gy) 9.52  11.0 6.80   
 V18Gy (cm3) 0.0 0.0 0.0   
 V12.3Gy 
(cm3) 
0.02 0.11 0.0   
Rib Dmax (Gy) 45.45 43.3 42.75   
 V40Gy (cm3) 1.55 1.40 1.47   
Chest Wall V30Gy (cm3) 20.12 16.95 16.44   
Combined Lung - 
ITV 
V10.5Gy 
(cm3) 
434.79 414.79 390.93   
 V11.4Gy 
(cm3) 
400.01 380.41 355.59   
Pericardium Dmax (Gy) 1.93 1.49 0.52   
 V24Gy (cm3) 19.53 19.91 18.46   
Skin Dmax (Gy) 0.50 0.49 0.49   
 V30Gy (cm3) 23.62 21.39 20.0   
Oesophagus Dmax (Gy) 9.82 12.47 6.64   
 V17.7Gy 
(cm3) 
0.0 0.0 0.0   
Aorta Dmax (Gy) 11.97 14.60 9.94   
 V39Gy (cm3) 0.0 0.0 0.0   
Trachea Dmax (Gy) 0.02 0.47 0.0   
 V15Gy (cm3) 6.05 7.2 5.6   
*Adjusted p value of post hoc tests. 
Abbreviations   
PA = coplanar partial arc technique; FA = coplanar full arc technique; NCA = non-coplanar 
technique utilising three partial arcs 
ITV = internal target volume, PTV = planned target volume, MLD = mean lung dose, CI = 
conformity index 
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Figure 6.1 - Dose wash through a transverse slice for each of the three techniques. A, Full arc. 
B, Non-coplanar partial arc. C, Partial arc.  
 
A
B
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Abstract 
Aim: To compare three non-coplanar delivery techniques (3-dimensional conformal radiation 
therapy (3DCRT), intensity modulated radiation therapy (IMRT) and volumetric modulated arc 
therapy (VMAT)) for the delivery of lung stereotactic ablative radiation therapy (SABR) to 
peripheral lung tumours. 
Methods and Materials: Treatment plans for 3DCRT, IMRT and VMAT were generated for 
each of the twenty patients.  The plans were compared by assessing the planning target volume 
(PTV) coverage, doses to organs at risk, high and intermediate dose constraints (D2cm and R50%) 
and delivery times using ANOVA for repeated measurements or Friedman’s test when 
appropriate. 
Results:  Mean PTV54Gy coverage was found to be 95.6%, 95.7% and 95.6% for the 3DCRT, 
IMRT and VMAT techniques respectively.  PTV48.6Gy coverage was increased for IMRT 
(99.99%) (p=<0.001) and VMAT (99.99%) (p=<0.001) when compared to 3DCRT (99.56%).  
No deviations to the intermediate dose constraints were found in 65%, 65% and 85% of the 
patients for the 3DCRT, IMRT and VMAT plans respectively.  Mean treatment times were 20.0 
minutes (16.4 – 21.5 minutes), 25.2 minutes (22.1 – 27.9 minutes) and 11.7 (8.0 – 15.2 minutes) 
minutes respectively for 3DCRT, IMRT and VMAT. 
Conclusion:  A non-coplanar VMAT technique was found to provide superior intermediate dose 
sparing with comparable prescription dose coverage when compared to non-coplanar 3DCRT or 
IMRT.  Additionally, VMAT was found to reduce the treatment times of SABR delivery for 
peripheral lung tumours.   
 
Introduction: 
Stereotactic ablative radiation therapy (SABR) is currently emerging as the standard of care for 
medically inoperable patients diagnosed with early stage lung cancer or pulmonary 
oligometastases.  The capability to deliver highly ablative doses with minimal clinical toxicity 
relies significantly on the ability to limit dose to normal tissues.  3 dimensional conformal 
radiation therapy (3DCRT) has traditionally been the delivery technique for lung SABR.  
Generally, a large number (>7) of beams with a non-coplanar contribution is required to reduce 
toxicities and satisfy intermediate dose constraints [79, 93].  The inclusion of non-coplanar 
beams is advantageous in the reduction of intermediate dose spillage and normal tissue sparing, 
however a longer treatment time is observed [80, 87].  Nevertheless, key dosimetric criteria 
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such as the prescription dose conformity, intermediate dose spillage and organ at risk (OAR) 
sparing should not, in principal, be significantly compromised in order to achieve reduced 
treatment times.   
Treatment modalities, including 3DCRT, intensity modulated radiation therapy (IMRT), 
dynamic conformal arc (DCA), tomotherapy and volumetric modulated arc therapy (VMAT) 
have previously been investigated for lung SABR [76, 80, 91, 92, 94, 97, 106-109, 118, 131-
133, 137-142].  Furthermore, various task groups have also reported on safe and effective 
delivery techniques for lung SABR, which address number of beams and direction (coplanar or 
non-coplanar) [35, 95, 143].  The consensus is that for 3DCRT and IMRT a large number of 
beams, the majority of which tend to be non-coplanar [131], are required to meet intermediate 
dose constraints (D2cm and R50%) and improve OAR sparing.  For VMAT, single or multiple full 
coplanar arcs have previously been compared to non-coplanar 3DCRT and IMRT.  VMAT 
produced similar or improved treatment plan quality, in shorter treatment times.  To extend on 
preceding reports, the authors have previously reported on the use of non-coplanar VMAT for 
the delivery of lung SABR [135].  It was found that non-coplanar VMAT produced superior 
plans than either single or partial arc coplanar VMAT.  To further investigate this non-coplanar 
VMAT technique this current study was designed to compare three different non-coplanar 
techniques for the delivery of SABR to early stage peripheral lung tumours.  Plans were 
critiqued using RTOG 1021[86] criteria to identify the most favourable technique in terms of 
both plan quality and efficiency.   
Methods: 
Institutional ethical clearance was granted to use the computed tomography (CT) data sets of 
twenty early stage lung cancer patients eligible for SABR.  Patient eligibility was defined as 
early stage (IA/B or IIA), with the gross tumour volume (GTV) volume measuring <5cm in the 
largest dimension and >2cm away from the proximal bronchial tree.   
 
Patients were simulated in the supine position with arms up, using a vac-lok cushion from above 
the head to below the torso and knee fix under knees to aid in rigid patient immobilization.  A 
10 phase 4 dimensional CT (4DCT) was captured at the time of simulation along with a free 
breathing scan for dose calculation.  Both data sets were exported to Pinnacle v9.4 (Philips 
Medical Systems, Stockholm, Sweden) for contouring and planning.  The internal target volume 
(ITV) was generated by contouring the different positions of the GTV during all phases of the 
breathing cycle.   
 
A planned target volume (PTV) was created by an isotropic 5mm expansion on the ITV.  
Organs at risk listed in table 1 were contoured.  A D2cm structure to measure intermediate dose 
spillage was created by removing a 2cm isotropic expansion of the PTV from the body.  A 
volume of 0.03 cm3 was defined as the maximum point dose. 
For all techniques, plans were prescribed to deliver 54 Gy to the periphery of the PTV in three 
fractions.  The PTV was planned to receive >95% of the prescription dose (PTV54Gy), and >99% 
coverage of the PTV with 90% of the prescription dose (PTV48.6Gy).  The 54 Gy isodose was 
optimized so that it fell somewhere between 59-90% of the maximum dose in the plan.  Plans 
were assessed by PTV coverage, the conformity of the prescription isodose to the PTV, 
intermediate dose constraints (D2cm and R50%), doses to OAR and treatment times.  Criteria for 
intermediate dose spillage are listed in table 2. Conformity index (CI) was calculated using the 
formula [124]; 
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A CI value of ≥0.75 was no deviation, ≥0.65 was an acceptable deviation and <0.65 was an 
unacceptable deviation.   
 
All treatment planning was carried out using Pinnacle v9.4 with a collapsed cone convolution 
algorithm.  The CCC algorithm is classified as a type B algorithm and is more rigorous in 
accounting for changes in lateral electron transport and is a nessicity in modern day lung SABR 
treatment planning.  The 3DCRT technique used 10 beams with a minimum of 6 non-coplanar 
angles.  The initial beam angles were based on a previous report [131] by the authors and altered 
by the planner as needed to improve intermediate dose spillage or doses to OAR.  Negative 
margins were used to shield the periphery of the PTV to ensure that the prescription isodose fell 
within the penumbra of the beam.  
 
The IMRT technique replicated the beam angles from the 3DCRT technique to avoid any bias.  
IMRT planning was replicated from a previous study [131].  The IMRT plans were optimized 
using the set of objectives (table 3)[131]  and other structures (spinal cord, oesophagus) were 
added to the optimization if required.  Segments numbers were limited to a mean of 7 per beam 
and optimized using the direct machine parameter optimization (DMPO) algorithm. 
 
The VMAT technique used three non-coplanar partial arcs, with gantry angles chosen by the 
planner to limit dose to the contra-lateral lung.   Each arc started at 180° and rotated between 
180-220° around the ipsilateral side.  Couch angles of 15, 340 and 0 were used for right sided 
tumours, and angles of 20, 345 and 0 were used for left sided tumours to avoid collisions.  A 
final gantry spacing of 4° was used which defines at how many degrees the control points for 
the arc occur.  Quite simply, there is a control point or segment change every 4°, meaning 91 for 
a full 360° arc (as both ) ° and 360° are define as a control point).  VMAT dose objectives used 
were similar to IMRT (table 3) and adjusted as necessary to compensate for the difference in 
delivery techniques. 
 
IMRT and VMAT used two different structures to limit intermediate dose spillage.  Firstly, a 
D2cm structure was created by expanding the PTV 2cm isotopically.   This structure is then 
removed from the body contour, leaving a donut structure to control the dose at 2cm from the 
PTV.   This structure was routinely able to also control the R50% constraint, however if this 
wasn’t possible, another donut like structure was created.  This was generally a 1 cm uniform 
expansion from PTV but was expanded asymmetrically in order to control the R50% as required.  
Planning objectives were prioritized as per Fitzgerald et al[131].  IMRT and VMAT plan 
specific quality assurance (QA) performed in which planned fluences were measured against 
actual delivered fluences for each field and arc of the IMRT and VMAT plans only, using a 
gamma analysis acceptance criteria of 3%/3mm [74]. 
 
The treatment plans were then delivered on a linear accelerator and treatment times were 
measured from the beam on time of the first beam/arc until the end of the last beam/arc and all 
associated treatment couch rotations in between.  No patient setup or imaging times were 
included in the measurements 
 
Results: 
PIVTV
TVPTV
*
)( 2
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The mean PTV size was 35.7 cm3 with 11 patients having PTVs that overlapped the chest wall.  
The mean volume of PTV overlapping the chest wall was 4.1 cm3.   Mean PTV54Gy coverage 
was 95.59%, 95.71% and 95.63% for the 3DCRT, IMRT and VMAT techniques respectively.  
Furthermore, there was a statistically significant difference in PTV48.6Gy coverage for the 
3DCRT (99.56%) to IMRT (99.99%) (p=<0.001) and 3DCRT to VMAT (99.99%) (p=<0.001). 
 
Mean dose statistics from each of the techniques are represented in table 4.  Protocol deviations 
for the D2cm, R50%, CI and OAR doses are listed in table 5.  Unacceptable deviations for each 
technique were only noted for OAR where either the maximum rib dose or volume constraint 
could not be met.  The VMAT technique provided greatest compliance with intermediate dose 
constraints with no deviations from protocol in 85% of plans, compared with 65% for both the 
3DCRT and IMRT plans respectively.  A previously reported (reference) scoring system was 
used to evaluate individual deviations to D2cm and R50%.  The 3DCRT, IMRT and VMAT plans 
produced mean absolute difference R50% values of 0.37, 0.25 and 0.08 away from the no 
deviation constraint in table 5.  The mean D2cm values were -0.86 Gy, -4.49 Gy and -5.72 Gy 
less than the no deviation constraint for the 3DCRT, IMRT and VMAT plans respectively.  
Overall the mean R50% and D2cm values were 4.64, 4.52 and 4.35 and 30.2, 26.6 and 25.3 for the 
3DCRT, IMRT and VMAT techniques respectively.  Furthermore, mean CI values for each 
technique were 0.80, 0.88 and 0.89 for the 3DCRT, IMRT and VMAT with a statistically 
significant difference for 3DCRT compared to VMAT (p = <0.001) and 3DCRT to IMRT (p 
<0.001). 
 
As reported, the only unacceptable deviations were due to the maximum rib dose and volume of 
rib receiving 40 Gy.  The maximum rib dose was violated by all techniques on patient 12, where 
12.5 cm3 of the PTV overlapped the chest wall.  This also resulted in the rib volumetric 
constraint being violated.  The maximum rib dose for this patient was 60 Gy, 58.3 Gy and 61.6 
Gy for the 3DCRT, IMRT and VMAT plans respectively, with the volume receiving 40 Gy 
being 5.79 cm3, 6.08 cm3 and 6.03 cm3 respectively.  Furthermore all plans had a rib volume 
constraint violated for patient 18 with 5.24 cm3, 6.95 cm3 and 6.44 cm3 receiving 40 Gy for the 
3DCRT, IMRT and VMAT plans respectively.  The 3DCRT technique also had a maximum rib 
dose violation for patient 8 (59.1 Gy).  For the patients whose PTV overlapped the chest wall, 
mean maximum rib doses for 3DCRT, IMRT and VMAT were 56.9 Gy, 56.0 Gy and 56.2 Gy 
respectively.    
    
For other OAR, VMAT showed preferential sparing.  Spinal cord maximum doses for VMAT 
(7.5 Gy) were lower than both the 3DCRT (9.9 Gy) and IMRT (8.9 Gy) techniques.  The 
volume of lung receiving 10.5 Gy and 11.4 Gy was also reduced using VMAT (table 4).  
Furthermore, there was a statistically significant difference in the mean lung dose (MLD) for 
VMAT when compared to 3DCRT (p = <0.001) and IMRT (p = < 0.001).   
 
Mean prescription isodoses for each technique were 69.2%, 66.3% and 66.0% for 3DCRT, 
IMRT and VMAT respectively.  For PTVs overlapping the chest wall mean prescription 
isodoses were 75.5% for 3DCRT, 70.8% for IMRT and 70.5% for VMAT.  For PTVs 
completely surrounded by lower density lung tissue, prescription isodoses were 61.5%, 60.8% 
and 60.4% for 3DCRT, IMRT and VMAT respectively.  Treatment times were recorded for the 
first ten plans per techinque and the mean times were, 20.0 minutes, 25.2 minutes and 11.7 
minutes respectively for 3DCRT, IMRT and VMAT.   
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Discussion: 
This study investigated the use of 3 different non-coplanar treatment techniques for the delivery 
of peripheral lung SABR.  All three techniques demonstrated the ability to deliver clinically 
suitable plans in over 90% of cases.  The only unacceptable deviations reported are maximum 
dose and volumetric deviations for the rib when the PTV is overlapping the chest wall.  In a 
clinical setting, the treating oncologist would have to make a clinical judgement call to either 
overdose the rib, or compromise PTV coverage. 
 
With respect to PTV coverage, IMRT showed preferential increases in the percentage of PTV 
receiving 48.6 Gy and 54 Gy when compared to 3DCRT (p=<0.0001 and p=0.048 respectively). 
However, the resultant increase in treatment time with IMRT may not outweigh the small gain 
in coverage.  VMAT however, demonstrated superior 48.6 Gy coverage when compared to 
3DCRT and had substantially reduced treatment times.  Brock et al [103] compared several 
coplanar and non-coplanar 3DCRT techniques with VMAT for lung SABR delivery 60 Gy in 8 
fractions, also finding an increase in the volume of PTV receiving 95% and 90% of the 
prescription dose.   
 
All of the techniques generated plans that adhered to both the R50% and D2cm constraints, with no 
unacceptable deviations in any plan.  However, the VMAT technique demonstrated the ability 
to produce a greater number of plans that had no deviation to either of the intermediate dose 
constraints.  Both the IMRT and VMAT techniques showed a statistically significant 
improvement to the D2cm constraint when compared to 3DCRT. Similarly to that of McGrath et 
al [118], our data also represents a statistically significant improvement of the R50% for VMAT 
when compared to 3DCRT.   
 
High dose conformity ensures that normal tissue directly adjacent to the PTV is not being 
unnecessarily exposed to the prescription dose or higher.  This present study shows that both 
IMRT and VMAT significantly improve the conformity of the prescription isodose when 
compared to 3DCRT.  The mean CI for 3DCRT was 0.81, with IMRT and VMAT producing 
mean CI values of 0.88 and 0.89 respectively, both with a statistically significant difference.  
For VMAT this is an increase of 9%, similar to the findings of Ong et al [97], who reported an 
increase in the CI of 7% when comparing VMAT to 3DCRT. 
 
The essence of stereotactic planning is to create a steep and isotropic dose fall off.  Therefore 
when planning used a fixed gantry angle technique such as 3DCRT or IMRT, beam 
arrangements are required to be spread out, minimizing the overlap of intermediate doses.  This 
occasionally results in treatment beams entering through an OAR. VMAT, however, has the 
advantage of limiting the gantry arc from entering through OAR.  The plans presented in this 
study started at 180°, and either moved clockwise or anti-clockwise 200-220°.  This meant that 
the spinal cord only received exit dose from the arc.  This resulted in a low mean maximum 
point dose to the spinal cord.  On average VMAT was able to lower the maximum spinal cord 
dose by 2.4 Gy and 1.4 Gy compared to 3DCRT and IMRT techniques respectively.  While still 
under tolerance it is advantageous to reduce dose to the spinal cord for a number of reasons, 
including but not limited to the possibility of future spinal metastases requiring irradiation.  
Furthermore, even though the VMAT technique technically delivered dose from more 
“individual beams”, the low weighting through each segment resulted in a higher ablative dose 
in the PTV and less dose to the lungs, this is evident with a reduction in the 10.5 Gy and 11.4 
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Gy isodose volume.  Furthermore, VMAT had a statistically significant lower mean lung dose 
than either the 3DCRT or IMRT techniques. 
 
Decreasing the influence of intra-fraction motion associated with extended treatment times is 
important.  Purdie et al [87] report for treatment times >34 minutes, intra-fractional shifts of up 
to 5mm can occur.  As this present study was a retrospective analysis, the beam on times 
measured were purely only dose delivery, and any time associated with couch and gantry 
rotations.  From these values alone, VMAT reduced the delivery time by 8.3 minutes (41.5%) 
and 13.5 minutes (53.4%), compared to 3DCRT and IMRT respectively.   These results sit 
favourably with those reported by McGrath et al [118] who report on average 6.15 minutes to 
deliver a 180°, 12 Gy per fraction arc.  Treatment times reported in this study are slightly 
extended due to delivering 18 Gy per fraction coupled with couch rotations.  VMAT will be 
able to further reduce treatment times with the inclusion of flattening filter free (FFF) beams 
[119].   
 
Conclusion: 
A non-coplanar VMAT technique provides superior intermediate dose and OAR sparing with 
comparable prescription dose coverage when compared to non-coplanar 3DCRT or IMRT.  
Treatment times can be reduced with the use of VMAT.  Future directions include the use of 
FFF treatment machine to reduce treatment times even further.   
 
 
Table 7.1 -. Organ at risk dose constraints 
 
 
Organ Constraint(s) 
Spinal Cord 18 Gy < 0.35 cm3 
12.3 Gy < 1.2 cm3 
MPD < 21.9 Gy 
Brachial Plexus 20.4 Gy < 3 cm3 
MPD < 24 Gy 
Aorta, SVC and  IVC 39 Gy < 10 cm3 
MPD < 49 Gy 
Pericardium 24 Gy < 15 cm3 
MPD < 30 Gy 
Trachea 15 Gy < 4 cm3 
MPD < 30Gy 
Combined Lungs – ITV 11.4 Gy < 1000 cm3 
10.5 Gy < 1500 cm3 
Oesophagus 17.7 Gy < 5 cm3 
MPD < 25.2 Gy 
Rib 40 Gy < 5 cm3 
MPD < 50 Gy 
CW 30 Gy < 30 cm3 (<70 cm3 for tumours on the 
CW) 
Skin 30 Gy < 10 cm3 
MPD < 33 Gy 
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Abbreviations IVC = inferior vena cava, SVC = superior vena cava, ITV = internal target 
volume, CW = chestwall, MPD = maximum point dose (defined as ≥0.03 cm3) 
 
 
 
 
 
Table 7.2 - Acceptable dose spillage guidelines from RTOG 1021 
 
Ratio of Prescription 
Isodose Volume to the 
PTV 
Ratio of 27 Gy Isodose 
Volume to the PTV R50% 
Maximum Dose at 2 cm from 
PTV in any direction as % of 
Prescribed dose (PD). D2cm (gy) 
= % x PD 
PTV 
Volume 
(cc) 
Deviation  Deviation Deviation 
None Acceptable None Acceptable None Acceptable 
<1.2 <1.5 <5.9 <7.5 <50.0 <57.0 1.8 
<1.2 <1.5 <5.5 <6.5 <50.0 <57.0 3.8 
<1.2 <1.5 <5.1 <6.0 <50.0 <58.0 7.4 
<1.2 <1.5 <4.7 <5.8 <50.0 <58.0 13.2 
<1.2 <1.5 <4.5 <5.5 <54.0 <63.0 22.0 
<1.2 <1.5 <4.3 <5.3 <58.0 <68.0 34.0 
<1.2 <1.5 <4.0 <5.0 <62.0 <77.0 50.0 
<1.2 <1.5 <3.5 <4.8 <66.0 <86.0 70.0 
<1.2 <1.5 <3.3 <4.4 <70.0 <89.0 95.0 
<1.2 <1.5 <3.1 <4.0 <73.0 <91.0 126.0 
<1.2 <1.5 <2.9 <3.7 <77.0 <94.0 163.0 
PTV = planning target volume 
 
Table 7.3 - List of starting objectives for all techniques 
 
ROI Objective Type Target Dose (Gy) Volume (%)* Weight 
PTV Minimum DVH 54 100 5 
ITV Minimum Dose 60  1 
ITV Maximum Dose 91.5  5 
D2cm Maximum Dose Table 3  5 
27 Gy Ring Maximum Dose 27  5 
54 Gy Ring Maximum Dose 54  1 
Abbreviations: ROI = Region of interest, DVH = Dose volume histogram, PTV = planning 
target volume, ITV = internal target volume 
* Only applicable for Maximum or Minimum DVH objective types  
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Table 7.4 - Mean dose statistics for each technique with associated P values. 
 
Metric Parameter 3DCRT IMRT VMAT P value* 
(3DCRT-
VMAT) 
P Value* 
(IMRT-
VMAT) 
P value* 
(3DCRT-
IMRT) 
PTV54Gy (%) 95.59 95.71 95.63   0.048 
PTV48.6Gy (%) 99.56 99.99 99.99 <0.0001  <0.0001 
D2cm Absolute 
Difference 
-0.86 -4.485 -5.72 <0.0001 <0.0001 <0.0001 
R50% Absolute 
Difference 
0.37 0.25 0.08 0.04 0.04  
CI  0.80 0.88 0.89 <0.0001  <0.0001 
MLD (Gy) 4.12 4.01 0.04 <0.0001 <0.0001  
Spinal Cord Dmax (Gy) 9.87  8.95 7.55    
 V18Gy (cm3) 0.00 0.00 0.00    
 V12.3Gy 
(cm3) 
0.22 0.07 0.00    
Rib Dmax (Gy) 44.10 43.5 43.87    
 V40Gy (cm3) 1.55 2.00 1.82    
Chest Wall V30Gy (cm3) 20.22 20.69 19.71    
Combined Lung - 
ITV 
V10.5Gy 
(cm3) 
447.94 450.44 369.60    
 V11.4Gy 
(cm3) 
440.16 404.01 338.09    
Pericardium Dmax (Gy) 22.34 21.02 19.74    
 V24Gy (cm3) 0.94 0.50 0.47    
Skin Dmax (Gy) 22.6 22.50 17.19    
 V30Gy (cm3) 0.19 0.30 0.25    
Oesophagus Dmax (Gy) 13.3 12.86 8.82    
 V17.7Gy 
(cm3) 
0.18 0.03 0.01    
Aorta Dmax (Gy) 16.3 15.63 11.03    
 V39Gy (cm3) 0.00 0.00 0.00    
Trachea Dmax (Gy) 9.44 9.1 7.68    
 V15Gy (cm3) 0.75 0.34 0.15    
*Adjusted p value of post hoc tests. 
Abbreviations   
PA = coplanar partial arc technique; FA = coplanar full arc technique; NCA = non-coplanar 
technique utilising three partial arcs 
ITV = internal target volume, PTV = planned target volume, MLD = mean lung dose, CI = 
conformity index 
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Table 7.5 - Protocol deviations for each technique, categorized into coplanar and non-coplanar 
and mean values for all coplanar and non-coplanar techniques combined with associated P 
values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CI = conformity index, 
OAR = organs at risk 
 3DCRT IMRT VMAT 
D2cm 
None 
Acceptable 
Unacceptable 
 
18 
2 
0 
 
20 
0 
0 
 
20 
0 
0 
R50% 
None 
Acceptable 
Unacceptable 
 
8 
12 
0 
 
6 
14 
0 
 
14 
6 
0 
CI 
None 
Acceptable 
Unacceptable 
 
19 
1 
0 
 
20 
0 
0 
 
20 
0 
0 
OAR 
None 
Acceptable 
Unacceptable 
 
9 
8 
3 
 
9 
9 
2 
 
9 
9 
2 
Total Deviations 
None 
Acceptable 
Unacceptable 
 
35 
22 
3 
 
21 
12 
7 
 
43 
15 
2 
Clinically Suitable Plans 17 18 18 
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This project compared three different delivery techniques for the delivery of stereotactic ablative 
radiation therapy (SABR) to the lung to treat early stage lung cancer.  The aim was to determine if 
lung SABR could be delivered in quicker treatment times with the use of VMAT, without a 
reduction in plan quality compared to both 3DCRT and IMRT.  To answer this question, the project 
was separated into two main components, the first being a like-for-like comparison between 
differing 3DCRT, IMRT and VMAT techniques.  This was an important step in the project as the 
“gold standard” for each technique needed to first be identified, before comparisons between the 
techniques could be made.  The second component was to compare 3DCRT with IMRT and VMAT 
to reach the primary end point for this project which was to find the optimal delivery technique for 
lung SABR.  This project used dose prescriptions, dose restraints to organs at risk and intermediate 
dose constraints that have been stated in RTOG protocols.[82-84, 86] 
 
The first paper of this project explored the 3DCRT treatment technique where six different beam 
arrangements using 3DCRT for 10 different patients were compared.   The dosimetric advantages of 
using non-coplanar beams has previously been reported, however, the results of the current study 
illustrate that non-coplanar beams are necessary to meet the intermediate and OAR dosimetric 
constraints for any single plan. [81]  It was found that a 10 field technique that had a majority of 
non-coplanar beams (≥6) provided the most optimal plan and adhered to the constraints as 
prescribed by RTOG 1021.  This finding was inline with another publication by Lim et al [91] that 
report that with an increasing number of non-coplanar beams, the intermediate doses, in particular 
the R50% value can be reduced.  This present study found that the R50% and D2cm values can be 
significantly reduced with the appropriate beam selection and adequate amount of non-coplanar 
beams.  There was no case where any technique apart from the 10NC was able to produce a plan 
with no protocol deviations.   
 
Increasing the number of fields (13C) resulted in a marginal improvement when compared to either 
of the coplanar and non-coplanar 7 and 9 field techniques, with fewer protocol deviations in regards 
to the intermediate dose.  However, it was not able to replicate the intermediate dose sparing 
achievable with the 10NC technique.   In theory, increasing the number of beams reduces the dose 
delivered with each beam, spreading out the low dose and overlapping beams, resulting in a lower 
intermediate dose.  This is crucial with SABR and allows for a steep isotropic fall off in dose. 
 
Our findings do however, differ from those reported by Richmond et al [94] where they report in  
89.5% of cases a 7 coplanar field technique had 2 or less minor deviations to the ROSEL protocol 
[95]. The difference in intermediate dose constraints between RTOG 1021 and ROSEL significantly 
alters which beam arrangements are deemed acceptable.  All the techniques tested in this study had 
intermediate doses that were acceptable following the ROSEL guidelines.  The difference in 
acceptable D2cm and R50% constraints is believed to be the main reason for disparity.  It is therefore 
important to take care in critiquing SABR results, and comparing studies as the starting protocol 
significantly influences the outcomes. 
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Paper two investigated IMRT for lung SABR re-iterated similar findings to that of  3DCRT, in 
which increasing the number of beams, especially the number of non-coplanar beams improved plan 
quality and better adhered to intermediate dose (D2cm and R50%) constraints.  This findings were 
consistent with those published by Holt et al [106] who also investigated non-coplanar IMRT for 
peripheral lung SABR.  Non-coplanar IMRT also reduced the maximum dose to the spinal cord. 
This project demonstrated that rib tolerances can be achieved in 63.3 % of cases regardless of 
technique.  Of the plans where rib maximum doses were unachievable, only four plans had an 
R50% that failed to reach an acceptable deviation.  This highlights that maximum rib dose 
constrains only impact intermediate dose objectives if 7 (coplanar on non-coplanar) or less 
fields are used.  Therefore, from the beam arrangements tested, >9 fields (either coplanar or 
non-coplanar) are required for tumours adjacent to the chest wall in order to meet both 
intermediate and OAR dose constraints.  
 
One potential limitation of both paper 1 and paper 2 is the mixture of location of the tumours.  Of the 
10 patients data sets used for each study, 50 % of tumours were adjacent to the chest wall, and 50 % 
were entirely surrounded by lung parenchyma.  Planning priorities in order were first and foremost, 
to adhere to the spinal cord and brachial plexus constraint, secondly to meet the high and 
intermediate dose constraints and lastly to meet the remaining OAR constraints.  Therefore, 
prioritizing intermediate doses before non-spinal cord OAR may in fact cause some bias as the non-
coplanar beam arrangements will always be superior to a coplanar arrangements in meeting 
intermediate does.  This is due to the fact that isotropic fall off will be more achievable with non-
coplanar beams[81], therefore allowing the planner to concentrate more on rib tolerances with non-
coplanar beam arrangements.  While the 3DCRT technique demonstrated that the only beam 
arrangement able to achieve rib tolerance was the 10NC, it was difficult to reach any conclusion.  
However, with the IMRT techniques, the 9C, 9NC, 13C and 10NC techniques were able to achieve 
maximum rib dose constraints.  This demonstrates that if IMRT is being used with ≥9 fields 
coplanar or non-coplanar then both intermediate and rib maximum doses are achievable, indicating 
no bias between coplanar and non-coplanar techniques. 
 
Paper three compared three different VMAT delivery techniques across 10 patients as part of 
the first component of this project.  Similarly to the first paper it also demonstrated that a non-
coplanar aspect to treatment planning produced superior quality plans than to those that had 
beams entering through only a coplanar (single plane) element.  Although, the single full arc 
coplanar VMAT plans were inferior to the non-coplanar plans, they did produce clinically 
suitable plans in 70 % of the patient cohort.  As a single full arc coplanar treatment would be 
quicker than a non-coplanar treatment technique with multiple couch rotations, the small gains 
in intermediate dose reduction may not outweigh any gains in treatment times.  However as 
treatment times were not measured, this theory can only by hypothesised for future work.   
 
Regardless if the conventional or hypofractionated radiation is being administered, a general 
concern for arc based treatments to the lung is the increased low dose wash, especially to the 
contra-lateral lung.  The effect of this low dose wash or “bathing” can be seen with the increase 
in the mean lung dose (MLD) of the full arc technique.  Paper 3 reports a MLD dose of 4.3 Gy 
which is similar to that of Holt et al  [106] (4.2 Gy) for single coplanar VMAT.  The MLD for 
the NCA (3.98 Gy) and PA (4.09 Gy) techniques were lower than the full arc technique.  In a 
matched analysis study, Palma et al investigated radiobiological and clinical pneumonitis after 
both VMAT (RapidArc) and 3DCRT and concluded that there was no difference in the severity 
of clinical or radiobiological sequelae after treatment [117].  
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Lastly, the fourth paper was the most important of this project.  After identifying the optimal 
delivery technique for each of the three respective technologies, they were compared in a larger 
cohort of 20 patients.  This compared 10 field non-coplanar 3DCRT, 10 field IMRT and 3 partial arc 
non-coplanar VMAT.  This paper found that the VMAT technique had the most optimal plans when 
critiqued against RTOG 1021 protocol criteria.  The intermediate dose wash and OAR sparing was 
increased with the VMAT technique while still producing higher doses to the tumour when 
compared to 3DCRT.  However, both the 3DCRT and IMRT technique did produce clinically 
acceptable plans. While IMRT showed improved tumour coverage and OAR sparing, the treatment 
time was increased when compared to 3DCRT.  As an increase in treatment time results in a baseline 
shift of tumour position, the small gains in a plan where OAR doses are under tolerance 3DCRT 
should be the treatment option of choice[87].  
 
Decreasing the influence of intra-fraction motion associated with extended treatment times was 
a secondary objective for this project.  Purdie et al [87] report for treatment times >34 minutes, 
intra-fractional shifts of up to 5mm can occur.  VMAT reduced the delivery time by 8.3 minutes 
(41.5%) and 13.5 minutes (53.4%), compared to 3DCRT and IMRT respectively.   These results 
sit favourably with those reported by McGrath et al [118] who report on average 6 minutes and 
nine seconds to deliver a 180°, 12 Gy per fraction arc.  IMRT should therefore only be used if 
OAR, in particular the rib, pericardium and spinal cord maximum or volumetric doses could not 
be achieved with 3DCRT.  Nonetheless, if VMAT is an available treatment option then it should 
be used over both 3DCRT and IMRT as treatment times are significantly reduced.  As the 
interplay effect is still a subjective phenomenon, it is suggested the departments take due course 
in implementing VMAT without an understanding of the dosimetric implications between leaf 
speed and tumour motion.  One other issue arising from IMRT and VMAT is the increased 
workload placed on physics within a deparmtnet.  The patient specific QA that is required for 
IMRT and VMAT far outweighs the time required to do a point dose check of a 3DCRT plan.  
As 3DCRT demonstrates the ability to produce clinically acceptable, then intensity modulation 
may best be reserved for those tumour streams where is a necessity, i.e. head and neck and 
prostate cancer, especially in a department where resources are stretched thin.  
 
A general concern with intensity modulated techniques investigated in this project is the 
interplay effect.  The interplay effect is the potential difference in the planned dose to the 
delivered dose due to patient respiration.  This is caused by differences in the MLC movements 
to tumour motion when comparing the static respiratory phase the planning CT captured with 
the breathing cycle during treatment [112].  Several groups have investigated this phenomenon 
(VMAT or RapidArc) and report that for a single fraction split over two arcs, or >1 treatment 
fractions, the interplay effect is negligible and the actual delivered dose is within reasonable 
tolerance to the planned dose. [111, 112, 136]  
 
While finding the optimal delivery technique was the primary aim for this project, some other 
interesting data came out of the project which could also lead to more efficient planning of lung 
SABR.  Ding et al [79] report that for linear accelerator based lung SABR, the optimal prescription 
isodose falls somewhere between the 59-69% isodose.  However, this range is only a guide and does 
not give a specific value that is achievable or should be aimed for.  And, as the results from papers 1, 
and 4 show, the value of the prescription isodose changes dramatically if the tumour is attached to 
the chest wall or completely surrounded by lung parenchyma.  Therefore an investigation took place 
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into observing if any correlation between the final plan and the prescription isodose was noticeable.  
It was found that when the density of the PTV plus a 2cm isotropic margin was plotted against the 
prescription isodose for individual plans, there was an R2 value of 0.88, signifying high correlation.  
This finding now allows for the prescription isodose to be calculated before beginning planning and 
removes the monotonous task of trial and error to find the optimal –prescription isodose for 
individual patients.  This data is currently being collated to be submitted to a peer reviewed journal. 
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8Chapter 9: Future work 
Future work from this project could include looking into the use of FFF for the delivery of lung 
SABR.  As iterated throughout this report, the main aim was to reduce the treatment times for 
patients.  FFF will most likely be bale to do this for lung SABR.  Although the MU can increase to 
2400 MU/min, the limit will be the MLC leaf speed.  If the VMAT plans are over modulated then 
the treatment delivery speed may not be much quicker, as the leaf speed is limiting the treatment and 
reducing treatment efficiency. 
 
Another avenue is the validate and report on any interplay effect present with these plans.  With the 
use of a 4D phantom, the MLC interplay could potentially be measured and the plans could be 
validated for delivery and the actual dose delivered to a moving target under a modulated beam. 
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9Chapter 10: Conclusion and 
Recommendations 
This project demonstrated that non-coplanar VMAT consisting of 3 partial arcs provided 
more optimal plans than either coplanar or non-coplanar 3DCRT, coplanar or non-coplanar IMRT 
and coplanar VMAT.  The ability to modulate the dose while delivering non-coplanar arcs that are 
continuously delivering the dose not only provided increased tumour coverage, but reduced doses to 
organs at risk and treatment times.  However, non-coplanar 3DCRT, non-coplanar IMRT and 
coplanar single full arc VMAT were still able to produce clinically acceptable plans in a majority of 
the cases and still meet RTOG criteria.  IMRT demonstrated only small improvements to plan 
quality, and no clinically significant improvements when compared to 3DCRT and significantly 
increased the treatment time. 
 
It is recommended that for patient comfort and treatment efficiency that the first technique 
that should be attempted for lung SABR is single full arc VMAT.  Even though the plans were 
slightly inferior to non-coplanar VMAT, the plans still fell within RTOG criteria and are able to be 
treated in a quicker treatment time than a technique that requires two floor rotations.  For those 
departments that do not have VMAT technology, then a 10 field 3DCRT technique with 6 or greater 
non-coplanar fields should be used.  IMRT should only be used in specific cases instead of 3DCRT 
when specific OAR constraints (such as the rib maximum dose) can not be achieved with 3DCRT 
due to extended treatment times with IMRT. 
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11Appendices 
11.1 APPENDIX A: PHASE 1 3DCRT RESULTS  
11.1.1 Patient 1 
 
 
 
 
ROI Objective 7FLDC 7FLDNC 9FLDC 9FLDNC 10FLDNC 13FLDC 
PTV 
95%  ≥ 100 % of PD 95.08% 95.10% 95.15% 95.17% 95.02% 95.14% 
99% ≥ 90 % of PD 99.67% 99.82% 99.65% 99.88% 99.77% 99.73% 
SC 
0.35cc <18Gy 0 0 0 0 0 0 
1.2cc < 12.3Gy 0.92 0.62 0 0.38 0 0 
21.9Gy max pt 13.1 12.9 11.8 12.7 8.1 11.7 
BP 3cc < 20.4Gy 
0 0 0 0 0 0 
24Gy max pt 0.6 0.8 0.6 0.8 0.9 0.6 
Heart 15cc < 24Gy 
0 0 0 0 0 0 
30Gy max pt 1 1.1 1 1 4.8 1 
IVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 0.2 0.3 0.2 0.3 0 0.2 
SVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 9.5 10.5 14.5 13.2 18.4 19.5 
Aorta 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 13.2 12.9 15.3 15.1 21.9 16.1
Pericardium 15cc < 24 Gy 
0 0 0 0 0 0
30Gy max pt 13.2 12.9 15.4 15.1 22 19.5 
Trachea 4cc < 15Gy 
0 0 0 0 3.26 2.95 
30Gy max pt 13.8 14 13.3 13.2 19 18.6 
Comb Lung - 
ITV 
1500cc < 10.5Gy 591.35 586.78 606.18 591.75 686.79 631.08 
1000cc < 11.4 Gy 550.55 545.51 569.14 555.56 628.4 583.09 
Oesophagus 5cc < 17.7 Gy 
0 0 0 0 0 0 
25.2Gy max pt 12.8 13 13.9 13.7 18.2 15.8 
Rib 5cc < 40Gy 
0 0 0 0 0 0 
50Gy max pt 34.8 34.9 30.5 31 26.5 31.8 
Skin 10cc < 30Gy 
0 0 0 0 0 0 
33Gy max pt 22.8 23.1 21.5 22 24.5 17.5 
CW 30cc < 30Gy 1.17 2.18 0.12 0.11 0 1.27
D2cm <29.8Gy <34.7 36.4 37.6 33.2 33.5 28.4 32.1 
R50% <4.5  <5.5 6.96 6.52 6.71 6.33 5.43 6.73 
TV(PTV)   24.04 24.05 24.06 24.06 24.02 24.06 
TV   25.28 25.28 25.28 25.28 25.28 25.28 
PIV   28.92 28.89 28.79 28.45 27.8 28.94 
CI   0.790485 0.7919642 0.795376 0.804881 0.820964 0.791254 
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11.1.2 Patient 2 
 
 
 
 
 
 
 
 
 
 
ROI Objective 7FLDC 7FLDNC 9FLDC 9FLDNC 10FLDNC 13FLDC 
PTV 
95%  ≥ 100 % of PD 95.03% 95.11% 95.13% 95.06% 95.55% 95.11% 
99% ≥ 90 % of PD 99.77% 99.70% 99.85% 99.91% 99.77% 99.99% 
SC 
0.35cc <18Gy 0 0 0 0 0 0 
1.2cc < 12.3Gy 0 0 0 0 0.61 0 
21.9Gy max pt 7.1 1 6.4 1.1 12.8 10.8 
BP 3cc < 20.4Gy 
0 0 0 0 0 0
24Gy max pt 0.1 0.23 0.11 0.22 0.28 0.13
Heart 15cc < 24Gy 
0 0 0.19 0.26 0 0.71 
30Gy max pt 22.4 23.6 26 26 20.4 26.7 
IVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 0.88 0.88 0.98 0.96 1.03 1 
SVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 16 12.4 16.5 14.3 13.7 21.1 
Aorta 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 11.7 11.8 11.7 12 9 18.8 
Pericardium 15cc < 24 Gy 
0 0 1.12 0.27 0 0.74 
30Gy max pt 22.8 22.2 26 26 20.4 26.7 
Trachea 4cc < 15Gy 
0 0 0 0 0 0 
30Gy max pt 1 0.9 1.14 1.03 1.04 1.17 
Comb Lung - 
ITV 
1500cc < 10.5Gy 518.82 526.51 501.55 507.51 485.26 487.67 
1000cc < 11.4 Gy 484.4 488.68 473.35 476.7 443.43 430.37 
Oesophagus 5cc < 17.7 Gy 
0 0 0 0 0 0 
25.2Gy max pt 9.5 1 11.9 6.7 8.2 12.1 
Rib  5cc < 40Gy 
0 0 0 0 0 0 
50Gy max pt 34.7 26.7 33.3 25.2 24.7 31.4 
Skin 10cc < 30Gy 
0 0 0 0 0 0 
33Gy max pt 31.7 20.2 25.5 24.8 19.7 20 
CW 30cc < 30Gy 6.09 0.84 4.6 0.2 0 3.06 
D2cm <29.7 <34.6 35.3 31.8 32 31.2 27.2 30.1 
R50% <4.5 <5.5 6.2 5.39 6.05 5.26 4.5 5.83
TV(PTV)   22.83 22.86 22.86 22.85 22.96 22.86
TV   24 24 24 24 24 24 
PIV   27.89 28.16 28.15 27.67 27.28 25.99 
CI   0.778668 0.77323 0.773504 0.786234 0.805171 0.83779 
Appendices Page 107 
© 2016 FITZGERALD Page 107 
11.1.3 Patient 3 
ROI Objective 7FLDC 7FLDNC 9FLDC 9FLDNC 10FLDNC 13FLDC 
PTV 
95%  ≥ 100 % of PD 95.12% 95.01% 95.18% 95.06% 95.06% 95.04% 
99% ≥ 90 % of PD 99.98% 99.97% 99.48% 99.96% 99.90% 99.99% 
SC 
0.35cc <18Gy 0 0 0 0 0 0 
1.2cc < 12.3Gy 0 0 1.12 0.82 0 0 
21.9Gy max pt 4 3.9 14.3 13.7 9.1 12.3 
BP 3cc < 20.4Gy 
0 0 0 0 0 0 
24Gy max pt 0 0.03 0.04 0.03 0.06 0.03 
Heart 15cc < 24Gy 
1.26 1.29 1.95 2.15 3.59 8.72 
30Gy max pt 30 29 30 30 29.9 34.9 
IVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 2 1.2 1.6 1.2 3.1 2.1 
SVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 3.5 3.8 5.7 6.7 1.12 6.6 
Aorta 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 23.2 20.9 21.5 20.7 17.9 19.7 
Pericardium 15cc < 24 Gy 
1.26 1.29 1.95 2.15 3.59 8.75 
30Gy max pt 30 29 30 30 29.9 34.9 
Trachea 4cc < 15Gy 
0 0 0 0 0 0 
30Gy max pt 0.6 0.6 0.7 0.8 0.8 0.7 
Comb Lung - 
ITV 
1500cc < 10.5Gy 766.23 736.48 739.26 700.22 706.63 684.22 
1000cc < 11.4 Gy 730.12 686.94 692.88 650.08 652.52 651.76 
Oesophagus 5cc < 17.7 Gy 
2.72 2.23 0 0 0 0 
25.2Gy max pt 23.2 20.7 14.7 14 17.7 15.6 
Rib 5cc < 40Gy 
0 0 0 0 0 0 
50Gy max pt 32.9 30.9 31.8 32.5 31.4 33 
Skin 10cc < 30Gy 
0 0 0 0 0 0 
33Gy max pt 28 29.3 27.1 25.9 22 22.8 
CW 30cc < 30Gy 1.41 1.28 0.76 0.65 0.11 0.64 
D2cm <31.6 <36.7 39.4 38 35 36.7 31 31.3 
R50% <4.3  <5.3 7.44 6.98 7.2 7.1 5.29 6.72 
TV(PTV)   33.52 33.49 33.52 33.49 33.5 33.49 
TV   35.2 35.2 35.2 35.2 35.2 35.2 
PIV   39.93 41.44 39.6 40.32 39.16 39.01 
CI   0.799404 0.768897 0.806065 0.790255 0.81415 0.816792 
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11.1.4 Patient 4 
ROI Objective 7FLDC 7FLDNC 9FLDC 9FLDNC 10FLDNC 13FLDC 
PTV 
95%  ≥ 100 % of PD 95.16% 95.02% 95.01% 95.02% 99.03% 95.15% 
99% ≥ 90 % of PD 99.58% 99.51% 99.59% 99.65% 99.93% 99.76% 
SC 
0.35cc <18Gy 0 0 0 0 0 0 
1.2cc < 12.3Gy 0.13 0 0 0 0 0.26 
21.9Gy max pt 13.1 1.1 6.9 0.92 6.5 12.8 
BP 3cc < 20.4Gy 
0 0 0 0 0 0 
24Gy max pt 1.08 1.15 1.13 1 1.16 1.12 
Heart 15cc < 24Gy 
0.16 0.2 0.06 0.29 0.19 0.02 
30Gy max pt 28 28.5 25.2 31 28 23.5 
IVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 0.42 0.69 0.48 0.59 0.48 0.49 
SVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 8.5 1.3 1.3 1.5 7.5 12.8 
Aorta 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 16 11.4 19 15.3 14.7 16.7 
Pericardium 15cc < 24 Gy 
2.27 1.11 3.81 1.68 1.64 10.6 
30Gy max pt 31.5 30.1 30.5 32.9 28.2 36 
Trachea 4cc < 15Gy 
0 0 0.58 0 0 0.1 
30Gy max pt 9.5 11.3 16.3 14.9 7.2 15.8 
Comb Lung - 
ITV 
1500cc < 10.5Gy 372.95 383.76 397.18 404.44 425.9 361.86 
1000cc < 11.4 Gy 348.61 344.77 366.63 368.26 378.04 318.12 
Oesophagus 5cc < 17.7 Gy 
0 0 0 0 0 0 
25.2Gy max pt 9.2 11.3 16.8 15.3 6.8 15.3 
Rib 5cc < 40Gy 
0 0 0 0 0 0 
50Gy max pt 25.5 26 29.5 23.2 28.4 26.1 
Skin 10cc < 30Gy 
0 0 0 0 0 0 
33Gy max pt 22.7 22.5 20 19.8 18.7 16.1 
CW 30cc < 30Gy 0 0 0 0 0 0 
D2cm <29.2 <34.0 30.9 27.4 30.3 28.8 28.4 29.2 
R50% <4.5 <5.5 4.53 3.9 4.41 4.16 4.12 4.45 
TV(PTV)   21.81 21.77 21.77 21.77 22.46 21.8 
TV   22.9 22.9 22.9 22.9 22.9 22.9 
PIV   24.21 23.9 24.06 24.15 28.29 24.54 
CI   0.857988 0.865931 0.860173 0.856967 0.778666 0.845674 
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11.1.5 Patient 5 
 
 
 
 
 
 
 
 
 
 
ROI Objective 7FLDC 7FLDNC 9FLDC 9FLDNC 10FLDNC 13FLDC 
PTV 
95%  ≥ 100 % of PD 95.09% 95.05% 95.01% 95.08% 95.41% 95.01% 
99% ≥ 90 % of PD 99.61% 99.62% 99.77% 99.84% 99.63% 99.88% 
SC 
0.35cc <18Gy 0 0 0 0 0 0 
1.2cc < 12.3Gy 0 0 0 0 0 0 
21.9Gy max pt 10.3 11.1 8.7 8.9 8.3 11.1 
BP 3cc < 20.4Gy 
            
24Gy max pt             
Heart 15cc < 24Gy 
0 0 0 0 0 0 
30Gy max pt 10.1 11.1 15.4 15.9 10.1 12.5 
IVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 0.5 0.6 0.4 0.5 0.6 0.4 
SVC 10cc < 39Gy 
0 0 0 0 0 0
45Gy max pt 12.3 13.5 10.5 12.1 11 16.3
Aorta 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 10.1 10.9 13.5 13.8 11.2 12.6 
Pericardium 15cc < 24 Gy 
0 0 0 0 0 0 
30Gy max pt 16.1 17.3 18.9 19.5 20.4 22 
Trachea 4cc < 15Gy 
0 0 0 0 0 0 
30Gy max pt 10.6 11.5 12 12.4 9.1 15.3 
Comb Lung - 
ITV 
1500cc < 10.5Gy 499.53 452.27 530.94 496.73 552.82 515.61 
1000cc < 11.4 Gy 470.91 425.78 495.56 464.32 506.07 465.85 
Oesophagus 5cc < 17.7 Gy 
0 0 0 0 0 0 
25.2Gy max pt 1.6 1.6 5.8 5.8 9 11.2 
Rib 5cc < 40Gy 
0 0 0 0 0 0 
50Gy max pt 29.3 31.2 30 29.8 29.5 30.4 
Skin 10cc < 30Gy 
0 0 0 0 0 0 
33Gy max pt 19.9 21.8 18.8 18.7 20.5 18 
CW 30cc < 30Gy 0.07 0.28 0.04 0.1 0.02 0.23 
D2cm <30.5 <35.8 32.4 33.6 31.2 32.2 29.3 29.2 
R50% <4.4 <5.4 5.5 5.34 5.21 4.9 4.38 4.93 
TV(PTV)   28.21 28.22 28.21 28.23 28.33 28.21 
TV   29.7 29.7 29.7 29.7 29.7 29.7 
PIV   32.86 32.46 31.64 31.32 31.85 30.7 
CI   0.815422 0.826055 0.846863 0.856729 0.848452 0.872793 
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11.1.6 Patient 6 
 
 
 
 
 
 
 
 
 
 
ROI Objective 7FLDC 7FLDNC 9FLDC 9FLDNC 10FLDNC 13FLDC 
PTV 
95%  ≥ 100 % of PD 96.27% 95.14% 95.32% 95.27% 95.00% 95.09% 
99% ≥ 90 % of PD 99.00% 99.00% 99.02% 99.00% 99.17% 99.16% 
SC 
0.35cc <18Gy 0 0 0 0 0 0 
1.2cc < 12.3Gy 0 0 0.3 0 0 0 
21.9Gy max pt 10.2 9.6 14.4 10.1 9.3 11.1 
BP 3cc < 20.4Gy   
24Gy max pt             
Heart 15cc < 24Gy 
0 0 0 0 0 0 
30Gy max pt 15.7 16.5 22.5 20.8 20.8 18.7 
IVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 11 12.4 18.4 16.7 22 17.9 
SVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 1.1 0.92 1.17 1.1 1.5 1.15 
Aorta 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 9.1 10.1 18.6 16.5 24.4 18.3 
Pericardium 15cc < 24 Gy 
0 0 0 0 0 0 
30Gy max pt 16.8 17.2 22.9 21.4 21.4 20.3 
Trachea 4cc < 15Gy 
0 0 0 0 0 0 
30Gy max pt 0 0 0 0 0.32 0 
Comb Lung - 
ITV 
1500cc < 10.5Gy 445.66 467.14 565.38 475.8 653.6 598.7 
1000cc < 11.4 Gy 418.79 436.11 525.21 441.67 603.76 504.59 
Oesophagus 5cc < 17.7 Gy 
0 0 0 0 0 0 
25.2Gy max pt 9.3 10.3 11 15.6 13.7 17.3 
Rib  5cc < 40Gy 
3.73 3.57 3.71 3.96 3.54 3.93 
50Gy max pt 63.3 60.8 62.3 60.2 56.7 60.2 
Skin 10cc < 30Gy 
0 0 0 0.74 0 1.16 
33Gy max pt 30.6 30.9 32.6 33.8 29.6 34.7 
CW 30cc < 30Gy 64.17 57.67 59.4 58.84 45.31 59.53 
D2cm < 36.4 <47.0 34.8 33 31.5 32.5 35.9 31.8 
R50%  < 3.4 < 4.7 4.1 3.76 3.91 3.82 4 3.92 
TV(PTV)   76.18 75.29 75.44 75.4 75.18 75.25 
TV   79.12 79.12 79.12 79.12 79.12 79.12 
PIV   93.45 89.21 89.38 91.68 93.22 90.84 
CI   0.784904 0.80311 0.804779 0.783758 0.766318 0.787861 
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11.1.7 Patient 7 
 
 
 
 
 
 
 
 
 
 
ROI Objective 7FLDC 7FLDNC 9FLDC 9FLDNC 10FLDNC 13FLDC 
PTV 
95%  ≥ 100 % of PD 95.00% 95.02% 95.04% 95.18% 95.55% 95.08% 
99% ≥ 90 % of PD 99.05% 99.67% 99.02% 99.56% 99.07% 99.24% 
SC 
0.35cc <18Gy 0 0 0 0 0 0 
1.2cc < 12.3Gy 0 0 0 0 0 0 
21.9Gy max pt 10.1 9.6 7.7 8.6 8.1 11.6 
BP 3cc < 20.4Gy 
0 0 0 0 0 0
24Gy max pt 0.2 0.3 0.2 0.3 0.5 0.2
Heart 15cc < 24Gy 
0 0 0 0 0 0 
30Gy max pt 20.8 17.9 16.6 22.6 14.5 14.7 
IVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 7.9 6.1 2 2 4.4 3.4 
SVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 7 6 9.7 10.9 13.7 8.9 
Aorta 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 19.1 13.5 14.5 16.2 14.6 14.9 
Pericardium 15cc < 24 Gy 
0 0 0 0 0 0 
30Gy max pt 21.1 17.9 16.8 22.6 15.1 14.7 
Trachea 4cc < 15Gy 
0 0 0 0 0 0 
30Gy max pt 1.3 1.2 1.4 1.4 1.9 1.4 
Comb Lung - 
ITV 
1500cc < 10.5Gy 301.48 352.44 305.8 374.38 372.88 300.08 
1000cc < 11.4 Gy 285.87 325.42 278.91 329.87 332.83 278.59 
Oesophagus 5cc < 17.7 Gy 
0 0 0 0 0 0 
25.2Gy max pt 4.2 8.7 14.1 15.8 5.1 10.5 
Rib  5cc < 40Gy 
3.12 3.27 3.09 3.06 2.59 3.12 
50Gy max pt 60.4 60.7 60.2 61.5 56.7 60.6 
Skin 10cc < 30Gy 
0 0 0 0 0 0 
33Gy max pt 25.9 22.2 19.8 22.7 22.5 14.7 
CW 30cc < 30Gy 39.33 36.84 41.14 37.47 34.66 38.93 
D2cm < 30.8 <34.1 31.9 30.3 31.5 31.6 30.6 26.5 
R50% <4.4 <5.4 4.94 4.55 4.89 4.71 4.4 4.65 
TV(PTV)   30.2 30.2 30.2 30.24 30.37 30.22 
TV   31.77 31.77 31.77 31.77 31.77 31.77 
PIV   36.64 35.1 36.3 35.56 38.34 35.4 
CI   0.783504 0.81788 0.790843 0.80944 0.757217 0.812023 
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11.1.8 Patient 8 
ROI Objective 7FLDC 7FLDNC 9FLDC 9FLDNC 10FLDNC 13FLDC 
PTV 
95%  ≥ 100 % of PD 95.09% 95.09% 95.12% 95.10% 95.02% 95.07% 
99% ≥ 90 % of PD 99.79% 99.76% 99.90% 99.61% 99.70% 99.15% 
SC 
0.35cc <18Gy 0 0 0 0 0 0 
1.2cc < 12.3Gy 0.06 0.14 0.34 0 0.23 1.1 
21.9Gy max pt 12.8 13.4 13.8 11.6 13.4 13.5 
BP 3cc < 20.4Gy 
0 0 0 0 0 0 
24Gy max pt 3.9 3.8 3.3 3.1 0.5 0.7 
Heart 15cc < 24Gy 
0 0 0 0 0 0 
30Gy max pt 15.7 9 14.8 17.7 14.1 11.8 
IVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 1.5 4.5 1.6 4.3 5.8 1.6 
SVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 12.9 2.5 12.2 8.3 13.2 11.2 
Aorta 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 13 8.7 12.3 7.3 14.9 10.2 
Pericardium 15cc < 24 Gy 
0 0 0 0 0 0 
30Gy max pt 15.9 18 14.8 17.7 16.7 16 
Trachea 4cc < 15Gy 
0 0 0 0 0 0 
30Gy max pt 1.8 1.8 2 1.9 9.7 1.9 
Comb Lung - 
ITV 
1500cc < 10.5Gy 449.36 415.56 486.02 408.27 529.21 390.56 
1000cc < 11.4 Gy 418.96 381.81 448.29 364.25 457.8 333.98 
Oesophagus 5cc < 17.7 Gy 
0 0 0 0 0 0 
25.2Gy max pt 9.5 8.9 10.8 16.6 13.3 11.1 
Rib  5cc < 40Gy 
4.3 4.51 4.11 4.05 3.23 4.11 
50Gy max pt 58.7 59.1 58.4 58.5 59.1 58.6 
Skin 10cc < 30Gy 
0 0 0 0 0 0 
33Gy max pt 21.1 21 20 19.4 17 21.2 
CW 30cc < 30Gy 53.27 49.39 52.75 49.78 45.33 51.61 
D2cm < 31.6 <36.7 31.7 30.6 30.6 28.6 30.9 28.9 
R50% <4.3 <5.3 5.36 5.17 5.26 5.05 4.96 5.16 
TV(PTV)   31.88 31.89 31.89 31.88 31.88 31.9 
TV   33.5 33.5 33.5 33.5 33.5 33.5 
PIV   40.43 39.96 39.35 38.87 39.9 38.9 
CI   0.750392 0.759694 0.771471 0.780508 0.760359 0.780885 
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11.1.9 Patient 9 
ROI Objective 7FLDC 7FLDNC 9FLDC 9FLDNC 10FLDNC 13FLDC 
PTV 
95%  ≥ 100 % of PD 95.08% 95.11% 95.09% 95.01% 95.11% 95.08% 
99% ≥ 90 % of PD 99.15% 99.04% 99.75% 99.48% 99.21% 99.50% 
SC 
0.35cc <18Gy 0 0 0 0 0 0 
1.2cc < 12.3Gy 0 0 0.05 0 0.15 0.56 
21.9Gy max pt 9.3 9.7 12.6 10.5 13.7 14.3 
BP 3cc < 20.4Gy 
0 0 0 0 0 0 
24Gy max pt 1.8 1.9 1.8 1.8 1.9 1.8 
Heart 15cc < 24Gy 
0 0 0 0 0 0 
30Gy max pt 0.9 1 1 1 1 1 
IVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 0.2 0.3 0.2 0.3 0.3 0.2 
SVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 11.3 13.8 19.5 23.4 18 15.5 
Aorta 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 13.2 12.1 18.5 21.6 9.7 13.9 
Pericardium 15cc < 24 Gy 
0 0 0 0.28 0 0 
30Gy max pt 13.2 13.8 21 24.3 18 15.6 
Trachea 4cc < 15Gy 
0 0 0.33 0.04 0 1.16 
30Gy max pt 14.7 12.9 17.6 15.2 12.8 16.8 
Comb Lung - 
ITV 
1500cc < 10.5Gy 189.99 196.3 216.62 195.96 240.97 199.02 
1000cc < 11.4 Gy 175.18 181.11 195.48 184.6 220.82 186.64 
Oesophagus 5cc < 17.7 Gy 
0 0 0.51 0 0 0 
25.2Gy max pt 13.1 12.1 19.7 16.7 11.7 15.6 
Rib  5cc < 40Gy 
1.43 1.25 1.45 1.28 1.19 1.43 
50Gy max pt 59.6 59.8 59.8 59.8 56.7 59.4 
Skin 10cc < 30Gy 
0 0 0 0 0 0 
33Gy max pt 22.7 20.7 20.2 21.5 17.8 14.5 
CW 30cc < 30Gy 18.18 17.45 17.32 15.35 14.2 16.82 
D2cm <28.3 Gy <33.2 31.2 31 29.1 27.8 28.3 27.9 
R50% <4.6 <5.6 5.33 4.81 5.05 4.7 4.57 5.04 
TV(PTV)   17.44 17.45 17.44 17.42 17.44 17.44 
TV   18.33 18.33 18.33 18.33 18.33 18.33 
PIV   20.36 20.72 19.89 19.35 20.04 19.93 
CI   0.814991 0.801749 0.834249 0.855565 0.828005 0.832575 
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11.1.10 Patient 10 
ROI Objective 7FLDC 7FLDNC 9FLDC 9FLDNC 10FLDNC 13FLDC 
PTV 
95%  ≥ 100 % of PD 95.12% 95.04% 95.18% 95.34% 95.14% 95.13% 
99% ≥ 90 % of PD 99.21% 99.68% 99.67% 99.05% 99.42% 99.94% 
SC 
0.35cc <18Gy 0 0 0 0 0 0 
1.2cc < 12.3Gy 0 0 0 0 1.14 1.18 
21.9Gy max pt 11.5 10.8 9.4 9.6 14.1 13.3 
BP 3cc < 20.4Gy 
0 0 0 0 0 0 
24Gy max pt 0 0.03 0 0.03 0 0 
Heart 15cc < 24Gy 
0 0 0 0 0 0 
30Gy max pt 11 14.5 11.6 10.8 18.7 15 
IVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 10.8 11.7 11.3 10.5 8 14.9 
SVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 0.8 0.7 0.8 0.7 1 0.9 
Aorta 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 5.4 6.3 7.8 10.2 18.6 14.2 
Pericardium 15cc < 24 Gy 
0 0 0 0 0 0 
30Gy max pt 11 14.5 11.6 10.8 18.7 15 
Trachea 4cc < 15Gy 
0 0 0 0 0 0 
30Gy max pt 0.1 0.1 0.1 0.1 0.2 0.1 
Comb Lung - 
ITV 
1500cc < 10.5Gy 366.05 422.14 379.61 410.82 507.14 486.45 
1000cc < 11.4 Gy 336.86 388.02 343.05 364.05 458.41 437.78 
Oesophagus 5cc < 17.7 Gy 
0 0 0 0 0.35 0 
25.2Gy max pt 1.9 10.5 4.3 6.3 18 15 
Rib  5cc < 40Gy 
1.35 2.21 1.69 1.45 1.26 2.08 
50Gy max pt 60.5 61.9 60.6 58.5 56.7 63 
Skin 10cc < 30Gy 
2.96 3.43 2.97 3 3.88 4.09 
33Gy max pt 47 52 46.5 46.8 48.4 51.5 
CW 30cc < 30Gy 14.97 14.9 15.09 14.58 14.58 16.07
D2cm < 29.2 <34 33.8 33.9 33.8 33.5 29 31 
R50% <4.5 <5.5 5.21 4.86 5.18 5.16 5.28 5.02 
TV(PTV)   21.7 21.68 21.71 21.74 21.7 21.7 
TV   22.8 22.8 22.8 22.8 22.8 22.8 
PIV   29.11 26.59 27.56 29.42 28.07 25.86 
CI   0.709484 0.775292 0.750077 0.704598 0.73577 0.798649 
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11.2 APPENDIX B: PHASE 1 IMRT RESULTS  
11.2.1 Patient 1 
ROI Objective 7FLDC 7FLDNC 9FLDC 
9FLDN
C 
10FLDN
C 
13FLD
C 
PTV 
95%  ≥ 100 % of PD 95.09% 95.03% 95.06% 95.03% 95.17% 95.05% 
99% ≥ 90 % of PD 99.91% 99.98% 99.79% 99.80% 99.98% 99.74% 
SC 
0.35cc <18Gy 0 0 0 0 0 0 
1.2cc < 12.3Gy 0 0 0 0 0 0 
21.9Gy max pt 12 12.3 12.2 10.7 10.8 11.8 
BP 3cc < 20.4Gy 
0 0 0 0 0 0 
24Gy max pt 0.7 0.8 0.6 0.8 0.9 0.7 
Heart 15cc < 24Gy 
0 0 0 0 0 0 
30Gy max pt 1.2 1.2 1.2 1.2 5.7 1.2
IVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 0.2 0.3 0.2 0.3 0.3 0.2 
SVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 12.6 13.3 22 21.7 14.8 18.8 
Aorta 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 13.4 13 22.4 22 12.4 18.1 
Pericardium 15cc < 24 Gy 
0 0 0 0 0 0 
30Gy max pt 13.4 13.3 22.4 22.1 16.6 18.1 
Trachea 4cc < 15Gy 
0 0 0 0 0 1.14 
30Gy max pt 14.5 14.3 12.7 14.3 15.2 16.4 
Comb Lung - 
ITV 
1500cc < 10.5Gy 619.22 599.11 656.78 663.01 642.03 695.51 
1000cc < 11.4 Gy 573.12 552.12 606.48 612.58 586.64 638.72 
Oesophagus 5cc < 17.7 Gy 
0 0 0 0 0 0 
25.2Gy max pt 13.4 13.1 15.3 13.6 9.1 15.7 
Rib 5cc < 40Gy 
0 0 0 0 0 0 
50Gy max pt 29.4 29.3 29.1 28.6 29.9 27.7 
Skin 10cc < 30Gy 
0 0 0 0 0 0 
33Gy max pt 22.9 22.6 22.4 23.2 19.1 20 
CW 30cc < 30Gy 0.06 0 0 0 0 0 
D2cm <29.8 <34.7 29.6 29.6 29.5 29.8 29.1 27.5 
R50% <4.5  <5.5 6.79 6.18 6.54 6.21 5.35 6.63 
TV(PTV)   24.05 24.03 24.03 24.03 24.07 24.03 
TV   25.28 25.28 25.28 25.28 25.28 25.28 
PIV   26.94 26.27 27.32 27.59 26.23 27.84 
CI  
 
0.849289 0.869502 0.836084 0.827902 0.873729 
0.82046
7 
 
 
 
 
 
 
 
 
Appendices Page 116 
© 2016 FITZGERALD Page 116 
 
11.2.2 Patient 2 
ROI Objective 7FLDC 7FLDNC 9FLDC 9FLDNC 10FLDNC 13FLDC 
PTV 
95%  ≥ 100 % of PD 95.22% 95.06% 95.05% 95.17% 96.38% 95.13% 
99% ≥ 90 % of PD 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 
SC 
0.35cc <18Gy 0 0 0 0 0 0 
1.2cc < 12.3Gy 0 0 0 0 0 0.13 
21.9Gy max pt 6.8 1.5 5.8 1.1 10.1 12.5 
BP 3cc < 20.4Gy 
0 0 0 0 0 0 
24Gy max pt 0.1 0.2 0.1 0.2 0.3 0.14 
Heart 15cc < 24Gy 
0 0 0.12 0.34 0 0.89 
30Gy max pt 22.7 22.6 24.6 25.9 20.1 26.3 
IVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 1 1 1.1 1.1 1.2 1.1 
SVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 16.8 15.6 19.2 20 8.5 20.5 
Aorta 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 14.9 14.5 15.7 17.8 9.4 18 
Pericardium 15cc < 24 Gy 
0 0 0.14 0.35 0 0.9
30Gy max pt 23.1 22.6 24.6 25.9 20.1 26.3
Trachea 4cc < 15Gy 
0 0 0 0 0 0 
30Gy max pt 1.1 1 1.3 1.2 1.1 1.3 
Comb Lung - 
ITV 
1500cc < 10.5Gy 509.43 528.46 556.35 551.94 425.36 523.56 
1000cc < 11.4 Gy 471.23 482.05 509.31 496.5 382.47 466.12 
Oesophagus 5cc < 17.7 Gy 
0 0 0 0 0 0 
25.2Gy max pt 10.8 1.2 14.9 15.8 10.7 11.7 
Rib 5cc < 40Gy 
0 0 0 0 0 0 
50Gy max pt 28.5 27.6 28 26.5 25 19 
Skin 10cc < 30Gy 
0 0 0 0 0 0 
33Gy max pt 22.3 22.9 20.8 23.6 18.5 19 
CW 30cc < 30Gy 1.1 0.4 0.55 0 0.08 1.35 
D2cm <29.7 <34.6 28 27.8 27.3 27.8 24 28.2 
R50% <4.5 <5.5 5.82 5.68 5.58 5.24 4.44 6.23 
TV(PTV)   22.88 22.85 22.84 22.87 23.16 22.86 
TV   24 24 24 24 24 24 
PIV   24.73 25.11 24.38 24.33 24.66 24.97 
CI  
 
0.882016 0.866392 0.891553 0.895734 0.906302 0.872012 
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11.2.3 Patient 3 
ROI Objective 7FLDC 7FLDNC 9FLDC 9FLDNC 10FLDNC 13FLDC 
PTV 
95%  ≥ 100 % of PD 95.13% 95.10% 95.21% 95.19% 95.10% 95.22% 
99% ≥ 90 % of PD 99.98% 99.94% 100.00% 99.99% 100.00% 100.00% 
SC 
0.35cc <18Gy 0 0 0 0 0 0 
1.2cc < 12.3Gy 0 0 0 0 0 1.06 
21.9Gy max pt 6.4 4 11.6 11.9 5.8 13.7 
BP 3cc < 20.4Gy 
0 0 0 0 0 0 
24Gy max pt 0 0.03 0 0.03 0.06 0 
Heart 15cc < 24Gy 
2.54 2.7 5.52 3.72 2.56 6.63 
30Gy max pt 30.4 31.5 31.2 30 28.1 31.5 
IVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 2.1 1.8 1.8 1.8 4.3 1.9 
SVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 7 7.5 10.3 8.7 1.2 7.5 
Aorta 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 21.3 21.5 19.2 19.4 20.7 21
Pericardium 15cc < 24 Gy 
2.54 2.7 5.51 3.72 2.56 6.63 
30Gy max pt 30.4 31.5 31.2 30 28.1 31.5 
Trachea 4cc < 15Gy 
0 0 0 0 0 0 
30Gy max pt 0.7 0.7 0.9 0.8 1 0.8 
Comb Lung - 
ITV 
1500cc < 10.5Gy 666.32 719.91 618.38 674.5 646.46 640.8 
1000cc < 11.4 Gy 633.29 678.4 591.2 647.28 590.87 610.75 
Oesophagus 5cc < 17.7 Gy 
0.23 0.28 0 0 0 0 
25.2Gy max pt 18.6 19 9.6 12.5 13 14.4 
Rib 5cc < 40Gy 
0 0 0 0 0 0 
50Gy max pt 30.3 31.5 36 35.8 34.5 32.4 
Skin 10cc < 30Gy 
0 0 0 0 0 0 
33Gy max pt 26.3 24.7 25.5 25.6 20.6 22.4
CW 30cc < 30Gy 0 0.24 1.77 1.81 0.36 0.29
D2cm <31.6 <36.7 35 35.6 33.7 34 30 30 
R50% <4.3  <5.3 7.06 7.08 6.05 6.9 5.1 6.04 
TV(PTV)   33.53 33.74 33.56 33.55 33.51 33.55 
TV   35.2 35.2 35.2 35.2 35.2 35.2 
PIV   38.98 40.61 35.72 37.41 35.36 36.51 
CI   0.819375 0.796369 0.895756 0.854781 0.902182 0.875852 
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11.2.4 Patient 4 
ROI Objective 7FLDC 7FLDNC 9FLDC 9FLDNC 10FLDNC 13FLDC 
PTV 
95%  ≥ 100 % of PD 95.17% 95.09% 95.06% 95.03% 99.07% 95.05% 
99% ≥ 90 % of PD 100.00% 99.99% 99.93% 99.99% 100.00% 100.00% 
SC 
0.35cc <18Gy 0 0 0 0 0 0 
1.2cc < 12.3Gy 0.26 0 0 0 0 0 
21.9Gy max pt 15.5 2 8.1 1 7.7 11.6 
BP 3cc < 20.4Gy 
0 0 0 0 0 0 
24Gy max pt 1.2 1.2 1.2 1.1 1.2 1.2 
Heart 15cc < 24Gy 
0.13 0.1 0.13 0.15 0 0.16 
30Gy max pt 26.8 26.5 24 27.7 23.8 27.1 
IVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 0.5 0.6 0.5 0.6 0.5 0.5 
SVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 7.5 1.6 1.4 6.5 9.7 10.7 
Aorta 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 16.3 11.7 81.7 12 15.5 14.7 
Pericardium 15cc < 24 Gy 
3.04 1.84 4.88 1.72 0.79 4.26
30Gy max pt 30.6 29.8 30.6 30.4 27.5 31.6
Trachea 4cc < 15Gy 
0 0 1.29 0 0 0 
30Gy max pt 11.7 11.7 18 12.4 7.8 13.3 
Comb Lung - 
ITV 
1500cc < 10.5Gy 446.98 396.01 464.64 422.38 436.26 422.81 
1000cc < 11.4 Gy 423.02 357.11 426.62 379.6 382.69 385.55 
Oesophagus 5cc < 17.7 Gy 
0 0 1.36 0 0 0 
25.2Gy max pt 11.2 11.5 18.8 12.7 7.2 12.9 
Rib 5cc < 40Gy 
0 0 0 0 0 0 
50Gy max pt 26.1 24 26.2 22.8 25.5 23.5 
Skin 10cc < 30Gy 
0 0 0 0 0 0 
33Gy max pt 21.2 21.8 19.4 21.5 17.9 16.3 
CW 30cc < 30Gy 0 0 0 0 0 0 
D2cm <29.2 <34.0 29.5 25.6 29.5 26.6 26.6 25.6 
R50% <4.5 <5.5 5.49 4.47 5.04 4.3 4.41 4.82 
TV(PTV)   21.81 21.79 21.78 21.78 22.7 21.78 
TV   22.9 22.9 22.9 22.9 22.9 22.9 
PIV   23.43 22.87 24.21 23.61 26.64 23.24 
CI  
 
0.886551 0.906594 0.855629 0.877373 0.84466 0.891342 
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11.2.5 Patient 5 
ROI Objective 7FLDC 7FLDNC 9FLDC 9FLDNC 10FLDNC 13FLDC 
PTV 
95%  ≥ 100 % of PD 95.23% 95.10% 95.17% 95.05% 95.00% 95.08% 
99% ≥ 90 % of PD 99.93% 100.00% 100.00% 100.00% 99.98% 100.00% 
SC 
0.35cc <18Gy 0 0 0 0 0 0 
1.2cc < 12.3Gy 0 0 0 0 0 0.3 
21.9Gy max pt 10.8 10.2 10.5 9.6 9.3 12.7 
BP 3cc < 20.4Gy 
            
24Gy max pt             
Heart 15cc < 24Gy 
0 0 0 0 0 0
30Gy max pt 10.6 12 14.6 17.4 11.5 11.9
IVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 0.5 0.7 0.5 0.7 0.8 0.5 
SVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 13.2 13.8 13.3 13.4 13.3 15.5 
Aorta 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 10.5 11 13.8 15.4 17.3 12.5 
Pericardium 15cc < 24 Gy 
0 0 0 0 0 0 
30Gy max pt 16.4 19 22 23 20.6 22.6 
Trachea 4cc < 15Gy 
0 0 0 0 0 0.34 
30Gy max pt 11 11.4 11.7 13.5 10.8 17.5 
Comb Lung - 
ITV 
1500cc < 10.5Gy 565.32 495.59 564.72 522.39 573.01 535.41 
1000cc < 11.4 Gy 533.45 464.41 526.53 487.4 505.17 484.38 
Oesophagus 5cc < 17.7 Gy 
0 0 0 0 0 0 
25.2Gy max pt 1.8 1.6 4.2 4.8 10.3 11.1 
Rib 5cc < 40Gy 
0 0 0 0 0 0 
50Gy max pt 30.8 29.8 31.5 30 30.5 30.4 
Skin 10cc < 30Gy 
0 0 0 0 0 0 
33Gy max pt 22 22.4 20.1 19.9 22 19.7 
CW 30cc < 30Gy 0.68 0.14 0.17 0.03 0.07 0.19 
D2cm <30.5 <35.8 31.3 29.4 27.3 28.1 27 26.2 
R50% <4.4 <5.4 5.91 5.3 5.41 5.16 4.44 5.25 
TV(PTV)   28.28 28.24 28.26 28.23 28.21 28.24 
TV   29.7 29.7 29.7 29.7 29.7 29.7 
PIV   30.5 30.27 29.92 30 29.36 29.77 
CI  
 
0.882882 0.887075 0.898724 0.894425 0.912628 0.901974 
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11.2.6 Patient 6 
 
 
 
 
 
 
 
 
ROI Objective 7FLDC 7FLDNC 9FLDC 9FLDNC 10FLDNC 13FLDC 
PTV 
95%  ≥ 100 % of PD 95.19% 95.11% 95.06% 95.21% 95.11% 95.25% 
99% ≥ 90 % of PD 99.97% 99.96% 99.97% 100.00% 100.00% 100.00% 
SC 
0.35cc <18Gy 0 0 0 0 0 0
1.2cc < 12.3Gy 0 0 0 0 0 0
21.9Gy max pt 9.4 9.3 11.4 8.3 11.8 12.2 
BP 3cc < 20.4Gy 
            
24Gy max pt             
Heart 15cc < 24Gy 
0 0 0 0 0 0 
30Gy max pt 12.2 11.4 20.3 19.8 20.7 16.4 
IVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 11.7 10.1 19.2 18.8 19.9 14.7 
SVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 1.2 1 1.3 1.1 1.5 1.2 
Aorta 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 12.1 10.4 13.7 14 15.6 12.6 
Pericardium 15cc < 24 Gy 
0 0 0 0 0 0 
30Gy max pt 15.5 13.5 22.2 21.8 21.5 17.1 
Trachea 4cc < 15Gy 
0 0 0 0 0 0 
30Gy max pt 0.2 0.2 0.2 0.2 0.4 0.2 
Comb Lung - 
ITV 
1500cc < 10.5Gy 473.99 455.25 457.24 444.24 576.9 473.99 
1000cc < 11.4 Gy 440.67 420.1 429.35 406.3 522.87 444.85 
Oesophagus 5cc < 17.7 Gy 
0 0 0 0 0 0 
25.2Gy max pt 12 10..2 10 12.7 12.4 14.4 
Rib  5cc < 40Gy 
4.23 4.34 4.71 4.24 4.38 3.85 
50Gy max pt 56.2 56.3 56.4 55.8 55.3 56.5 
Skin 10cc < 30Gy 
0.55 0.77 0.72 0.42 0.3 0.32 
33Gy max pt 35.8 36.5 36 34.5 32.7 33.4 
CW 30cc < 30Gy 65.77 68.66 67.63 57.9 58.88 58.43 
D2cm < 36.4 <47.0 28.1 28.3 27.4 26.6 28.6 26.1 
R50%  < 3.4 < 4.7 3.98 4.03 4.1 3.67 3.81 3.74 
TV(PTV)   75.34 75.28 75.24 75.35 75.28 75.38 
TV   79.12 79.12 79.12 79.12 79.12 79.12 
PIV   82.89 83.05 82.37 80.27 81.35 80.39
CI   0.865492 0.862449 0.868645 0.893978 0.880472 0.893355 
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11.2.7 Patient 7 
 
 
 
 
 
 
 
ROI Objective 7FLDC 7FLDNC 9FLDC 9FLDNC 10FLDNC 13FLDC 
PTV 
95%  ≥ 100 % of PD 95.25% 95.03% 95.14% 95.13% 96.81% 95.32% 
99% ≥ 90 % of PD 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 
SC 
0.35cc <18Gy 0 0 0 0 0 0 
1.2cc < 12.3Gy 0 0 0 0 0 0 
21.9Gy max pt 10.7 10 7.5 9.2 10.4 11.7 
BP 3cc < 20.4Gy 
0 0 0 0 0 0 
24Gy max pt 0.2 0.2 0.3 0.3 0.4 0.2
Heart 15cc < 24Gy 
0 0 0 0 0 0 
30Gy max pt 23.3 20.1 18.6 22.1 12.9 14.7 
IVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 8.8 6.1 4.1 2.2 6.4 4.6 
SVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 6.5 6 5.6 8.5 6.3 6.7 
Aorta 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 11.3 11.1 16 16.2 12 14.5 
Pericardium 15cc < 24 Gy 
0 0 0 0 0 0 
30Gy max pt 23.3 20.1 19.3 22.1 12.9 14.7 
Trachea 4cc < 15Gy 
0 0 0 0 0 0 
30Gy max pt 1.4 1.3 1.5 1.4 1.3 1.6 
Comb Lung - 
ITV 
1500cc < 10.5Gy 311.88 381.63 310.46 362.42 301.19 311.9 
1000cc < 11.4 Gy 295.18 346.28 294.49 335.3 267.84 293.56 
Oesophagus 5cc < 17.7 Gy 
0 0 0 0 0 0 
25.2Gy max pt 5.2 8.7 10.7 13.9 7.6 10.1 
Rib  5cc < 40Gy 
5.1 5.24 4.83 4.58 3.83 4.51
50Gy max pt 56.6 56.5 56.7 56.2 56.7 56.6
Skin 10cc < 30Gy 
0 0 0 0 0 0 
33Gy max pt 24.3 22.1 21.8 23.3 19.3 16 
CW 30cc < 30Gy 59.44 57.06 57.98 51.97 37.56 50.35 
D2cm < 30.8 <34.1 31.9 31.8 31.5 31 25.8 27.6 
R50% <4.4 <5.4 6.7 6.15 6.23 5.82 4.3 5.41 
TV(PTV)   30.27 30.21 30.24 30.23 30.76 30.29 
TV   31.77 31.77 31.77 31.77 31.77 31.77 
PIV   35.01 34.46 33.74 34.68 33.84 32.72 
CI   0.823788 0.833622 0.853103 0.82943 0.880086 0.882608 
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11.2.8 Patient 8 
 
 
 
 
 
 
 
 
ROI Objective 7FLDC 7FLDNC 9FLDC 9FLDNC 10FLDNC 13FLDC 
PTV 
95%  ≥ 100 % of PD 95.15% 95.00% 95.29% 95.16% 95.12% 95.16% 
99% ≥ 90 % of PD 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 
SC 
0.35cc <18Gy 0 0 0 0 0 0 
1.2cc < 12.3Gy 0 0 0.63 0 0 0.52 
21.9Gy max pt 8.7 9.4 13.6 11.4 9.6 13.1 
BP 3cc < 20.4Gy 
0 0 0 0 0 0 
24Gy max pt 2.3 3.9 2.7 3.5 0.5 0.8
Heart 15cc < 24Gy 
0 0 0 0 0 0 
30Gy max pt 15.9 9.9 12.7 11.9 13.4 10.5 
IVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 3.7 5.8 2 5.1 6.5 2 
SVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 13.2 4 11.2 8.7 9.9 9.5 
Aorta 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 12.7 9 10.6 9.1 11.3 10.5 
Pericardium 15cc < 24 Gy 
0 0 0 0 0 0 
30Gy max pt 16.2 16 13.1 15.7 14.4 12.1 
Trachea 4cc < 15Gy 
0 0 0 0 0 0 
30Gy max pt 2.1 1.8 2.1 1.8 7.1 2.1 
Comb Lung - 
ITV 
1500cc < 10.5Gy 454.58 390.24 337.43 356.93 404.17 344.07 
1000cc < 11.4 Gy 416.02 323.78 292.44 302.21 340.95 304.03 
Oesophagus 5cc < 17.7 Gy 
0 0 0 0 0 0 
25.2Gy max pt 6.1 8 8.4 12.6 13.9 10.8 
Rib  5cc < 40Gy 
4.6 4.83 4.11 4.68 4.52 4.35
50Gy max pt 57.3 57.6 58.5 56.3 56.5 56.4
Skin 10cc < 30Gy 
0 0 0 0 0 0 
33Gy max pt 24.6 21.6 19.5 19.1 20.9 19.1 
CW 30cc < 30Gy 57.4 57.94 48.69 58.13 55 54.79 
D2cm < 31.6 <36.7 31.9 29.2 25.5 27.7 26.9 26.3 
R50% <4.3 <5.3 5.87 5.45 4.42 5.23 5.01 5 
TV(PTV)   31.9 31.86 31.95 31.91 31.89 31.91 
TV   33.5 33.5 33.5 33.5 33.5 33.5 
PIV   35.18 34.75 34.07 35.9 34.89 35.48 
CI   0.863457 0.871951 0.894386 0.84667 0.870088 0.856693 
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11.2.9 Patient 9 
 
 
 
 
 
 
 
 
ROI Objective 7FLDC 7FLDNC 9FLDC 9FLDNC 10FLDNC 13FLDC 
PTV 
95%  ≥ 100 % of PD 95.24% 95.26% 95.01% 95.26% 95.30% 95.40% 
99% ≥ 90 % of PD 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 
SC 
0.35cc <18Gy 0 0 0 0 0 0 
1.2cc < 12.3Gy 0 0 0 0 0.59 0.13 
21.9Gy max pt 12 10.9 11 11.1 14.7 12.7 
BP 3cc < 20.4Gy 
0 0 0 0 0 0 
24Gy max pt 2 2 2 2.1 2.2 2.1 
Heart 15cc < 24Gy 
0 0 0 0 0 0 
30Gy max pt 1 1 1 1 1.1 1 
IVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 0.2 0.4 0.2 0.4 0.4 0.2 
SVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 12.9 11.9 20.6 20.7 20.8 17.6 
Aorta 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 12.3 12.1 18.8 19.1 11.8 12.8 
Pericardium 15cc < 24 Gy 
0 0 0 0 0 0 
30Gy max pt 12.9 12.5 21.2 21.1 20.8 17.6
Trachea 4cc < 15Gy 
0 0 0 0 0 0.58 
30Gy max pt 13.8 13.6 14.6 14.4 15.1 16.1 
Comb Lung - 
ITV 
1500cc < 10.5Gy 214.19 220.36 213.97 219.1 231.37 220.04 
1000cc < 11.4 Gy 202 203.37 203.5 207.93 212.91 209.82 
Oesophagus 5cc < 17.7 Gy 
0 0 0 0 0 0 
25.2Gy max pt 12.3 12.1 15.2 14.8 14.1 13.9 
Rib  5cc < 40Gy 
1.54 1.6 1.45 1.48 1.63 1.51 
50Gy max pt 58.3 58.8 56.1 56.6 55.1 56.7 
Skin 10cc < 30Gy 
0 0 0 0 0 0 
33Gy max pt 20.7 20.2 18.7 18.2 17.6 15 
CW 30cc < 30Gy 21.24 21.07 18.74 19.45 18.06 20.01 
D2cm <28.3 Gy <33.2 28.6 28.3 26 25.5 24.6 25.8 
R50% <4.6 <5.6 5.59 5.53 5.19 5.23 5.03 5.46
TV(PTV)   17.47 17.47 17.43 17.48 17.48 17.5 
TV   18.33 18.33 18.33 18.33 18.33 18.33 
PIV   19.06 18.99 18.66 18.72 19.14 18.8 
CI   0.873576 0.876796 0.88822 0.89046 0.87092 0.888701 
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11.2.10 Patient 10 
 
 
 
 
 
 
 
 
ROI Objective 7FLDC 7FLDNC 9FLDC 9FLDNC 10FLDNC 13FLDC 
PTV 
95%  ≥ 100 % of PD 95.08% 95.21% 95.30% 95.05% 95.19% 95.20% 
99% ≥ 90 % of PD 99.96% 99.97% 100.00% 99.99% 99.99% 99.97% 
SC 
0.35cc <18Gy 0 0 0 0 0 0 
1.2cc < 12.3Gy 0 0 0 0 0 0.43 
21.9Gy max pt 11.5 11.5 10.9 10.2 1.5 14.3 
BP 3cc < 20.4Gy 
0 0 0 0 0 0 
24Gy max pt 0 0 0 0 0 0 
Heart 15cc < 24Gy 
0 0 0 0 0 0 
30Gy max pt 15.9 14.6 12.6 12.4 9.5 13.2
IVC 10cc < 39Gy 
0 0 0 0 0 0
45Gy max pt 15.3 14.1 12.6 12.1 3.7 31.2 
SVC 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 0.8 0.7 0.9 0.8 3.3 1.03 
Aorta 10cc < 39Gy 
0 0 0 0 0 0 
45Gy max pt 3 3.5 10.4 9.5 10.6 9.3 
Pericardium 15cc < 24 Gy 
0 0 0 0 0 0 
30Gy max pt 15.9 14.6 12.6 12.4 9.5 13.2 
Trachea 4cc < 15Gy 
0 0 0 0 0 0 
30Gy max pt 0.1 0.1 0.1 0.1 4.3 0.1 
Comb Lung - 
ITV 
1500cc < 10.5Gy 341.54 328.43 403.47 393.11 337.98 412.7 
1000cc < 11.4 Gy 306.65 293.62 365.98 353.47 296.18 362.04 
Oesophagus 5cc < 17.7 Gy 
0 0 0 0 0 0
25.2Gy max pt 2 1.9 7.5 6.8 9 10.1 
Rib  5cc < 40Gy 
2.5 2.68 2.49 2.68 2.54 2.4 
50Gy max pt 58.7 57.1 57.1 56.2 56.1 58 
Skin 10cc < 30Gy 
4.78 5.58 4.75 6.1 5.61 5.15 
33Gy max pt 51.5 51.8 50.5 52 51.1 52 
CW 30cc < 30Gy 18.06 18.66 17.56 19.44 18.75 18.26 
D2cm < 29.2 <34 26 24.3 24.3 23.3 24.8 25.1 
R50% <4.5 <5.5 4.39 4.46 4.59 4.63 4.5 4.69 
TV(PTV)   21.68 21.72 21.74 21.68 21.71 21.71 
TV   22.8 22.8 22.8 22.8 22.8 22.8 
PIV   24.36 24.12 23.61 23.85 24.02 24.07 
CI   0.846265 0.857842 0.877987 0.864361 0.860621 0.858833 
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11.3 APPENDIX C: PHASE 1 VMAT RESULTS  
11.3.1 Patient 1 
 
 
 
 
 
ROI Objective VFULLARC VPARARC VNONCOP 
PTV 
95%  ≥ 100 % of PD 95.03% 95.09% 95.08% 
99% ≥ 90 % of PD 99.98% 99.77% 99.96% 
SC 
0.35cc <18Gy 0 0 0 
1.2cc < 12.3Gy 0 0 0 
21.9Gy max pt 12.1 12 9.1 
BP 3cc < 20.4Gy 
0 0 0 
24Gy max pt 0.7 0.6 0.8 
Heart 15cc < 24Gy 
0 0 0 
30Gy max pt 1.3 1.1 1.4 
IVC 10cc < 39Gy 
0 0 0 
45Gy max pt 0.2 0.2 0.1 
SVC 10cc < 39Gy 
0 0 0 
45Gy max pt 16.1 15.5 18 
Aorta 10cc < 39Gy 
0 0 0 
45Gy max pt 17.1 10.9 15.5 
Pericardium 15cc < 24 Gy 
0 0 0 
30Gy max pt 17.2 15.5 18 
Trachea 4cc < 15Gy 
3.81 0.24 0 
30Gy max pt 18.9 16.3 12.6 
Comb Lung - 
ITV 
1500cc < 10.5Gy 604.2 663.85 565.54 
1000cc < 11.4 Gy 553.56 625.42 511.52 
Oesophagus 5cc < 17.7 Gy 
0 0 0 
25.2Gy max pt 17.2 11.2 8.5 
Rib 
5cc < 40Gy 0 0 0 
50Gy max pt 29.7 33.7 31 
Skin 10cc < 30Gy 
0 0 0 
33Gy max pt 16.6 21.5 15 
CW 30cc < 30Gy 0.04 4.26 0.12 
D2cm <29.8 <34.7 28.9 34 29.1 
R50% <4.5  <5.5 6.26 8.2 5.26 
TV(PTV)   24.03 24.04 24.04 
TV   25.28 25.28 25.28 
PIV   25.88 30.6 25.81 
CI  
 
0.882604627 0.747085712 0.885735094 
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11.3.2 Patient 2 
 
ROI Objective VFULLARC VPARARC VNONCOP 
PTV 
95%  ≥ 100 % of PD 95.01% 95.18% 95.03% 
99% ≥ 90 % of PD 99.93% 99.81% 100.00% 
SC 
0.35cc <18Gy 0 0 0 
1.2cc < 12.3Gy 0 0 0 
21.9Gy max pt 7.6 5.3 3.2 
BP 3cc < 20.4Gy 
0 0 0 
24Gy max pt 0.1 0.1 0.1 
Heart 15cc < 24Gy 
0.06 0 0 
30Gy max pt 24.2 20.5 18.5 
IVC 10cc < 39Gy 
0 0 0 
45Gy max pt 1.1 1 1.2 
SVC 10cc < 39Gy 
0 0 0 
45Gy max pt 20.3 17.4 14 
Aorta 10cc < 39Gy 
0 0 0 
45Gy max pt 16 12.2 10.5 
Pericardium 15cc < 24 Gy 
0.06 0 0 
30Gy max pt 24.2 20.5 18.5 
Trachea 4cc < 15Gy 
0 0 0 
30Gy max pt 1.3 1.1 2.5 
Comb Lung 
- ITV 
1500cc < 10.5Gy 452.39 500.06 402.09 
1000cc < 11.4 Gy 408.22 460.96 364.47 
Oesophagus 5cc < 17.7 Gy 
0 0 0 
25.2Gy max pt 10.7 7.3 5.5 
Rib 5cc < 40Gy 
0 0 0 
50Gy max pt 28.8 30.5 26.2 
Skin 10cc < 30Gy 
0 0 0 
33Gy max pt 17.8 18.4 14.2 
CW 30cc < 30Gy 1.57 3.85 0.28 
D2cm <29.7 <34.6 27.7 31.9 24.8 
R50% <4.5 <5.5 5.46 6.14 4.45 
TV(PTV)   22.83 22.87 22.83 
TV   24 24 24 
PIV   24.44 25.99 23.6 
CI  
 
0.888585822 0.838522669 0.920213453 
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11.3.3 Patient 3 
ROI Objective VFULLARC VPARARC VNONCOP 
PTV 
95%  ≥ 100 % of PD 95.11% 95.08% 95.05% 
99% ≥ 90 % of PD 99.99% 99.86% 99.99% 
SC 
0.35cc <18Gy 0 0 0 
1.2cc < 12.3Gy 0.62 0.05 0 
21.9Gy max pt 12.8 12.4 7 
BP 3cc < 20.4Gy 
0 0 0 
24Gy max pt 0 0 0.03 
Heart 15cc < 24Gy 
8.55 15.4 2.88 
30Gy max pt 30.7 36.8 29 
IVC 10cc < 39Gy 
0 0 0 
45Gy max pt 2 1.6 4.3 
SVC 10cc < 39Gy 
0 0 0 
45Gy max pt 9.1 9.1 6.5 
Aorta 10cc < 39Gy 
0 0 0 
45Gy max pt 22.5 23.2 19.4 
Pericardium 15cc < 24 Gy 
8.57 15.74 2.88 
30Gy max pt 30.7 36.8 30 
Trachea 4cc < 15Gy 
0 0 0 
30Gy max pt 0.8 0.7 1.1 
Comb Lung 
- ITV 
1500cc < 10.5Gy 620.05 609.68 539.66 
1000cc < 11.4 Gy 588.85 578.47 506.39 
Oesophagus 5cc < 17.7 Gy 
0 0 0 
25.2Gy max pt 14.5 14.3 9.7 
Rib 5cc < 40Gy 
0 0.79 0 
50Gy max pt 35.8 45.5 36.5 
Skin 10cc < 30Gy 
0 0cc 0 
33Gy max pt 23.4 28.9 20.1 
CW 30cc < 30Gy 1.68 13.3 1.42 
D2cm <31.6 <36.7 30.5 40 29.7 
R50% <4.3  <5.3 5.72 7.7 5.08 
TV(PTV)   33.52 33.55 33.5 
TV   35.2 35.2 35.2 
PIV   35.72 48.51 34.89 
CI  
 
0.893622111 0.65919076 0.913789116 
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11.3.4 Patient 4 
ROI Objective VFULLARC VPARARC VNONCOP 
PTV 
95%  ≥ 100 % of PD 95.11% 95.16% 97.46% 
99% ≥ 90 % of PD 99.87% 99.90% 100.00% 
SC 
0.35cc <18Gy 0 0 0 
1.2cc < 12.3Gy 0 0 0 
21.9Gy max pt 8.2 4.9 3.5 
BP 3cc < 20.4Gy 
0 0 0 
24Gy max pt 1 1 2.5 
Heart 15cc < 24Gy 
0 0 0 
30Gy max pt 20.8 23 24.6 
IVC 10cc < 39Gy 
0 0 0 
45Gy max pt 0.4 0.4 0.7 
SVC 10cc < 39Gy 
0 0 0 
45Gy max pt 10.6 7.9 4.3 
Aorta 10cc < 39Gy 
0 0 0 
45Gy max pt 14.4 11.9 9.5 
Pericardium 15cc < 24 Gy 
5.27 3.52 2.33 
30Gy max pt 30.5 30.1 30 
Trachea 4cc < 15Gy 
0 0 0 
30Gy max pt 14.3 11.8 7.6 
Comb Lung - 
ITV 
1500cc < 10.5Gy 370.59 354.66 401.9 
1000cc < 11.4 Gy 331.85 326.8 366.98 
Oesophagus 5cc < 17.7 Gy 
0 0 0 
25.2Gy max pt 13 10.2 6.5 
Rib 5cc < 40Gy 
0 0 0 
50Gy max pt 25.3 28.8 19.9 
Skin 10cc < 30Gy 
0 0 0 
33Gy max pt 10.2 13 13 
CW 30cc < 30Gy 0 0 0 
D2cm <29.2 <34.0 28 31.5 24 
R50% <4.5 <5.5 4.68 4.84 4.5 
TV(PTV)   21.79 21.81 22.34 
TV   22.9 22.9 22.9 
PIV   23.83 24.23 24.73 
CI  
 
0.870071485 0.857279492 0.88126544 
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11.3.5 Patient 5 
 
 
 
 
 
 
 
 
 
 
ROI Objective VFULLARC VPARARC VNONCOP 
PTV 
95%  ≥ 100 % of PD 95.01% 95.06% 95.75% 
99% ≥ 90 % of PD 99.98% 99.97% 100.00% 
SC 
0.35cc <18Gy 0 0 0 
1.2cc < 12.3Gy 0 0 0 
21.9Gy max pt 10.2 7.8 5.5 
BP 3cc < 20.4Gy 
      
24Gy max pt       
Heart 15cc < 24Gy 
0 0 0 
30Gy max pt 11.1 10.2 8.2 
IVC 10cc < 39Gy 
0 0 0 
45Gy max pt 0.5 0.4 0.7 
SVC 10cc < 39Gy 
0 0 0 
45Gy max pt 15.4 12.9 13.2 
Aorta 10cc < 39Gy 
0 0 0 
45Gy max pt 11.8 9.2 8.2 
Pericardium 15cc < 24 Gy 
0 0 0 
30Gy max pt 21.8 20.4 21.6 
Trachea 4cc < 15Gy 
0.08 0 0.05 
30Gy max pt 16 14.2 15.3 
Comb Lung 
- ITV 
1500cc < 10.5Gy 478.78 522.79 450.3 
1000cc < 11.4 Gy 441.96 470.99 409.39 
Oesophagus 5cc < 17.7 Gy 
0 0 0 
25.2Gy max pt 8.5 6.5 4.8 
Rib 5cc < 40Gy 
0 0 0 
50Gy max pt 30.5 31.8 31.5 
Skin 10cc < 30Gy 
0 0 0 
33Gy max pt 11.3 14.1 10.5 
CW 30cc < 30Gy 0.3 0.87 0.24 
D2cm <30.5 <35.8 26.7 29.1 24.5 
R50% <4.4 <5.4 4.84 4.98 4.38 
TV(PTV)   28.21 28.23 28.43 
TV   29.7 29.7 29.7 
PIV   29.69 30.16 29.61 
CI  
 
0.90248403 0.889680291 0.919091739 
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11.3.6 Patient 6 
 
ROI Objective VFULLARC VPARARC VNONCOP 
PTV 
95%  ≥ 100 % of PD 95.12% 95.06% 95.09% 
99% ≥ 90 % of PD 99.98% 99.87% 99.99% 
SC 
0.35cc <18Gy 0 0 0 
1.2cc < 12.3Gy 0 0 0 
21.9Gy max pt 11.6 11.9 8.7 
BP 3cc < 20.4Gy 
      
24Gy max pt       
Heart 15cc < 24Gy 
0 0 0 
30Gy max pt 17.7 13.8 11.6 
IVC 10cc < 39Gy 
0 0 0 
45Gy max pt 18.1 13.8 9.6 
SVC 10cc < 39Gy 
0 0 0 
45Gy max pt 1.4 1.3 1.9 
Aorta 10cc < 39Gy 
0 0 0 
45Gy max pt 15.6 12.9 6.2 
Pericardium 15cc < 24 Gy 
0 0 0 
30Gy max pt 18.7 16.6 15.2 
Trachea 4cc < 15Gy 
0 0 0 
30Gy max pt 0.2 0.2 0.2 
Comb Lung - 
ITV 
1500cc < 10.5Gy 436.88 483.48 423.14 
1000cc < 11.4 Gy 403.57 443.03 384.4 
Oesophagus 5cc < 17.7 Gy 
0 0 0 
25.2Gy max pt 13.5 13.6 6.4 
Rib 5cc < 40Gy 
3.7 4.23 3.87 
50Gy max pt 56.7 55.6 56.1 
Skin 10cc < 30Gy 
1.11 2.21 0.39 
33Gy max pt 38.5 39.5 33 
CW 30cc < 30Gy 52.36 62.07 53.33 
D2cm < 36.4 <47.0 26.6 28 26.1 
R50%  < 3.4 < 4.7 3.53 3.68 3.49 
TV(PTV)   75.28 75.24 75.8 
TV   79.12 79.12 79.12 
PIV   79.53 84.56 81.13 
CI  
 
0.900620773 0.846147978 0.895098144 
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11.3.7 Patient 7 
ROI Objective VFULLARC VPARARC VNONCOP 
PTV 
95%  ≥ 100 % of PD 95.14% 95.08% 96.48% 
99% ≥ 90 % of PD 100.00% 100.00% 100.00% 
SC 
0.35cc <18Gy 0 0 0 
1.2cc < 12.3Gy 0 0 0 
21.9Gy max pt 11.6 8.6 7.1 
BP 3cc < 20.4Gy 
0 0 0 
24Gy max pt 0.2 0.2 0.2 
Heart 15cc < 24Gy 
0 0 0 
30Gy max pt 14.3 16 17.3 
IVC 10cc < 39Gy 
0 0 0 
45Gy max pt 4.1 4 3.4 
SVC 10cc < 39Gy 
0 0 0 
45Gy max pt 5.7 3.5 2.5 
Aorta 10cc < 39Gy 
0 0 0 
45Gy max pt 14.9 12.7 11.81 
Pericardium 15cc < 24 Gy 
0 0 0 
30Gy max pt 14.3 16 17.3 
Trachea 4cc < 15Gy 
0 0 0 
30Gy max pt 1.5 1.4 2.6 
Comb Lung - 
ITV 
1500cc < 10.5Gy 275.02 290.26 293.55 
1000cc < 11.4 Gy 256.76 271.87 272.11 
Oesophagus 5cc < 17.7 Gy 
0 0 0 
25.2Gy max pt 10.2 7.4 5 
Rib 5cc < 40Gy 
3.28 3.29 3.17 
50Gy max pt 56.1 55.8 56.7 
Skin 10cc < 30Gy 
0 0 0 
33Gy max pt 13.6 14.8 13.9 
CW 30cc < 30Gy 38 38.18 36.04 
D2cm < 30.8 <34.1 24.9 26.4 25.1 
R50% <4.4 <5.4 4.37 4.33 4.3 
TV(PTV)   30.24 30.22 30.66 
TV   31.77 31.77 31.77 
PIV   33.29 33.14 33.83 
CI  
 
0.864634506 0.867399567 0.874631448 
 
 
 
 
 
 
 
 
 
 
Appendices Page 132 
© 2016 FITZGERALD Page 132 
11.3.8 Patient 8 
ROI Objective VFULLARC VPARARC VNONCOP 
PTV 
95%  ≥ 100 % of PD 95.04% 95.06% 96.00% 
99% ≥ 90 % of PD 100.00% 99.99% 100.00% 
SC 
0.35cc <18Gy 0 0 0 
1.2cc < 12.3Gy 0 0.17 0.03 
21.9Gy max pt 12.1 12.8 12.3 
BP 3cc < 20.4Gy 
0 0 0 
24Gy max pt 1.9 1.2 1 
Heart 15cc < 24Gy 
0 0 0 
30Gy max pt 11 12.3 11.9 
IVC 10cc < 39Gy 
0 0 0 
45Gy max pt 2 2.5 2.1 
SVC 10cc < 39Gy 
0 0 0 
45Gy max pt 9.4 12.7 12 
Aorta 10cc < 39Gy 
0 0 0 
45Gy max pt 11.8 10.7 6.6 
Pericardium 15cc < 24 Gy 
0 0 0 
30Gy max pt 14.1 15.5 14.9 
Trachea 4cc < 15Gy 
0 0 0 
30Gy max pt 2.2 2.2 3.1 
Comb Lung 
- ITV 
1500cc < 10.5Gy 331.54 409.53 340.26 
1000cc < 11.4 Gy 299.72 357.88 296.93 
Oesophagus 5cc < 17.7 Gy 
0 0 0 
25.2Gy max pt 13.4 9.4 8.6 
Rib 5cc < 40Gy 
3.35 3.66 3.7 
50Gy max pt 57.2 57.7 56.7 
Skin 10cc < 30Gy 
0 0 0 
33Gy max pt 18.9 21.9 18.9 
CW 30cc < 30Gy 42.91 46.13 40.43 
D2cm <31.6 <36.7 26 29.3 25.6 
R50% <4.3 <5.3 4.41 4.69 4.28 
TV(PTV)   31.87 31.87 32.19 
TV   33.5 33.5 33.5 
PIV   36.32 37.17 35.65 
CI  
 
0.834782777 0.815693044 0.867636097 
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11.3.9 Patient 9 
 
 
 
 
 
 
 
 
 
ROI Objective VFULLARC VPARARC VNONCOP 
PTV 
95%  ≥ 100 % of PD 95.18% 95.14% 95.58% 
99% ≥ 90 % of PD 100.00% 100.00% 100.00% 
SC 
0.35cc <18Gy 0 0 0 
1.2cc < 12.3Gy 0.49 0 0 
21.9Gy max pt 13.5 11.9 7.4 
BP 3cc < 20.4Gy 
0 0 0 
24Gy max pt 1.8 1.7 3.1 
Heart 15cc < 24Gy 
0 0 0 
30Gy max pt 1.1 1 1.1 
IVC 10cc < 39Gy 
0 0 0 
45Gy max pt 0.2 0.2 0.1 
SVC 10cc < 39Gy 
0 0 0 
45Gy max pt 15.7 14 12.9 
Aorta 10cc < 39Gy 
0 0 0 
45Gy max pt 13.3 8.9 7.3 
Pericardium 15cc < 24 Gy 
0 0 0 
30Gy max pt 16.2 14 12.9 
Trachea 4cc < 15Gy 
0.8 0 0 
30Gy max pt 16.5 12.5 11 
Comb Lung - ITV 1500cc < 10.5Gy 
192.88 203.93 193.71 
1000cc < 11.4 Gy 184.08 191.5 176.88 
Oesophagus 5cc < 17.7 Gy 
0 0 0 
25.2Gy max pt 14.2 10.8 7.5 
Rib  5cc < 40Gy 
1.36 1.33 1.31 
50Gy max pt 56.3 57.5 56.7 
Skin 10cc < 30Gy 
0 0 0 
33Gy max pt 11.9 12.8 10.4 
CW 30cc < 30Gy 17.79 19.08 16.01 
D2cm <28.3 <33.2 26.2 27 22.1 
R50% <4.6 <5.6 4.94 5.09 4.41 
TV(PTV)   17.46 17.45 17.53 
TV   18.33 18.33 18.33 
PIV   18.7 18.45 18.78 
CI  
 
0.889373955 0.900392828 0.892700503 
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11.3.10 Patient 10 
 
 
ROI Objective VFULLARC VPARARC VNONCOP 
PTV 
95%  ≥ 100 % of PD 95.18% 95.16% 95.56% 
99% ≥ 90 % of PD 100.00% 99.98% 100.00% 
SC 
0.35cc <18Gy 0 0 0 
1.2cc < 12.3Gy 0 0 0 
21.9Gy max pt 9.8 7.6 4.2 
BP 3cc < 20.4Gy 
0 0 0 
24Gy max pt 0 0 0 
Heart 15cc < 24Gy 
0 0 0 
30Gy max pt 11.4 9.9 6.2 
IVC 10cc < 39Gy 
0 0 0 
45Gy max pt 10.7 10.1 5.4 
SVC 10cc < 39Gy 
0 0 0 
45Gy max pt 1 0.9 1.4 
Aorta 10cc < 39Gy 
0 0 0 
45Gy max pt 8.6 7.1 4.4 
Pericardium 15cc < 24 Gy 
0 0 0 
30Gy max pt 11.4 9.9 6.2 
Trachea 4cc < 15Gy 
0 0 0 
30Gy max pt 0.1 0.1 0.1 
Comb Lung - 
ITV 
1500cc < 10.5Gy 385.56 309.7 299.11 
1000cc < 11.4 Gy 335.55 273.22 266.86 
Oesophagus 5cc < 17.7 Gy 
0 0 0 
25.2Gy max pt 9.5 7.5 3.9 
Rib (9th) 5cc < 40Gy 
2.29 2.2 2.61 
50Gy max pt 56.7 57.6 56.2 
Skin 10cc < 30Gy 
3.78 2.84 4.52 
33Gy max pt 51.7 51.3 51 
CW 30cc < 30Gy 14.86 13.48 16.49 
D2cm < 29.2 <34 24 24.8 22.3 
R50% <4.5 <5.5 4.36 4.13 4.48 
TV(PTV)   21.89 21.71 21.79 
TV   22.8 22.8 22.8 
PIV   23.94 23.92 24.21 
CI  
 
0.877874694 0.864218631 0.860171054 
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11.4 APPENDIX D: PHASE 2 RESULTS  
11.4.1 Patient 11 
 
 
 
 
 
 
 
 
ROI Objective 3DCRT IMRT VMAT 
PTV 
95%  ≥ 100 % of PD 95.14% 95.16% 95.01% 
99% ≥ 90 % of PD 99.48% 99.99% 99.93% 
SC 
0.35cc <18Gy 0 0 0 
1.2cc < 12.3Gy 0 0 0 
21.9Gy max pt 10.5 9.8 10.7 
BP 3cc < 20.4Gy 
0 0 0 
24Gy max pt 1.7 1.7 1.9 
Heart 15cc < 24Gy 
0 0 0 
30Gy max pt 0.8 0.8 0.9 
IVC 10cc < 39Gy 
0 0 0 
45Gy max pt 0.2 0.2 0.1 
SVC 10cc < 39Gy 
0 0 0 
45Gy max pt 19 20.7 19.5 
Aorta 10cc < 39Gy 
0 0 0 
45Gy max pt 18.9 17.5 17 
Pericardium 15cc < 24 Gy 
0 0 0.03 
30Gy max pt 23.7 23.1 24 
Trachea 4cc < 15Gy 
3.89 3.99 1.37 
30Gy max pt 22.9 22.7 19.5 
Comb Lung - 
ITV 
1500cc < 10.5Gy 483.31 493.66 422.56 
1000cc < 11.4 Gy 444.87 454.78 388.92 
Oesophagus 5cc < 17.7 Gy 
1.19 0.31 0 
25.2Gy max pt 20.2 19.6 16.7 
Rib 5cc < 40Gy 
0 0 0 
50Gy max pt 23.6 23.1 23.5 
Skin 10cc < 30Gy 
0 0 0 
33Gy max pt 22.4 19.1 12.3 
CW 30cc < 30Gy 0cc 0 0 
D2cm <29.7 <34.6 28.5 25.5 26.6 
R50% <4.5 <5.5 4.65 4.89 4.51 
TV(PTV)   23.42 23.42 23.38 
TV   24.6 24.6 24.6 
PIV   27.3 25.16 24.85 
CI  
 
0.816725334 0.886192433 0.894185274 
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11.4.2 Patient 12 
 
ROI Objective 3DCRT IMRT VMAT 
PTV 
95%  ≥ 100 % of PD 95.07% 95.14% 95.17% 
99% ≥ 90 % of PD 99.39% 100.00% 99.97% 
SC 
0.35cc <18Gy 0 0 0 
1.2cc < 12.3Gy 0 0 0 
21.9Gy max pt 4.5 6.6 3.8 
BP 3cc < 20.4Gy 
      
24Gy max pt       
Heart 15cc < 24Gy 0.78 0.65 0.27 
30Gy max pt 30.6 27.4 26.3 
IVC 10cc < 39Gy 0 0 0 
45Gy max pt 0.6 0.7 3 
SVC 10cc < 39Gy 
0 0 0 
45Gy max pt 10.7 12.9 3.1 
Aorta 10cc < 39Gy 0 0 0 
45Gy max pt 15 20.9 7.7 
Pericardium 15cc < 24 Gy 10.86 5.44 2.12 
30Gy max pt 40.8 34 31.2 
Trachea 4cc < 15Gy 
0 0 0 
30Gy max pt 2.5 4 3.8 
Comb Lung 
- ITV 
1500cc < 10.5Gy 489.45 477.83 278.82 
1000cc < 11.4 Gy 446.56 427.45 257.93 
Oesophagus 5cc < 17.7 Gy 0 0 0 
25.2Gy max pt 3.1 7 4 
Rib 5cc < 40Gy 
5.79 6.08 6.03 
50Gy max pt 60 58.3 61.6 
Skin 10cc < 30Gy 0 0 0 
33Gy max pt 21.8 26.5 15.8 
CW 30cc < 30Gy 74.69 70.17 69.32 
D2cm <34.9Gy 36.6 31.2 28
R50% <3.7 4.7 4 3.6 
TV(PTV)   60.46 60.51 60.52 
TV   63.6 63.6 63.6 
PIV   76.81 63.03 63.26 
CI  
 
0.748275292 0.913376604 0.91035658 
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11.4.3 Patient 13 
ROI Objective 3DCRT IMRT VMAT 
PTV 
95%  ≥ 100 % of PD 99.57% 99.68% 99.72% 
99% ≥ 90 % of PD 100.00% 100.00% 100.00% 
SC 
0.35cc <18Gy 0 0 0 
1.2cc < 12.3Gy 0.06 0 0 
21.9Gy max pt 12.9 9.6 11.3 
BP 3cc < 20.4Gy 
0 0 0 
24Gy max pt 0.4 0.4 0.2 
Heart 15cc < 24Gy 
0.1 0.02 0.28 
30Gy max pt 25.3 23.8 25.7 
IVC 10cc < 39Gy 
0 0 0 
45Gy max pt 1.6 1.6 1.6 
SVC 10cc < 39Gy 
0 0 0 
45Gy max pt 13.5 12.1 14.7 
Aorta 10cc < 39Gy 
0 0 0 
45Gy max pt 16.4 16.6 10.2 
Pericardium 15cc < 24 Gy 
0.31 0.19 0.59 
30Gy max pt 27 26.2 26.7 
Trachea 4cc < 15Gy 
0 0 0 
30Gy max pt 6.1 6.4 2.5 
Comb Lung 
- ITV 
1500cc < 10.5Gy 339.11 384.26 360.7 
1000cc < 11.4 Gy 293.81 349.03 321.21 
Oesophagus 5cc < 17.7 Gy 
0.47 0.25 0.09 
25.2Gy max pt 22 19.1 18.5 
Rib 5cc < 40Gy 
0 0 0 
50Gy max pt 19.8 17.9 18.1 
Skin 10cc < 30Gy 
0 0 0 
33Gy max pt 17.8 17.5 10.7 
CW 30cc < 30Gy 0 0 0 
D2cm 30.2Gy 29.3 24.3 23.5 
R50% <4.4 4.2 4.36 4.4 
TV(PTV)   27.57 27.6 27.61 
TV   27.7 27.7 27.7 
PIV   35.35 32.22 33.79 
CI  
 
0.776254883 0.853518343 0.814450797 
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11.4.4 Patient 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ROI Objective 3DCRT IMRT VMAT 
PTV 
95%  ≥ 100 % 
of PD 95.03% 95.04% 95.08% 
99% ≥ 90 % of 
PD 99.29% 99.98% 100.00% 
SC 
0.35cc <18Gy 0 0 0 
1.2cc < 12.3Gy 1.18 0.41 0.37 
21.9Gy max pt 16 13.8 13.7 
BP 3cc < 20.4Gy 
0 0 0 
24Gy max pt 15.8 9.8 10 
Heart 15cc < 24Gy 
0 0 0 
30Gy max pt 1.1 1.1 0.6 
IVC 10cc < 39Gy 
0 0 0 
45Gy max pt 0.1 0.1 0.1 
SVC 10cc < 39Gy 
0 0 0 
45Gy max pt 8.9 12.5 9 
Aorta 10cc < 39Gy 
0 0 0 
45Gy max pt 11.3 12.8 7 
Pericardium 
15cc < 24 Gy 0 0 0 
30Gy max pt 11.3 12.8 10.6 
Trachea 4cc < 15Gy 
3.99 0.36 0.19 
30Gy max pt 21.6 15.9 15.8 
Comb Lung - 
ITV 
1500cc < 
10.5Gy 229.87 263.91 208.94 
1000cc < 11.4 
Gy 205.89 224.63 191.63 
Oesophagus 5cc < 17.7 Gy 
1.49 0 0 
25.2Gy max pt 23 17.5 15.5 
Rib 5cc < 40Gy 
2.13 1.9 1.82 
50Gy max pt 56.7 56.6 55.8 
Skin 10cc < 30Gy 
0 0 0 
33Gy max pt 15.2 20.3 12.9 
CW 30cc < 30Gy 19.36 16.26 15.46 
D2cm <28.6Gy 26.5 24.5 22.2 
R50% <4.6 5.49 4.64 4.43 
TV(PTV)   18.45 18.46 18.47 
TV   19.4 19.4 19.4 
PIV   22.02 20.18 20.48 
CI  
 
0.796844715 0.87044333 0.858622191 
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11.4.5 Patient 15 
 
ROI Objective 3DCRT IMRT VMAT 
PTV 
95%  ≥ 100 % of PD 95.19% 95.18% 95.12% 
99% ≥ 90 % of PD 99.93% 100.00% 100.00% 
SC 
0.35cc <18Gy 0 0 0 
1.2cc < 12.3Gy 0 0 0.05 
21.9Gy max pt 10.3 11.5 12.4 
BP 3cc < 20.4Gy 
      
24Gy max pt       
Heart 15cc < 24Gy 
0 0 0 
30Gy max pt 16.8 16.8 9.1 
IVC 10cc < 39Gy 
0 0 0 
45Gy max pt 1.5 1.6 2.3 
SVC 10cc < 39Gy 
0 0 0 
45Gy max pt 12 9.1 7.2 
Aorta 10cc < 39Gy 
0 0 0 
45Gy max pt 14.8 13.3 7.5 
Pericardium 15cc < 24 Gy 
0 0 0 
30Gy max pt 17.1 17 12.6 
Trachea 4cc < 15Gy 
0 0 0 
30Gy max pt 10.3 7.2 3.1 
Comb Lung - 
ITV 
1500cc < 10.5Gy 486.53 411.24 273.77 
1000cc < 11.4 Gy 398.87 353.41 241.94 
Oesophagus 5cc < 17.7 Gy 
0 0 0 
25.2Gy max pt 13.5 16 10.6 
Rib 5cc < 40Gy 
1.98 2.42 2.03 
50Gy max pt 56.5 56.7 56.5 
Skin 10cc < 30Gy 
0 0 0 
33Gy max pt 20.2 20.8 16.2 
CW 30cc < 30Gy 32.83 30.1 27.57 
D2cm <30.2Gy 28.2 26 22.9 
R50% <4.4 5.07 4.54 4.15 
TV(PTV)   26.06 26.25 26.05 
TV   27.4 27.4 27.4 
PIV   30.33 28.17 27.46 
CI  
 
0.81719528 0.892732212 0.901912403 
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11.4.6 Patient 16 
 
 
 
 
 
 
 
 
 
 
ROI Objective 3DCRT IMRT VMAT 
PTV 
95%  ≥ 100 % of PD 95.10% 95.14% 95.01% 
99% ≥ 90 % of PD 99.79% 99.98% 99.98% 
SC 
0.35cc <18Gy 0 0 0 
1.2cc < 12.3Gy 0 0 0 
21.9Gy max pt 0.5 0.5 3.3 
BP 3cc < 20.4Gy 
      
24Gy max pt       
Heart 15cc < 24Gy 
0 0 0 
30Gy max pt 3.4 3.8 4.2 
IVC 10cc < 39Gy 
0 0 0 
45Gy max pt 0.3 0.4 0.1 
SVC 10cc < 39Gy 
0 0 0 
45Gy max pt 8.9 6.5 6.8 
Aorta 10cc < 39Gy 
0 0 0 
45Gy max pt 17.9 17.2 13.3 
Pericardium 15cc < 24 Gy 
0 0 0 
30Gy max pt 19.8 19.3 20.4 
Trachea 4cc < 15Gy 
0 0 0 
30Gy max pt 11.2 11.2 7.9 
Comb Lung - 
ITV 
1500cc < 10.5Gy 482.85 438.89 331.86 
1000cc < 11.4 Gy 433.56 379.41 304.37 
Oesophagus 5cc < 17.7 Gy 
0.16 0 0 
25.2Gy max pt 18 17.4 8.2 
Rib (9th) 5cc < 40Gy 
0 0 0 
50Gy max pt 33.4 30.4 33.3 
Skin 10cc < 30Gy 
0 0 0 
33Gy max pt 22.5 20 17.7 
CW 30cc < 30Gy 0.15 0 0 
D2cm <28.6Gy 27.7 26 26.5 
R50% <4.6 5.18 4.89 4.9 
TV(PTV)   18.63 18.63 18.61 
TV   19.6 19.6 19.6 
PIV   21.99 20.15 19.6 
CI  
 
0.805275357 0.878809186 0.901530873 
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11.4.7 Patient 17 
 
ROI Objective 3DCRT IMRT VMAT 
PTV 
95%  ≥ 100 % of PD 95.04% 95.02% 95.12% 
99% ≥ 90 % of PD 99.15% 99.84% 100.00% 
SC 
0.35cc <18Gy 0 0 0 
1.2cc < 12.3Gy 0 0 0 
21.9Gy max pt 11 8 4.7 
BP 3cc < 20.4Gy 
0 0 0 
24Gy max pt 2 2.4 1.9 
Heart 15cc < 24Gy 
0 0 0 
30Gy max pt 4.1 2 5 
IVC 10cc < 39Gy 
0 0 0 
45Gy max pt 0.3 0.4 0.2 
SVC 10cc < 39Gy 
0 0 0 
45Gy max pt 21.1 23.1 25 
Aorta 10cc < 39Gy 
0 0 0 
45Gy max pt 21.1 23.3 24 
Pericardium 15cc < 24 Gy 
0.07 0.42 0.69 
30Gy max pt 24.8 27.2 27.4 
Trachea 4cc < 15Gy 
0 0 0 
30Gy max pt 10.5 10.4 11 
Comb Lung - 
ITV 
1500cc < 10.5Gy 608.93 586.39 449.69 
1000cc < 11.4 Gy 548.83 521.71 416.67 
Oesophagus 5cc < 17.7 Gy 
0 0 0 
25.2Gy max pt 6.6 7.4 7.7 
Rib (3rd) 5cc < 40Gy 
2.62 4.62 4.48 
50Gy max pt 56.2 56 55.2 
Skin 10cc < 30Gy 
0 0 0 
33Gy max pt 21.4 19.7 19.5 
CW 30cc < 30Gy 34.18 33.86 41.6 
D2cm <35.6 32.2 25.5 25.3 
R50% <3.5 3.44 3.3 3.35 
TV(PTV)   70.02 70 70.08 
TV   73.65 73.65 73.65 
PIV   79 74.65 74.23 
CI  
 
0.842644461 0.891237634 0.898330147 
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11.4.8 Patient 18 
 
 
 
 
 
 
 
 
 
 
ROI Objective 3DCRT IMRT VMAT 
PTV 
95%  ≥ 100 % of PD 95.68% 95.21% 95.15% 
99% ≥ 90 % of PD 99.02% 100.00% 100.00% 
SC 
0.35cc <18Gy 0 0 0 
1.2cc < 12.3Gy 0.94 0.3 0.28 
21.9Gy max pt 13 13 13 
BP 3cc < 20.4Gy 
0.12 0 0 
24Gy max pt 23.5 19.7 19.5 
Heart 15cc < 24Gy 
0 0 0 
30Gy max pt 1.4 3.6 1.8 
IVC 10cc < 39Gy 
0 0 0 
45Gy max pt 0.3 0.3 0.2 
SVC 10cc < 39Gy 
0 0 0 
45Gy max pt 23.3 19.4 18.7 
Aorta 10cc < 39Gy 
0 0 0 
45Gy max pt 22.8 19.5 10.6 
Pericardium 15cc < 24 Gy 
2.01 0 0 
30Gy max pt 30 22.5 20.7 
Trachea 4cc < 15Gy 
3.85 2.45 1.41 
30Gy max pt 21.8 19.7 18.8 
Comb Lung - 
ITV 
1500cc < 10.5Gy 406.43 433.49 357.82 
1000cc < 11.4 Gy 389.56 414.42 344.09 
Oesophagus 5cc < 17.7 Gy 
0 0 0 
25.2Gy max pt 10.3 14.6 13.5 
Rib (4th) 5cc < 40Gy 
5.24 6.95 6.44 
50Gy max pt 56.7 56.2 55.3 
Skin 10cc < 30Gy 
0 0 0 
33Gy max pt 23.5 21.3 15.8 
CW 30cc < 30Gy 60.82 67.53 65.19 
D2cm <36.7 39.4 28.2 26.5 
R50% <3.41 3.84 3.62 3.41 
TV(PTV)   79.69 80.05 79.27 
TV   83.3 83.3 83.3 
PIV   91.82 84.39 82.22 
CI  
 
0.830281505 0.91156299 0.91747712 
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11.4.9 Patient 19 
 
 
 
 
 
 
 
 
 
 
ROI Objective 3DCRT IMRT VMAT 
PTV 
95%  ≥ 100 % of PD 95.00% 95.12% 95.10% 
99% ≥ 90 % of PD 99.78% 100.00% 99.99% 
SC 
0.35cc <18Gy 0 0 0 
1.2cc < 12.3Gy 0 0 0 
21.9Gy max pt 6.4 4.4 6 
BP 3cc < 20.4Gy 
      
24Gy max pt       
Heart 15cc < 24Gy 
0 0 0 
30Gy max pt 0.8 0.7 1.7 
IVC 10cc < 39Gy 
0 0 0 
45Gy max pt 0.2 0.2 0.1 
SVC 10cc < 39Gy 
0 0 0 
45Gy max pt 12.8 16 8.6 
Aorta 10cc < 39Gy 
0 0 0 
45Gy max pt 12.2 13.7 5.6 
Pericardium 15cc < 24 Gy 
0 0 0 
30Gy max pt 15.2 17.5 8.6 
Trachea 4cc < 15Gy 
0 0 0 
30Gy max pt 8.7 10.8 7.5 
Comb Lung - 
ITV 
1500cc < 10.5Gy 309.93 345.95 264.16 
1000cc < 11.4 Gy 270.51 311.24 239.4 
Oesophagus 5cc < 17.7 Gy 
0 0 0 
25.2Gy max pt 10.7 13.3 6.1 
Rib (4th) 5cc < 40Gy 
1.39 1.09 0.88 
50Gy max pt 54.3 52.4 51.1 
Skin 10cc < 30Gy 
0 0 0 
33Gy max pt 21 19.5 10.6 
CW 30cc < 30Gy 5.7 5.72 6.53 
D2cm <28.6Gy 26.3 23.8 23.8 
R50% <4.6 4.2 4.65 4.44 
TV(PTV)   18.46 18.49 18.48 
TV   19.43 19.43 19.43 
PIV   21.44 19.81 20.34 
CI  
 
0.81802356 0.888211816 0.864132192 
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11.4.10 Patient 20 
 
 
 
 
ROI Objective 3DCRT IMRT VMAT 
PTV 
95%  ≥ 100 % of PD 95.04% 95.17% 95.03% 
99% ≥ 90 % of PD 99.72% 99.98% 99.95% 
SC 
0.35cc <18Gy 0 0 0 
1.2cc < 12.3Gy 0 0 0 
21.9Gy max pt 8.8 10 4.1 
BP 3cc < 20.4Gy 
      
24Gy max pt       
Heart 15cc < 24Gy 
0 0 0 
30Gy max pt 8.4 5.8 3.3 
IVC 10cc < 39Gy 
0 0 0 
45Gy max pt 0.4 0.4 0.3 
SVC 10cc < 39Gy 
0 0 0 
45Gy max pt 17.6 18.9 5.1 
Aorta 10cc < 39Gy 
0 0 0 
45Gy max pt 19.1 21.1 18.3 
Pericardium 15cc < 24 Gy 
0.24 0.54 0.67 
30Gy max pt 26.4 28.8 28 
Trachea 4cc < 15Gy 
0 0 0 
30Gy max pt 11.1 9.7 7.6 
Comb Lung - ITV 1500cc < 10.5Gy 
561.13 598.37 534.46 
1000cc < 11.4 Gy 518.99 555.51 499.71 
Oesophagus 5cc < 17.7 Gy 
0 0 0 
25.2Gy max pt 17.3 17.9 9.1 
Rib 5cc < 40Gy 
0 0 0 
50Gy max pt 38.3 36.9 39.6 
Skin 10cc < 30Gy 
0 0 0 
33Gy max pt 24.6 25.7 12.2 
CW 30cc < 30Gy 2.32 1.42 4.31 
D2cm <31Gy 29.8 28.6 27.7 
R50% <4.3 5.14 5.2 5.27 
TV(PTV)   30.81 31.06 30.8 
TV   32.4 32.4 32.4 
PIV   36.97 33.94 32.78 
CI  
 
0.792481141 0.877295809 0.893197448 
